### FHN DAILY TRIAL - FORMS TABLE OF CONTENTS

	FRINDAILT TRIAL - FURINS TABLE OF CONTENTS			
Form #	Version Date	Form Name		
104	01/MAY/2007	Co-Morbidity and Medical History Form		
105	12/MAR/2006	Baseline Demographics, Employment, and Income Form		
107	30/JUN/2006	Direct Patient Contact Form		
108	26/MAR/2008	U.S. Patient Future Linkage Form		
110	26/FEB/2008	Daily Trial Eligibility Confirmation (Screening) Form		
111	16/MAR/2007	Documentation of Six Consecutive Days Form		
112	16/MAY/2007	Daily Trial Pre-Randomization Drop-out Form		
113	29/AUG/2007	Daily Study Ready for Randomization Confirmation		
202	17/MAY/2006	Amputation Form		
203	10/JAN/2006	Monthly IV Iron Therapy		
204	10/FEB/2007	Injectable Medications Form		
205	21/MAR/2007	Medications and Supplements Form		
206	13/FEB/2009	Residual Renal Function		
207	26/FEB/2008	Biochemistry Laboratory Data Form		
208	10/FEB/2007 18/JAN/2007	Participant In-Center Log Sheet (Non-dialytic Aspects of HD)		
218	10/FEB/2007	Final MRI Scheduled		
220	14/JUL/2009	SF-36 (English and Spanish), v1		
221	10/FEB/2007	Beck Depression Inventory, v1 Cousineau Self-Perceived Burden Scale		
223	10/FEB/2007	Health Utilities Index 3 Form		
224	10/FEB/2007	Central Interview Study Special Study Questions		
225	10/FEB/2007	MOS Sleep Scale		
230	16/MAR/2007	Feeling Thermometer Form		
231	26/FEB/2008	Modified Mini Mental Status		
232	17/JUL/2008	Trail Making B Form		
233	25/JUL/2007	Clinical Center Miscellaneous Questions		
234	01/MAY/2007	The FHN Combination Physical Function Tests Form		
235	18/OCT/2007	BDI Suicide Question Response (Not Included)		
242	16/MAR/2007	Single Frequency Bioelectrical Impedance (BIA) Assessment		
250	10/FEB/2007	Dialysis Session Before MRI		
251	16/JAN/2009	MRI Mailing Form		
252A	03/SEP/2008	Central MRI Data Entry Results		
252B	03/SEP/2008	Central MRI Data Entry Wall Motion Score		
253	13/MAY/2008	Daily Trial Central Heart Rate Variability Mailing Form		
254	30/MAY/2006	Daily Trial Central Holter Reading Facility Data Transmission Form		
255	29/NOV/2006	U.S. Biological Specimen Repository Mailing Form		
256	29/NOV/2006	International Biological Specimen Repository Mailing Form		
257	10/FEB/2007	Canadian Repository Collection Date Form		
271	13/JUN/2008	Access Used for Chronic Hemodialysis		
273	09/OCT/2009	Monthly Kinetic Modeling Form		
274	07/FEB/2007	Retrospective Kinetic Modeling Data		
275	26/FEB/2008	Attendance at In-Center Dialysis Sessions Form		
276	06/AUG/2010	Access Repair Procedure		
277	06/AUG/2010	Permanent Access Failure or Access Removal Form		

### FHN DAILY TRIAL - FORMS TABLE OF CONTENTS

Form #	Version Date	Form Name
278	10/JAN/2006	New Access Placement
302	26/FEB/2008	Clinical Center Hospitalization Notification Form
303	26/FEB/2008	Clinical Center Detailed Hospitalization Form
305	26/FEB/2008	Clinical Center Death Notification Form
306	26/FEB/2008	Clinical Center Detailed Death Form
307	01/FEB/2007	Adverse Event Reporting Form
308	15/APR/2009	Serious Adverse Event Reporting Form
309	16//OCT/2008	Planned Therapy Deviation
310	16//OCT/2008	Detected Therapy Deviations
311	11/MAY/2006	Daily Trial Central Holter Reading Facility Clinical Alerts Form
312	11/MAY/2006	Central Cardiac MRI Clinical Alerts Form
313	01/SEP/2006	Post Randomization Patient Transplant or Peritoneal Dialysis Form
400	05/DEC/2008	Patient Transfer Form
401	10/FEB/2007	Re-enrollment of Previously Enrolled Patient
404	23/SEPT/2009	Canadian Centers Vital Status
405	07/MAY/2010	End of Trial Patient Status
406	26/FEB/2008	Documentation of Consent for Repositories Form
501	13/FEB/2009	Outcome Committee Hospitalization Review Form
503	13/FEB/2009	Outcome Committee Death Review Form
700	17/JUN/2008	Thirty Days After F12 Data

Center-Specific Forms		
Form #	Version Date	Form Name
600	26/FEB/2008	Study Staff Information Form
601	26/FEB/2008	Clinical Center Form
602	26/FEB/2008	Other Study Facilities Form (Lab, Holter)
603	26/FEB/2008	Dialysis Unit Details Form
604	26/FEB/2008	Cardiac MRI Facility
605	11/OCT/2005	Consortium Core
606	24/JAN/2008	Documentation of Local Laboratory Method, Instrument, and Normal Ranges

### FREQUENT HEMODIALYSIS NETWORK Daily Study Baseline Visit Schedule

#### Daily Study - Screening/Baseline Visit B-01

Form #	Form Name
110	Eligibility Confirmation (Screening) Form
202	Amputation Form
206	Residual Renal Function (24-Hour Urine)
207	Biochemistry Laboratory Data Form
271	Access Used for Chronic Hemodialysis (patient's current access)
273	Monthly Kinetic Modeling
274	Retrospective Kinetic Modeling Data

#### Daily Study - Visit Number: B-02

107	Direct Patient Contact Form (Accessed at QOL center's website)
108	Patient Future Linkage (USRDS) for U.S. only
273	Monthly Kinetic Modeling
274	Retrospective Kinetic Modeling Data

#### These Forms can be completed at either B-01 or B-02

These Forms can be completed at either B-01 or B-02			
104	Comorbidity and Medical History Form		
105	Baseline Demographics, Employment and Income Form		
111	Documentation of Six Consecutive Days Form		
113	Daily Trial Ready for Randomization Confirmation		
203	Monthly IV Iron Therapy		
204	Injectable Medications Form		
205	Medications and Supplements Form		
208	Participant In-Center Log Sheets (non-Dialytic Aspects of HD)		
220*	SF-36, v1		
221*	Beck Depression Inventory, v1		
222*	Cousineau Self-Perceived Burden Scale		
223*	Health Utilities Index 3 (HUI3)		
224*	Special Study Questions		
225*	MOS Sleep Disturbance Survey		
230	Feeling Thermometer		
231	Modified Mini Mental Status		
232	Trail Making B		
233	Clinical Center Miscellaneous Questions (Q4)		
234	Physical Function Tests		
242	Bioimpedance Form		
250	Dialysis Session Before MRI		
251	Cardiac MRI Mailing Form		
253	Heart Rate Variability Mailing Form		
255	U.S. Biological Specimen Repository Mailing Form		
257	Canadian Repository Collection Data		
406	Consent for Repository Form		

### FREQUENT HEMODIALYSIS NETWORK Daily Study Baseline Visit Schedule

Forms completed on an as need basis:

Form #	Form Name
112	Pre-Randomization Drop-Out Form
271	Access Used for Chronic Hemodialysis (if access changed during baseline)
276/277/278	Access Related Forms
401	Re-enrollment of Previously Excluded Patient

(report)	Patient Suitability for Randomization Report
(ICPOIL)	Tationt Duttability for Randomization Report

## FREQUENT HEMODIALYSIS NETWORK DAILY STUDY

### Follow-Up Visit Schedule

#### Daily Follow-up Visit Number: F-0 (Month 0) - Randomization Month

Form #	Form Name
207	Local Biochemistry Form
273	Monthly Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Sessions

Forms for Month 0-the month subject was randomized are not mandatory. However, they are strongly encouraged especially when the subject is randomized at the beginning of the month.

#### Daily Follow-up Visit Number: F-01 (Month 1)

Form #	Form Name	
203	Monthly IV Iron Therapy	
207	Local Biochemistry Form	
242	Bioimpedance Form (BIA) (completed approx. 1 month from randomization)	
273	Monthly Kinetic Modeling Form	
274	Retrospective Dialysis Run Sheet Data	
275	Attendance at In-Center Dialysis Sessions	

### Daily Follow-up Visit Number: F-02 (Month 2)

Form #	Form Name	
203	Monthly IV Iron Therapy	
207	Local Biochemistry Form	
273	Monthly Kinetic Modeling Form	
274	Retrospective Dialysis Run Sheet Data	
275	Attendance at In-Center Dialysis Sessions	

#### Daily Follow-up Visit Number: F-03 (Month 3)

Form #	Form Name	
203	Monthly IV Iron Therapy	
207	Local Biochemistry Form	
273	Kinetic Modeling Form	
274	Retrospective Dialysis Run Sheet Data	
275	Attendance at In-Center Dialysis Sessions	

Daily Follow-Up Visit Number: F-04 (Month 4)

Form #	Form Name
203	Monthly IV Iron Therapy
204	Injectable Medications Form
205	Medications and Supplements
206	Residual Renal Function (24-hour Urine)
207	Biochemistry Laboratory Data Form (plus Q8 & 9)
208	Participant In-Center Log Sheets (non-Dialytic Aspects of HD)
220*	SF-36 v1
221*	Beck Depression Inventory, v1
222*	Cousineau Self-Perceived Burden Scale
223*	Health Utilities Index-3 (HUI-3)
224*	Central Interview Special Study Questions (Q12 only)
225*	MOS Sleep Scale
230	Feeling Thermometer
231	Modified Mini Mental
232	Trailmaking Test B
234	Physical Function Tests (Guralnik Battery)
242	Bioimpedance (BIA)
255	U.S. Biological Specimen Repository Mailing Form
257	Canadian Repository Collection Date Form
273	Monthly Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Session

Daily Follow-up Visit Number: F-05 (Month 5)

Form #	Form Name
203	Monthly IV Iron Therapy
207	Local Biochemistry Form
273	Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Sessions

Daily Follow-up Visit Number: F-06 (Month 6)

Form #	Form Name
203	Monthly IV Iron Therapy
207	Local Biochemistry Form
273	Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Sessions

**Daily Follow-up Visit Number: F-07 (Month 7)** 

Form #	Form Name
203	Monthly IV Iron Therapy
207	Local Biochemistry Form
273	Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Sessions

Daily Follow-Up Visit Number: F-08 (Month 8)

Form #	Form Name
203	Monthly IV Iron Therapy
204	Injectable Medications Form
205	Medications and Supplements
207	Biochemistry Laboratory Data Form (plus Q8 & 9)
208	Participant In-Center Log Sheets (non-Dialytic Aspects of HD)
273	Kinetic Modeling
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Session

Daily Follow-Up Visit Number: F-09 (Month 9)

Form #	Form Name
203	Monthly IV Iron Therapy
207	Biochemistry Laboratory Data Form
273	Kinetic Modeling
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Session

Daily Follow-up Visit Number: F-10 (Month 10)

Form #	Form Name
203	Monthly IV Iron Therapy
207	Local Biochemistry Form
273	Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Sessions

Daily Follow-up Visit Number: F-11 (Month 11)

Form #	Form Name
203	Monthly IV Iron Therapy
207	Local Biochemistry Form
218	Final MRI Scheduled
273	Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Sessions

Daily Follow-Up Visit Number: F-12 (Month 12)

Form #	Form Name
203	Monthly IV Iron Therapy
204	Injectable Medications Form
205	Medications and Supplements
206	Residual Renal Function (24-hour Urine)
207	Biochemistry Laboratory Data Form (plus Q8 & 9)
208	Participant In Center Log Sheets (non-Dialytic Aspects of HD)
220*	SF-36 v1
221*	Beck Depression Inventory, v1
222*	Cousineau Self-Perceived Burden Scale
223*	Health Utilities Index-3 (HUI-3)
224*	Central Interview Special Study Questions (all questions)
225*	MOS Sleep Scale
230	Feeling Thermometer
231	Modified Mini Mental
232	Trail Making B
233	Clinical Center Miscellaneous Questions (Q7-11 only)
234	Physical Function Tests (Guralnik Battery)
242	Bioimpedance (BIA)
250	Dialysis Session Before MRI
251	Cardiac MRI Mailing Form
253	Heart Rate Variability Mailing Form
255	U.S. Biological Specimen Repository Mailing Form
257	Canadian Repository Collection Date Form
273	Monthly Kinetic Modeling Form
274	Retrospective Dialysis Run Sheet Data
275	Attendance at In-Center Dialysis Session

## FORMS COMPLETED DURING FOLLOW-UP, AS NEEDED Follow-Up Visit Number is the same number as the month of the event

Form #	Form Name
202	Amputation Form
256	International Biological Specimen Repository Mailing Form
271	Access Used for Chronic Hemodialysis
276	Access Repair Procedure
277	Permanent Access Failure or Access Removal
278	New Access Placement
302	Clinical Center Hospitalization Notification Form
303	Clinical Center Detailed Hospitalization
305	Clinical Center Death Notification Form

306

Clinical Center Detailed Death Form

Form #	Form Name
307	Adverse Reaction Reporting Form
308	Serious Adverse Reaction Reporting Form
309	Planned Therapy Deviation
310	Detected Therapy Deviations
313	Post Randomization Patient Transplant or Peritoneal Dialysis Form

400	Patient Transfer Form (complete and fax to DCC)
4()()	rauent transier form (combiete and tax to D.C.)
	1 with 11 miles 1 erin (compress with the 2 ere)

### Frequent Hemodialysis Network CO-MORBIDITY ASSESSMENT and MEDICAL HISTORY - FORM #104

Instructions: The patient's primary physician should provide a list of the patient's medical history which should include any current diagnoses and past pertinent medical history. In the event this list is not prepared, the FHN study physician will review the patient's medical records. Medical records might include, but are not limited to: hospital discharge summaries, consultation letters, MD progress notes, problem lists, medication records and imaging reports [i.e. x-ray, ultrasound, CT].

	1	. Partic	cipant 1	D#		2.	Alph Cod			3a.Visi Type		3b. Vis	sit Num	ber			4. Г	Date: (	dd/moi	n/yyyy			
5	Med	lical l	histo	rv re	viewe	ed fi	rom	what	nei				/			1	to		/				
٥.	5. Medical history reviewed from what period:/ to/																						
His	History of Any of the Following Medical Conditions: For Questions 6-33: 0=No, 1=Yes, except where indicated otherwise																						
6.					rction 6d, if					ry not	onl	ly by	EKC	3 ch	ang	es]?	(from	n Charl	son)				_
	b. M	lyoca	ırdial	infa	rctio	n in	past	year	?														_
	c. M	yoca	ırdial	infa	rction	n be	fore	the p	oast	year'	?					•••••							_
	d. A	trial	fibril	latio	n?											•••••							_
7.					rt Fa 8, if Y					m Charl	son)			•••••		•••••	•••••	•••••	•••••	•••••			_
	b. A	dmit	ted to	o hos	pital	onc	e in	the p	ast	year	for	CHF	/fluid	l ov	erlo	ad (	post	-ESI	RD)?	·			_
	c. A	dmit	ted to	o hos	pital	moi	e tha	an or	<u>ice</u>	in the	pa	st yea	ar for	· CF	IF/f	luid	ove	rloac	d (po	st-E	SRE	)?_	_
8.										asculit													_
9.	(Incli	ides i	nterm	ittent	claudi	icatio	on, hi	story	of by	ortic a ypass, urysm	gan	grene,											_
10.	Hist	ory c	of abo	lomi	nal a	ortic	ane	urys	m <u>r</u>	<u>epair</u>	or t	ypas	ss gra	ıftin	g?								_
	11. A previous history of amputation and location: question moved to Form 202-needed for KM reports																						
12.	Curr	ent i	nfect	ion,	ulcer	atio	n or	gang	ren	e of a	ı diş	git or	limb	?									

Revision of 01/MAY/2007	PID:	Date:	_/	/	Form #104 Page 2 of 3
For Questions 6-33: 0=No,	1=Yes, contin	ued:			
13. Cerebrovascular disease	? (from Charlson)				
(Includes history of CVA with	n minor or no resid	dua and transient ischen	nic attacks)	)	
14. Hemiplegia? (from Charlson) (Includes paraplegia/hemiple	gia resulting from	1 CVA or other condition	ı)		
15. Dementia? (from Charlson)					
16. Chronic pulmonary disea	ase? (from Charlson	)			
17. Rheumatologic condition	n?				
18. Ulcer disease? (from Charlso	n)				
19. Diabetes <u>without</u> end-org (For example, a diabetic whe					
20. Diabetes with end-organ	damage (retine	opathy, neuropathy	or kidney	failure)?	(from Charlson)
21. Hepatitis B surface antig	gen positive?				
22. Hepatitis C positive?					
23. Mild Liver Disease (with	nout portal hyp	ertension, includes of	chronic h	epatitis)?	(from Charlson)
24. Moderate or Severe Live	er Disease (sucl	h as portal hypertens	sion or ja	undice)? (f	rom Charlson)
25. Leukemia (acute or chro	nic)? (from Charlso	on)			
26. Lymphoma? (from Charlson)					
27. Multiple myeloma?					
28. Tumor without metastas	es (exclude if 5	years from diagnos	sis)? (from (	Charlson)	
29. Metastatic solid tumor?	(from Charlson)				
30. Gout?					
31. Human immunodeficien	cy virus (HIV)	?			
32. Uses nasal CPAP at nigh	nt?				
33. Legally blind?  Note: A patient is legation his or her better eye, even	ally blind if he or	r she has central visua	l acuity of	f 20/200 or	less in
34. History of cigarette smol 1=Never smoked, 2=Use					

Revisio	on of <mark>01/MAY/2007</mark>	PID:	Date:	/	/	Form #104 Page 3 of 3
0=	story of excess alcohol =No history =Yes, used to drink in		2=Yes, cur			<u> </u>
	story of illicit drug use =No history, 2=Yes, in					
	the past year, how ma =Not admitted, 1=Adm	-	•		ensive care	e unit?
	the past year, how man re unit (0=Not admitte	•	-			
01= 02= 03= 04= 05= 06= 07= obs 88=	mary reason kidneys f =Diabetic nephropathy =Hypertensive nephrose =Glomerulonephritis (i membranoproliferative gl failure with proteinuria, n =Polycystic kidney dis =Physical trauma =Analgesic nephropath =Obstructive uropathy tructive uropathy-congenit =Other (includes, but not vesico-ureteral reflux, ren =Unknown	sclerosis includes, but not lin omerulonephritis, rephritic syndrome sease  ny (includes, but not al, urinary tract sto limited to: heredit	mited to: membranous mesangial proliferative without biopsy, IGA no limited to: obstructive nes)	nephropat glomerulo ephropathy uropathy-a	thy, focal sconephritis, clay, other glora	lerosis, hronic renal nerulonephritis)
0=1 1=1 2=1 3=1 4=1 5=1	The patient currently or No, patient is currently No, possibility of trans No, patient refuses a trans No, patient was assess No, patient is expectin No, reason unknown of Yes	y being assessed splant was never cansplant or is n ed and told he/s g a living donor	I to be on the list r discussed with part ot interested in bein he was medically in	tient ng assess	ed for trar	_
41. Nu	mber of previous kidn	ey transplants?	(0 for none, 1 for o	ne, etc.)		
42. Ha	s the patient previously	y received perit	oneal dialysis? (0=1	No, 1=Y	es)	
43. Ge	nerally uses a wheelch	nair to move aro	und? (0=No, 1=Yes	s)		<u> </u>
200.	Date this form compl					
201.	Username of person r		leteness of this forr	n		
For Cl 202. 203.	linical Center Use On Username of person Date Entered: (dd/n		form:	——— ———		

# Frequent Hemodialysis Network BASELINE DEMOGRAPHICS, EMPLOYMENT, and INCOME - FORM #105

Instructions: This form is completed at baseline.							
1. Participant ID# 2. Alpha 3a.Visit	3b. Visit Number 4. Date: dd/mon/yyyy						
Code Type							
5. Marital status:	<del></del>						
1=Never been married	4=Separated						
2=Married	5=Divorced						
3=Common law marriage/partnered/ living together unmarried	6=Widowed						
ar i and collection distinguished							
6. Household Size: (For Questions 6 a-d: 0=No,	· · · · · · · · · · · · · · · · · · ·						
· · · · · · · · · · · · · · · · · · ·	rents):						
b. Lives alone:							
c. Lives with others (e.g., retirement communid. Homeless:							
u. Homeless							
7. Highest level of formal education achieved?							
1=Nursery school - 8th Grade	6=Associate degree						
2=9th-12th grade, no diploma	7=Bachelor's degree						
3=High school graduate	8=Refused						
4=Vocational/technical/business	9=Unknown						
5=Some college, no degree	10=Master's/Doctorate						
8. Has the patient ever been employed for pay? (0	=No, 1=Yes)						
9. What was the last year the patient was employe	A9						
(Enter current year if currently employed)	u:						
( is a substitute of the subst							
10. Current work status:							
01=Student, not employed	07=Not working, seeking work, not disabled						
02=Student, employed	08=Employed full-time						
03=Homemaker	09=Employed part-time 10=Retired						
04=Not working, not seeking work, disabled 05=Not working, not seeking work, not disabled	10=Retired 06=Not working, seeking work, disabled						
03-110t working, not seeking work, not disabled	99=Unknown						

Revision	on of <mark>12/MAR/2006</mark> II	)	Date	_//		Form #105 Page 2 of 2
1=- 2=- 3=- 4=-	rrent household gross and <\$10,000 \$10,000-\$14,999 \$15,000-\$19,999 \$20,000-\$29,999 \$30,000-\$39,000	nual income (in your 6=\$40,000-\$49 7=\$50,000-\$99 8=>\$100,000 9=Unknown o	9,000 9,000	try's curren	cy)?	
12. Co Co		ealth insurance does insurance plans the p th Maintenance Org	the patien patient liste anization)'	t have? ed ?	A Have?	B HMO?
a. b. c. d. e. f. g. h.	Medicare:	cal Assistance:	Medicare olan:odialysis?	supplemen	partment.)	
200. D	ate this form completed (	(dd/mon/yyyy)		······ <u> </u>	_//	
201. U	sername of person review	ving completeness of	f this form			
For C	linical Center Use Only	:				
202.	Username of person en	tering this form: _				
203.	Date Entered: (dd/mor	n/yyyy)/	_/			

### Frequent Hemodialysis Network PATIENT CONTACT - FORM #107

This form is completed as soon as the patient signs the consent form for participation in the FHN Trials. The DCC does **not** have access to this form. You will need to login to the QOL website at <a href="https://surveyweb2.ucsur.pitt.edu/DialysisQOL/index.php">https://surveyweb2.ucsur.pitt.edu/DialysisQOL/index.php</a>. Your center's login information can be obtained by writing to survey@pitt.edu.

		1. Participant ID #  2. Alpha Code  3. Date dd/mon/yyyy
4.		ent's Full Name: Last Name:
	b.	First Name:
	c.	Middle Initial:
5.	Tria	ıl:
	a.	Daily Study
	b.	Nocturnal Study
5.	Visi	t:
	a.	Baseline
	b.	First Follow-up (F4 or F5)
	c.	Final Follow-up (F12 or F14)
7.	Stati	us:
	a.	Baseline
	b.	Still in Trial
	c.	Withdrew from Trial, agreed to be contacted for QOL interview
	d.	Withdrew from Trial, do not contact for QOL interview
	e.	Deceased
3.	Age	:
	a.	Adult 18 years old and over
	b.	17 years old and younger
9.	Pref	erred Interview Language:
	a.	English
	b.	Spanish

10.	Best times to Call:
	Phone 1:
	Time 1
	Phone 2
	Time 2
	Phone 3
	Time 3
11.	Emergency contacts:
	Name 1
	Phone 1
	Name 2
	Phone 2
	Name 3
	Phone 3

### Frequent Hemodialysis Network PATIENT FUTURE LINKAGE - FORM #108

This form is for U.S. patients only. This form is completed as soon as the patient signs the consent form for participation in the FHN Trial. It is ideal for the subject to provide his/her social security number (SSN). However, if the subject refuses to provide SSN but is willing to submit other key data items, then complete the appropriate data items below. The DCC does **not** have access to this form.

This	Director of Information Systems USRDS 914 South 8th Street, Suite D-206 Minneapolis, MN 55404
	1. Participant ID # 2. Alpha Code 3. Date dd/mon/yyyy
4.	Did patient agree to provide this information for future linkage with USRDS?
Prin	t the following:
5.	Clinical Center name:
6.	Patient name: a) *Last name:
	b) *First name:
	c) Middle initial:
7.	*Date of Birth: (dd/mon/yyyy)
8.	*Gender: (1=Male, 2=Female)
	ted States:  a. Social Security Number: (numeric)
	b. *Month and year patient was first treated for ESRD (with hemodialysis,
	peritoneal dialysis, or kidney transplantation) (mon/yyyy)
	(1voie. This date should be the same date that appears on Form 100/110, Q12a)
10.	
	(Note: Do not complete item 10 if patient refused to provide SSN.)

### Frequent Hemodialysis Network DAILY TRIAL ELIGIBILITY CONFIRMATION FORM - FORM #110

**Instructions:** This form is to be completed and entered into the FHN database. The first 4 digits in the patient id need to be the number assigned to the dialysis unit where this patient is being enrolled. The last two digits will be assigned by the study coordinator. The alpha code (item 2) will be generated automatically by the database when the form is key entered and saved. You will need to record this alpha code as it will be used in combination with the patient's ID number throughout the trial.

	1. Participant ID # 2. Alpha Code	3a.Visit Type	3b. Visit Number	4. Date: dd/mon/yyyy
5.	Date trial consent form signed (dd/n			////
Ms	andatory Section (Questions 6-19):	Complete f	or all consenti	ng natients
	•	complete i	or an consenu	ng patients
	mographics Date of birth (dd/mon/yyyy)			///
	Note: Age less than 13 is an exclusion.			
7.	Gender? (1=Male, 2=Female)			
8.	a. Race			
	1=Native American, Aboriginal C	Canadian	4=Black, A	frican American, <mark>African</mark>
	or Alaskan Native, First Nation Aboriginal Australian	on,	5=White <mark>/C</mark>	aucasian an one race (multiracial)
	2=Asian			n or not reported
	3=Native Hawaiian or Other Paci	fic Islander	•	
	b. Hispanic or Latino ethnicity? (0=)	No, 1=Yes,	, 9=Unknown o	r not reported)
Co	mmunication			
9.		_	•	· · · · · · · · · · · · · · · · · · ·
	b. Can the patient speak English? (0	)=No, 1=Yo	es)	<u> </u>
	c. Can the patient read English? (0=	No, 1=Yes)	)	
	d. Can the patient speak Spanish? (0	⊨No, 1=Y€	es)	
	e. Can the patient read Spanish? (0=	No, 1=Yes	)	<u> </u>
10.	. Can the patient him/herself commun	icate over	a standard telep	hone? (0=No, 1=Yes)
$H_{o}$	ight and Weight			
	. a. Lowest weight recently achieved	l post dialy	sis (kg)	<u> </u>
	b. Most recent height (measure sup	ine length	in those unable	to stand) (cm)
	For bilateral amputees, use historic he Be sure to note on the <mark>Amputation For</mark> t	ight <mark>m #202</mark> , if the	patient is a bilate	ral amputee.

Rev	ision of <mark>26/FEB/2008</mark>	PID:	I	Date:	//		Form #110 Page 2 of 4
	ney Failure and Dialys a. Month and year pa peritoneal dialysis,	tient was <u>first</u>					
	b. Has patient been of (0=No, 1=Yes) (Note: Incident patient						
13.	Patient currently requirements hemodialysis? (0=No (Note: The need for ex.)	, 1=Yes, occas	sionally, 2=Y	es, always	s)		
14.	Currently using a non- (Note: Use of a non-perm			odialysis?	(0=No, 1	=Yes)	
15.	If randomized to rece to dialysis unit six tin (This would include ab	nes per week u	p to 2.75 hou	ırs per trea	ntment? (0	0 = No, 1 = Yes	
16.	On the basis of the ph his or her hemodialys 9=Unknown, patient	is regimen? (0	=No, non-ad	herent, 1=	Yes, adhe	erent,	
17.	Able to have a cardia (Note: Inability to have 1=Yes	_	_	•			
	2=No, reason: patient 3=No, reason: patient 4=No, reason: patient (Metallic objects in 5=No, reason: patient 6=No, reason: patient	has a pacema has another maclude certain is claustropho	ker or implant netallic object mechanical hobic even if re	nted defibre t in body deart value eceives m	illator or or is scheons, brain and ld sedativ	is scheduled f duled for such neurysm clips re.	placement.
	7=No, reason: patient patient's height and ma	is too large to					
18.	How many <b>minutes</b> of residence to the d if randomized to the	ialysis unit wh	nere he/she w	ould recei	ve daily h	emodialysis	
19.	Would the patient or (i.e., gas, parking, fa for daily hemodialys	ares for public	transportation	n, other) t	raveling to	the dialysis	
(0=1)	lusion Criteria: No, 1=Yes) <i>Note: Any</i> may skip to Question						
20.	Life expectancy less t	than six month	s?				<u> </u>

Rev	rision of <mark>26/FEB/2008</mark>	PID:	Date	:/	/	Form #110 Page 3 of 4		
	lusion criteria, continu No, 1=Yes) Note: Any		:Yes" is a reaso	n for exc	lusion.			
21.	. Has a medical history that might limit his/her ability to undergo the study treatments for 12 months? Examples include but are not limited to: currently receiving chemo or radiotherapy for a malignant neoplastic disease other than localized non-melanoma skin cancer, active systemic infection, AIDS (but not HIV)?							
22.	Currently on short-da	ily dialysis?						
23.	Currently on nocturna	al dialysis?						
24.	Less than 3 months si in allograft failure							
25.	5. Currently requires hemodialysis more than 3 times per week for a medical indication other than ultrafiltration (such as, but not limited to: systemic oxalosis, or requiring total parenteral nutrition.)?							
26.	Native kidney function	on expected to re	cover without i	need for l	ong-term di	alysis?		
27.	Currently admitted to	an acute or chro	onic care hospit	al?		······ <u> </u>		
28.	Currently uses one or	more investigat	ional drugs?					
29.	Currently participatin or interferes with ther 0=Not currently in an 1=Currently in anothe or outcomes 2=Currently in anothe FHN therapies or o	rapies or measure other trial er trial that contre er trial but the tri	ed outcomes in radicts or interferial does not con	this trial t	? FHN therap	pies vith		
30.	Currently pregnant? (	8=Not applicabl	e)			······ <u> </u>		
31.	Actively planning to l	become pregnan	t in the next ye	ar? (8=No	ot applicabl	e)		
32.	Has contraindications or heparin-induced th	-		••••••				
33.	Unable or unwilling to (including reasons such		• •	•		<u> </u>		
34.	Based on the clinical function estimated to							

Revision of 26/FEB/2008 PID:\_\_\_\_\_ Date:\_\_\_/\_\_\_\_\_

Revision of 26/FEB/2	008 PID:	- — — -	_ Date://_	Form #110 Page 4 of 4			
Within the next year:	(0=No, 1=Yes)						
35. Scheduled for a l	iving donor kidne	ey transpla	nt?				
36. Scheduled to star	t peritoneal dialys	sis?					
37. Scheduled to star	t home hemodialy	ysis?					
38. Plans to relocate	to another hemod	lialysis cen	ter not participating in th	nis study?			
(Note: Frequent 1	39. Expects to be geographically unavailable for more than 2 consecutive weeks?						
for more than 4 v	veeks total (exclud	des unavai	n a unit participating in tability due to scheduled				
	lomized based on form if patient is ine		n this form? (0=No, 1=Y	es)			
recommended that the patients at this location used by a number of speople with answering	42. <b>Emergency Contact Information</b> : You must provide three names and phone numbers. It is recommended that the persons listed on this contact form be physicians who have access to the patients at this location and are aware of emergency mental health resources. Information will be used by a number of sources, especially the Central Quality of Life Interviewing Center. Choose people with answering services or pagers so they will be available in the evening, if necessary. One emergency contact should be the study PI.						
(a) Last Name	(b) First Name	(c) Role	(d) Phone Number (xxx-xxx-xxxx)	(e) E-Mail Address			
1.			(АЛА-АЛА-АЛАА)				
2.							
3.							
For all subjects: (Use of Central Lab needed only if pt's blood work will not be analyzed at the same lab during both baseline and follow-up)  43. Does this pt's blood work need to be shipped to the FHN central laboratory? (0=No, 1=Yes)							
200. Date this form completed (dd/mon/yyyy)							
201. Username of person reviewing completeness of this form							
For Clinical Center Use Only:  202. Username of person entering this form:							
203. Date Entered: (dd/mon/yyyy)//							

# Frequent Hemodialysis Network DAILY STUDY DOCUMENTATION OF SIX CONSECUTIVE DAYS - FORM #111

This form is completed by study staff to determine if a consented patient demonstrates ability to attend the daily dialysis treatment. This form is completed once during baseline. The patient should use the same transportation that will be used during the follow-up period and must be done six days in a row.

	1. Participant ID # 2. Alpha Code			
3.	Record six <u>consecutive</u> visit dates within one week (three of the	ese dates wi	ll be dialysis	s days)
	a. Date of visit #1: (dd/mon/yyyy)	/	/	
	b. Date of visit #2: (dd/mon/yyyy)	/	/	
	c. Date of visit #3: (dd/mon/yyyy)	/	/	
	d. Date of visit #4: (dd/mon/yyyy)	/	/	
	e. Date of visit #5: (dd/mon/yyyy)	/	/	
	f. Date of visit #6: (dd/mon/yyyy)	/	/	
<ul><li>4.</li><li>5.</li></ul>	Did the patient demonstrate the ability to come into the unit: (0) In the opinion of the Study Staff, is this patient capable of comidialysis unit six (6) days per week for the duration of the trial?	ing into the	participating	<u> </u>
201. <b>For</b>	Date this form completed (dd/mon/yyyy)  Username of person reviewing completeness of this form  Clinical Center Use Only:			
202.	Username of person entering this form:	_		
203.	Date Entered: (dd/mon/yyyy)////			

### Frequent Hemodialysis Network DAILY TRIAL PRE-RANDOMIZATION DROPOUT - FORM #112

This form is completed when it is determined that a patient who appeared to be eligible for the *daily* trial enrolled in baseline and was subsequently found to be ineligible. So this patient consented but was not randomized.

	1. Participant ID #	2. Alpha Code	3. Pre-Randomization Dropout Date dd/mon/yyy
--	---------------------	---------------	--

#### **Primary - 1st Tier Reasons:**

- 00=Patient died.
- 01=Patient received a kidney transplant
- 02=Permanent access failed and was not replaced during baseline period, i.e., patient continues to use a non-tunneled catheter for HD
- 03=Unable to achieve a mean eKt/V of > 1.0 on at least two baseline sessions
- 04=Baseline residual renal urea clearance >3 mL/min per 35L
- 05=For transportation or associated costs reasons, was unable or unwilling to come to the dialysis unit 6 days per week.
- 06=For reasons *other than* transportation, was unable or unwilling to come to the dialysis unit 6 days per week.
- 07=Based on physician or health care provider judgment, patient would not be adherent to daily hemodialysis
- 08=Unable to have a baseline cardiac MRI
- 09=Unexpected finding was identified on cardiac MRI (such as a tumor), which limits the patient's ability to take trial treatments for the 12 month duration of the study
- 10=Unable to have baseline quality of life assessment
- 11=Lowest weight achieved post-dialysis <30kg
- 12=Admitted to an acute or chronic care hospital with no planned discharge in near future
- 16=Family does not support patient joining the study
- 17=Dialyzing 6x per week conflicts with the patient's personal schedule
- 18=The unit where the patient would be dialyzed has no room for a patient at this time

#### Secondary - Tier 2 Reasons

- 30=Currently requires HD more than 3 times per week for a medical indication other than ultrafiltration (such as, but not limited to: systemic oxalosis, or required total parenteral nutrition.)
- 31=Native kidney function recovered or expected to recover without need for long-term dialysis
- 32=Life expectancy is less than six months
- 33=Has a medical history that limits the patient's ability to take trial treatments for the 12 month duration of the study. Examples include but are not limited to: currently receiving chemo or radiotherapy for a malignant neoplastic disease other than localized non-melanoma skin cancer, active systemic infection, AIDS (but not HIV)

Revision of 16/MAY/2007	ID	Date	/	/	Form #112 Page 2 of 2
34=Less than 3 months since (such as, failed trans) 35=Currently uses one or mo 36=Currently participates in a or measured outcomes in 37=Patient unable to verbally 38=Patient's age less than 13 39=Currently pregnant 40=Actively planning to become	plant, short-dare investigation another clinical this trial communicate years  ome pregnant ineparin, include	aily HD, nocturnal Fonal drugs al trial that contradic e in either English o in the next 12 montl ding allergy or hepa	ID, perit cts or int r Spanis hs rin-indu	toneal dia terferes w h	replacement modality alysis) with therapies
42=Unable or unwilling to fo such as mental incomper 43=Scheduled for living done 44=Currently on or scheduled 45=Currently on short-daily of 46=Currently on nocturnal di 47=Scheduled to start home if 48=Plans to relocate to anoth 49=Expects to be geographic weeks in the next 12 mo 50=Anticipates not having hi 51=More than 12 weeks pass 52=Logistics reasons 96=DCC use only: Study site 97=Patient was lost to follow 98=Patient preference	tence) or kidney trans I to go on peri lialysis alysis nemodialysis er HD center ally unavailab nths s/her HD in a ed since basel	splant within next ye itoneal dialysis not participating in to ble at the dialysis unit	ear this stud it for >2	ly consecut	tive next 12 months
If you have a reason for code.	er drop-out no	ot found on this list	ing, pled	ase conta	ect the DCC for a new
5. Secondary Reason for F (Use codes from Q4)	re-Randomiz	ation Dropout			
6. If Q4 or Q5 is "52=Logis	stics reasons",	, describe what happ	pened.		
200. Date this form completed (201. Username of person review					
For Clinical Center Use Only: 202. Username of person enter 203. Date Entered: (dd/mon/	ring this form	n:		<u>-</u>	

# Frequent Hemodialysis Network DAILY STUDY - READY FOR RANDOMIZATION CONFIRMATION FORM - #113

	structions: This form should be completed in the two weeks prior to the date of a patient's adomization into the Daily Study.
	1. Participant ID#  2. Alpha 3a.Visit 3b. Visit Number Code Type
5.	Does the patient's planned dialysis unit have an open slot available so this patient can dialyze six times a week? (0=No, 1=Yes)
(Th	ms 6 through 11 document the discussion between an FHN Study staff member and the patient. ne staff member may be from the clinical center or from the Core. It is strongly recommended that is be a different person than the person who has interacted with this patient the most.)
6.	Is the dialysis unit's open time slot acceptable to the patient? (0=No, 1=Yes)
7.	a. Does the patient have a plan for reliable and convenient transportation to the patient's planned dialysis unit for dialysis sessions six times a week? (0=No, 1=Yes) (Please keep a note in the local file for this patient regarding the patient's plan for transportation.)
	b. Now that the patient has experienced the baseline MRI, is the patient still willing to do an F12 MRI?
8.	Does the patient still want to be in the study? (0=No, 1=Yes)
9.	Spouse/partner/caregiver status:
10.	FHN username of the staff member who talked with the patient:
11.	Date of discussion: (dd/mon/yyyy)
12.	Did the team of staff who will be following the patient meet to discuss whether they feel the patient should be randomized? (0=No, 1= Yes, complete 13)
13.	Date of team meeting: (dd/mon/yyyy)
200	). Date this form completed (dd/mon/yyyy)
201	1. Username of person reviewing completeness of this form
For	r Clinical Center Use Only:
202	2. Username of person entering this form:
203	3. Date Entered: (dd/mon/yyyy)///

## Frequent Hemodialysis Network AMPUTATION FORM #202

<u>Baseline</u>: This form is **required by all study participants once during baseline**. It is needed for the kinetic modelling reporting program and must be entered at baseline before a KM report can be generated.

<u>Follow-up:</u> Complete this form during follow-up every time it is identified that a patient has undergone an amputation.
1. Participant ID# 2. Alpha 3a.Visit 3b. Visit Number 4. Visit Date: dd/mon/yyyy
Code Type  5. Location of amputation:
a. Left leg (0=none, 1=toe(s), 2=below ankle, 3=below knee, 4=above knee)
b. Right leg (0=none, 1=toe(s), 2=below ankle, 3=below knee, 4=above knee)
c. Left arm (0=none, 1=finger(s), 2=below wrist, 3=below elbow, 4=above elbow)
d. Right arm (0=none, 1=finger(s), 2=below wrist, 3=below elbow, 4=above elbow)
If amputation occurred during follow-up, please be sure to complete the hospitalization forms 302 and 303.
200. Date this form completed (dd/mon/yyyy)
201. Username of person reviewing completeness of this form
For Clinical Center Use Only:
202. Username of person entering this form:
203. Date Entered: (dd/mon/yyyy)////

## Frequent Hemodialysis Network MONTHLY IV IRON THERAPY FORM #203

#### Instructions:

Review patient medication records for **monthly** IV Iron use. <u>Record only intravenous (IV) iron on this form.</u>

For EPO and other injectable medications, use Form 204.

For all other medications, over-the-counter meds, and supplements, use Form 205. Oral (po) iron should also be recorded on Form 205.

	hedule for form compleseline and monthly duri	•	and nocturnal st	tudies, this form is	completed at
	1. Participant ID#	1	Visit 3b. Visit Numb	per 4. Visit D	ate: dd/mon/yyyy
5.	Has the participant use 0=No, skip to quest 1=Yes, complete T	tion 200.			
	IV Iron Medication Name	Medication Code*	Route of Admini- stration 0=Not IV 1=IV	Number of times given during month being reported	TOTAL milligrams given during month being reported
	6.		_		
	*The medicatio	n code is electronically f	found on the code lis	st accessed during data	entry.
20	0. Date this form comp	leted (dd/mon/yyyy)		/	_/
20	1. Username of person	reviewing completer	ness of this form	······ <u> </u>	
Fo	or Clinical Center Use	Only:			
20	2. Username of person	n entering this form	n:	. ——	
20	3. Date entered: (dd/	mon/yyyy)/_	/	_ <del></del>	

## Frequent Hemodialysis Network INJECTABLE MEDICATIONS (other than IV Iron) - FORM #204

**Instructions**: Record only the IV medications listed below. *Use Form #203 to record IV iron use.* 

**Schedule:** Daily: Baseline, F-4, F-8 and F-12.

Nocturnal v3.0: Baseline, F-4, F-8, and F-12. (Nocturnal v2.1: Baseline, F-5, F-9, and

*F-14)*.

On this form, record only the following medications:

IV or SC erythropoietin (Procrit, Epogen)

IV or SC darbepoetin (Aranesp)

IV vitamin D/vitamin D analogues:

IV calcitriol (Calcijex)

IV alfacalcidol (One-Alpha)

IV doxercalciferol (Hectorol)

IV paricalcitol (Zemplar)

*Use Form #205 to record all other medications, over-the-counter medications, and supplements.* 

	1. Participant ID #	2. Alpha Code	3a.Visit Type	3b. Visit Number	4. Date: dd/mon/yyyy	
5.	Has the participant use the last 4 weeks? 0=No, skip to quest 1=Yes, continue with	tion 200			_	
6.	a. Has the participant the last 4 weeks? 0=No, skip to Q7a 1=Yes, continue wi		hropoietin (l	EPO, Procrit, or I	Epogen) during	

ERYTHROPOIETIN (PROCRIT, EPOGEN) USE DURING THE LAST 4 WEEKS:

Medication Name	Medication Code**	Route of administration  1=IV 2=SC	How many times was erythropoietin given during the last ONE WEEK?	What was the TOTAL number of units given during the last ONE WEEK?	What was the TOTAL number of units given during the last FOUR WEEKS?
6b.					
6c.					

<sup>\*\*</sup>The medication code is electronically found on the code list accessed during data entry.

Rev	rision of <mark>10/FEB/2007</mark> I	D	Date	_//	
					Page 2 of 2
7.	a. Has the participant used (0=No, skip to Q8a, 1=	•	- ·	during the last	4 weeks?
DA	RBEPOETIN (ARANES	P) USE DURIN	NG THE LA	ST 4 WEEKS:	
	Medication Name	Medication Code**	Route of administration  1=IV 2=SC	How many tin was Aranes given during last FOUR WEEKS?	the given during
	7b.				
IV	week? (0=No, 1=Yes, omonth but not within the These include: IV calci IV alfacalcidol (1-Alph IV doxercalciferol (Heat IV paricalcitol (Zempla VITAMIN D/VITAMIN	ne last week.) triol (Calcijex, F a) ctorol) ar)	Rocaltrol)		
	Medication Nam	Medi		How many times was the medication given during the last ONE WEEK?	What was the TOTAL number of micrograms given during the last ONE WEEK?
	8b.				
	8c.				
200	. Date this form completed	d (dd/mon/yyyy)			/ /
	. Username of person revi				
For	Clinical Center Use Onl	y:			
202	. Username of person en	tering this form	n:		
203					

<sup>\*\*</sup>The medication code is electronically found on the code list accessed during data entry.

### Frequent Hemodialysis Network MEDICATIONS AND SUPPLEMENTS FORM #205

For all meds <u>other than</u> Erythropoietin, Darbopoetin, IV Iron, and IV Vitamin D Analogues

**Instructions:** Record all prescription medications, over-the-counter (OTC) medications, and supplements on this form (include prn medications). *Use Form 203 to record IV Iron use. Use Form 204 to record EPO, Procrit, Epogen, Aranesp, and IV vitamin D analogues.* 

Schedule: Daily: Baseline, F-4, F-8 and F-12.
Nocturnal v3.0: Baseline, F-4, F-8, and F-12. (*Nocturnal v2.1: Baseline, F-5, F-9, and F-14*).

On this form, please be especially sure to capture:

- oral vitamin D and calcimimetic use
- blood pressure medications

	may write additional r as many medications		n a separat	e attached page. 7	The computer w	ill allow you	to
	1. Participant ID#	2. Alpha	3a.Visit	3b. Visit Number	4. Date: dd/n	200/22222	
	1.1 articipant 1D #	Code	Type	30. VISIT NUMBER	4. Date. dd/II	юп/уууу	
5. <i>EPO</i>	Is the participant pre D/Epogen, Procrit, Aranesp, IV or supplements?	Iron, IV vitam	in D anale	-	ounter meds,	er than 	
6.	Is the participant pre (0=No, skip to O11,	•	-				

Oral Phosphate Binder Name (Enter generic name or U.S. or Canadian trade name)	Medication Code*	Total Prescribed <u>Daily</u> Dose (in milligrams)
7.		
8.		
9.		
10.		

PARTICIPANT'S MEDICATIONS: continued on the following page

<sup>\*</sup>The medication code is electronically found on the code list accessed during data entry.

#### PARTICIPANT'S MEDICATIONS: continued,

You may write additional medications on a separate attached page. The computer will allow you to enter as many medications as needed. Include medications taken on a prn basis.

(Enter generic name or U.S. or Canad	ian Medication Code*
trade name)	
11.	
12.	
13.	
14.	
15.	
16.	
17.	
18.	
19.	
20.	
21.	
22.	
23.	
24.	
25.	
26.	
27.	
28.	
29.	
30.	

<sup>\*</sup>The medication code is electronically found on the code list accessed during data entry.

### Frequent Hemodialysis Network RESIDUAL RENAL FUNCTION - FORM #206

**Instructions**: This form is to be completed with the results received from your local laboratory.

<b>Schedule:</b> Daily: Baseline and at months 4 and 12 Nocturnal v3.0: Baseline, F-4 and F-12. ( <i>Nocturnal v2.1: Baseline, F-5 and F-14</i> ).										
Urine collections should be obtained over an 18 hour period for the daily study and a 24 hour for the nocturnal study ending with a kinetic modeling session.	period									
1. Participant ID# 2. Alpha 3a.Visit 3b. Visit Number 4. Date of Visit: dd/mon/y Code Type	уууу									
5. Does the patient currently produce urine? (0=No, 1=Yes)										
6. a. Start date of urine collection: (dd/mon/yyyy)										
b. Start time of urine collection: (24-hour clock):_										
7. a. <u>End</u> date of urine collection: (dd/mon/yyyy)										
b. End time of urine collection: (24-hour clock):: _										
8. Volume of urine collection: (ml)										
9. a. <u>Start</u> date of preceding dialysis: (dd/mon/yyyy)										
b. Start time of preceding dialysis (24-hour clock)::_										
10. a. End date of preceding dialysis: (dd/mon/yyyy)//										
b. End time of preceding dialysis (24-hour clock)::_										
Note: This day <u>must</u> be a kinetic modeling day (Form 273, item 4)										
11. a. Start date of subsequent dialysis: (dd/mon/yyyy)										
b. Start time of subsequent dialysis (24-hour clock)										

Revi		Form #206 Page 2 of 2
Resu	ults:	
13.	Urine urea nitrogen (mg/dL)  or in SI units (mmol/dl)	
	or in SI units (mmol/day)	
	b. Lab where test was performed: (use lab number identified in Form 602)	····
14.	Urine creatinine (mg/dL)	
	or in SI units (mmol/ <mark>dl)</mark>	
	or in SI units (mmol/day)	
	b. Lab where test was performed: (use lab number identified in Form 602)	···· <u> </u>
15.	a. Urine phosphorus (mg/dL) (database will calculate 24 hour result)	·
	or in SI units (mmol/dl)	
	or in SI units (mmol/ <mark>day</mark> )	
	b. Lab where test was performed: (use lab number identified in Form 602)	
200.	Date this form completed (dd/mon/yyyy)	
201.	Username of person reviewing completeness of this form	
For 202.	Clinical Center Use Only: Username of person entering this form:	
203.	Date Entered: (dd/mon/yyyy)///	

### Frequent Hemodialysis Network BIOCHEMISTRY LABORATORY DATA FORM - FORM #207

This form is completed with the results received from your local laboratory. Use the most recent blood test value available. Follow-up values must be <u>after</u> randomization.

	1. F	Participant ID#  2. Alpha Code  Code
Loc	al Seri	um Values Baseline and once per month
5.	a.	Pre-dialysis Bicarbonate (HCO <sub>3</sub> ) or Total CO <sub>2</sub> (mmol/L=mEqL)
	b.	Date sample drawn (dd/mon/yyyy)
	c.	Lab where test was performed: (use lab number identified in Form 602)
6.	a.	Pre-dialysis Sodium (mmol/L=mEqL)
	b.	Date sample drawn (dd/mon/yyyy)
	c.	Lab where test was performed: (use lab number identified in Form 602)
7		
7.	a.	Pre-dialysis Potassium (mmol/L=mEqL)
	b.	Date sample drawn (dd/mon/yyyy)
	c.	Lab where test was performed: (use lab number identified in Form 602)
8.	a.	Pre-dialysis Calcium (mg/dL)
		or in SI units (mmol/L)
	b.	Date sample drawn (dd/mon/yyyy)
	c.	Lab where test was performed: (use lab number identified in Form 602)
9.	a.	Pre-dialysis Hemoglobin (g/dL)or in SI units (g/L)
	b.	Date sample drawn (dd/mon/yyyy)
	c.	Lab where test was performed: (use lab number identified in Form 602)

Revi	Sion of 26/FEB/2008 PID: Date:// Form #207 Page 2 of 2
ever	al Iron and PTH Profile  Baseline (i.e., up to 4 months before randomization) and once ry 3-4 months post randomization. [For retrospective baseline values for Q10-12, you will need ax this completed form to the DCC after all other baseline forms have been entered.]
clos	exercises centers obtaining these values more often than every 3 months, please enter value obtained est to: F4, F8, and F12 for daily study and nocturnal study v3.0. <i>In nocturnal study v2.1, values ald be obtained closest to F5, F9, and F14</i> ).
	Report transferrin saturation as a percent (%) $\underline{OR}$ in SI units $\underline{OR}$ iron and TIBC.
10.	a. Pre-dialysis Transferrin saturation (%)
	or in SI units (mmol/L)
	b. Date sample drawn (dd/mon/yyyy)
	c. Lab where test was performed: (use lab number identified in Form 602)
	If you completed item 10a - do not complete items 10d & e. The database will not allow the form to be saved.
	d. Pre-dialysis iron (ug/dL)
	e. Total iron binding capacity (ug/dL)
11	b. Pre-dialysis Ferritin (ng/mL = $\mu$ g/L )
	or in SI units (pmol/L)
	b. Date sample drawn (dd/mon/yyyy)
	c. Lab where test was performed: (use lab number identified in Form 602)
12.	a. Pre-dialysis Parathyroid hormone (pg/mL = ng/L)
	or in SI units (pmol/L)
	b. Method used to measure PTH (1=Intact, 2=Bi-PTH)
	c. Date sample drawn (dd/mon/yyyy)
	d. Lab where test was performed. (use lab humber identified in Form 602)
200.	Date this form completed (dd/mon/yyyy)
201.	Username of person reviewing completeness of this form
For	Clinical Center Use Only:
202.	Username of person entering this form:

203.

### **Frequent Hemodialysis Network** PARTICIPANT IN-CENTER LOG SHEET - FORM #208

Study Coordinator Instructions: This form is filled out by all participants dialyzing in center (conventional, daily, and any participants who failed home nocturnal). The study coordinator should explain to the participant how to fill out the following log sheet for a 1week period. For participants receiving conventional dialysis, fill out sessions 1, 2, and 3.

**Schedule:** Daily: Baseline, F-4, F-8 and F-12.

Nocturnal v3.0: Baseline, F-4, F-8, and F-12. (Nocturnal v2.1: Baseline, F-5, F-9, and F-14).

For Daily participants, fill out sessions 1 - 6. Please LEAVE THE FORM ON THE FRONT OF THE CHART so that the participant can be reminded to fill it out at each dialysis session during the week. The Study Coordinator should pick up the form at the end of the week or beginning of the next week.

							_		_			_						
1. P	articipa	ant ID	#		2. A	Alpha	-	3a.Visit		3b. Vis	it Num	ber	4. Dat	e: dd.	/mon/y	уууу		
					Cod	e		Tvpe										

Dialysis Session	Date of	Travel Time to and from	Waiting time before	Waiting time before leaving	<b>Dietician Visits</b> <ul><li>number of</li></ul>	Physiotherapist Visits - number of				
Number	Session	dialysis unit	dialysis	dialysis unit	minutes (put 0 if	minutes (put 0 if				
Number	(dd/mon/yyyy)	(minutes)	(minutes)	(minutes)	did not talk to	did not talk to				
	(dd/mon/yyyy)	(minutes)	(IIIIIutes)	(minutes)	dietician)	physiotherapist)				
1					,					
2										
3										
4										
5										
6										
TOTAL N	MINUTES*:									
Number of times participant communicated with health care professional:										

The computer will calculate the numbers in the grey area.

Continued on page 2

Revision of 10/FEB/2007	ID Date/	Form #208 Page 2 of 2

Dialysis Session Number	Date of Session (dd/mon/yyyy)	Social Worker Visits- number of minutes (put 0 if did not talk to social worker)	Nurse Practitioner /Physician Assistant Visits- number of minutes (put 0 if did not talk to nurse practitioner)	Physician Visits - number of minutes (put 0 if did not talk to physician)
1				
2				
3				
4				
5				
6				
TOTAL MINUTES*:				
Number of times participant communicated with health care professional:				

For Study Coordinator Completion:

Total number of dialysis sessions for which this form was completed	

The computer will calculate the numbers in the grey areas. The data entry person should copy down the numbers into spaces provided.

numbe	rs inio spaces provided.
7.	How was this form completed?
200.	Date this form completed (dd/mon/yyyy)
201.	Username of person reviewing completeness of this form
For Cl	inical Center Use Only:
202.	Username of person entering this form:
203.	Date entered: (dd/mon/yyyy)//

### Frequent Hemodialysis Network FINAL MRI SCHEDULED - FORM #218

**Instructions:** MRI data are one of two co-primary outcomes for the FHN study. A final MRI is required for each randomized patient, whether he or she is complying to the randomized treatment or not.

It is vital that the F-12 MRIs be done while a patient is receiving his/her randomized treatment. Centers are strongly encouraged to schedule each patient in the beginning of the patient's month 12. If you have any doubts as to whether you can do an MRI during month 12, you should schedule the patient's MRI toward the end of the patient's F-11 month. Please enter this form into the FHN database by Day 15 of each patient's F-11 month.

Nocturnal Study only: If a patient originally consented to protocol version 2.1 and continues to follow the schedule of protocol 2.1, the MRI should be done in the F-14 window. If you have any doubts as to whether you can do this during the month14, you should schedule the patient's MRI toward the end of the patient's F-13 window. For these patients, please enter this form into the FHN database by Day 15 of each patient's F-13 month.

1. Participant ID # 2. Alph	na Code		
3. Date final MRI scheduled: (dd/mon/yyyy)	/	/	
200. Date this form completed (dd/mon/yyyy)		/	
201. Username of person reviewing this form			
For Clinical Center Use Only:			
202. Username of person entering this form:	_		
203. Date entered: (dd/mon/yyyy)//			

Revisi	on of <mark>11</mark>	<mark>/JAN/2006</mark>	PID	Date	/	_/	_ Form # 220 Page 2 of 4
							C
	g.	_					
	h.	_					
	i.	· ·					
	j.	Bathing or	dressing yourself		•••••		·····
8.			eeks, have you had lly activities as a re	•	U 1		•
	a.		on the amount of tir	• •			
	b.	Accomplish	ned less than you w	ould like			·····
	c.	Were limite	ed to the kind of wo	ork or other ac	tivities		
	d.		lty performing the le, it took extra effo		activities		
9.	or other	regular dail	eeks, have you had y activities as a res s)? (0=No, 1=Yes)	ult of any emo	0 1		-
	a.		he amount of time ivities				
	b.	Accomplish	ned less than you w	ould like			
	c.	Did not do	work or other activ	rities as carefu	lly as usu	al	
10.	proble	ms interfered	veeks, to what exted with your normal	social activiti	es with fa	mily, friends,	neighbors,
	1=No 2=Sl 3=M 4=Q	ot at all ightly oderately uite a bit stremely					
11.	1=No 2=Vo 3=M 4=M 5=Se	one ery Mild ild oderate	ain have you had <u>d</u>	uring the past	4 weeks?		

For items 5-15, possible responses may include: 8=Don't know, 9=Refused to answer (these responses will be considered as missing data.)

12.	(include 1=N 2=S 3=N 4=C	the past 4 weeks, how much did pain interfere with your normal work ling both work outside the home and housework)?
	These weeks been for 1=A 2=N 3=A 4=S 5=A	questions are about how you feel and how things have been with you during the past 4. For each question, please give the one answer that comes closest to the way you have eeling.  All of the time  A Good bit of the time  Tome of the time  A little bit of the time  None of the time
13.	How n	nuch of the time during the past 4 weeks:
	a.	Did you feel full of pep?
	b.	Have you been a very nervous person?
	c.	Have you felt so down in the dumps that nothing could cheer you up?
	d.	Have you felt calm and peaceful?
	e.	Did you have a lot of energy?
	f.	Have you felt downhearted and blue?
	g.	Did you feel worn out?
	h.	Have you been a happy person?
	i.	Did you feel tired?
14.	emotic relative 1=A 2=N 3=S 4=A	the past 4 weeks, how much of the time has your physical health or onal problems interfered with your social activities (like visiting with friends, es, etc.)?
15.	1=D	TRUE or FALSE is each of the following statements for you? Definitely True Mostly True

Revision of 11/JAN/2006 PID \_\_\_\_ \_ Date \_\_\_/\_ \_\_\_\_

Form # 220 Page 3 of 4

For items 5-15, possible responses may include: 8=Don't know, 9=Refused to answer (these responses will be considered as missing data.)

Revisio	on of <mark>11/JAN/2006</mark>	PID	Date	_/	_/	Form # 220 Page 4 of 4
	3=Don't Know 4=Mostly False 5=Definitely Fals	se				1 age 4 01 4
	a. I seem to get sic.	k a little easier	than other people	•••••		
	b. I am as healthy a	as anybody I kr	now	•••••		····· <u> </u>
	c. I expect my heal	th to get worse				
	d. My health is exc	ellent				
QOI	Center Only					
100.	Language used to d	complete this fo	orm? (1=English, 2	2=Spanis	h)	
101.	1=Telephoned per	rson at home (corson when he or son at another	or patient returned r she was at the dia location	QOL pho	one call shor	tly after)
102.	0=N/A, instrume 1=Not completed 2=Attempted but	ent was completed due to patient to unable to be continuable to be continuable to be continuable to continuable to be continuable.	ted logistics (phone d ompleted - patient ompleted - patient	isconnec too sick	eted, on vaca	tion)
201.	Username of person	n completing in	terview		<u> </u>	

Please contact the DCC for further information.

# Frequent Hemodialysis Network COUSINEAU SELF-PERCEIVED BURDEN SCALE - FORM #222

**Instructions**: This form is completed by Central Interview.

<b>Schedule:</b> Daily: Baseline, F-4 and F-12. Nocturnal v3.0: Baseline, F-4 and F-12. ( <i>Nocturnal v2.1: Baseline, F-5 and F-14</i> ).
1. Participant ID#  2. Alpha  3a.Visit  3b. Visit Number  4a. Date of Questionnaire: dd/mon/yyyy
1. Participant ID # 2. Alpha 3a.Visit 3b. Visit Number 4a. Date of Questionnaire: dd/mon/yyyy  Code Type
4b. Time of interview? (hh:mm:ss)::::
We are interested in how you feel about the relationship that you have with the person (or people) who helps you out with your day-to-day activities. You may need a little bit or a lot of help with things like driving, carrying groceries, preparing meals and getting dressed or bathed. The person who helps you may be a friend, neighbor, or a member of your family – someone who is NOT paid to help you. We will refer to this person as your caregiver.
Please rate each statement on a scale of how often you feel this way, from "none of the time" to "all of the time".
For Questions 5 - 14, use the following codes: 1=None of the time, 2=A little of the time 3=Some of the time, 4=Most of the time, 5=All of the time
5. I worry that the health of my caregiver could suffer as a result of caring for me
6. I worry that my caregiver is overextending him/herself in helping me
7. I am concerned that it costs my caregiver a lot of money to care for me
8. I feel guilty about the demands that I make on my caregiver
9. I am concerned that my caregiver is helping me beyond their capacity
10. I am concerned that I am "too much trouble" to my caregiver
11. I am concerned that because of my illness, my caregiver is trying to do too many things at once
12. I am confident that my caregiver can handle the demands of caring for me
13. I think that I make things hard on my caregiver
14. I feel that I am a burden to my caregiver

Revisi	ion of 10/MAR/2006 ID Date/	Form #223 Page 3 of 5
23.	During the past week, have you been able to walk at all?	
24.	Have you needed mechanical support, such as braces or a cane or crutches, to be able to walk around the neighborhood?	
25.	Have you needed the help of another person to walk?	
26.	Have you needed a wheelchair to get around the neighborhood?	
27.	Have you needed the help of another person to get around in the wheelchair? 0=No, 1=Yes, 8=Don't know, 9=Refused	
HANI	DS AND FINGERS	
28.	During the past week, have you had the <i>full use</i> of both hands and ten fingers? 0=No, 1=Yes, 8=Don't know, 9=Refused  If yes, interviewer go to item 32.	
29	Have you needed the help of another person because of limitations in the use of your hands or fingers?	<u> </u>
30.	Have you needed the help of another person with some tasks, most tasks, or all ta 1= Some tasks, 2= Most tasks, 3= All tasks, 8= Don't know, 9= Refused	asks?
31.	Have you needed special equipment, for example special tools to help with dressing or eating, because of limitations in the use of your hands or fingers? 0=No, 1=Yes, 8=Don't know, 9=Refused	
SEL E	C-CARE	
32.	During the past week, have you been able to eat, bathe, dress and use the toilet without difficulty?  0=No, 1=Yes, 8=Don't know, 9=Refused	
	If yes, interviewer go to item 35.	
33.	Have you needed the help of another person to eat, bathe, dress or use the toilet? 0=No, 1=Yes, 8=Don't know, 9=Refused	
34.	Have you needed special equipment or tools to eat, bathe, dress or use the toilet? 0=No, 1=Yes, 8=Don't know, 9=Refused	
FEEI	LINGS	
35.	During the past week, have you been feeling happy or unhappy? 1=Happy, 2= Unhappy, 8=Don't know, 9=Refused  If unhappy, interviewer go to item 37.	

Revis	sion of 10/MAR/2006 ID D	ate//	Form #223 Page 4 of 5
36.	Would you describe yourself as having felt 1=Happy and interested in life, 2=S If happy and interested in life or somewhat	omewhat happy, 8=Don't know	y, 9=Refused
37.	Would you describe yourself as having felt 1=Somewhat unhappy 2=Very unhappy 3=So unhappy that life is not worth	8=Don't know 9=Refused	
38.	During the past week, did you ever feel free or depressed?		<u> </u>
39.	How often did you feel fretful, angry, irrita rarely, occasionally, often, or almost alway 1=Rarely, 2=Occasionally, 3=Often	s?	
40.	During the past week did you feel <i>extremel</i> or depressed; to the point of needing profes 0=No, 1=Yes, 8=Don't know, 9=Re	sional help?	
<b>MEM</b> 41.	How would you describe your ability to rer 1=Able to remember most things, 2 4=Unable to remember anything at	=Somewhat forgetful, 3=Very	
THIN	NKING		
42.	How would you describe your ability to thi	• • •	ems,
	during the past week? ?		roblems
PAIN	N AND DISCOMFORT		
43.	Have you had any trouble with pain or disc 0=No, 1=Yes, 8=Don't know, 9=Re	, ,	
44.	If no, interviewer go to item 45.  How many of your activities, during the pa or discomfort: none, a few, some, most, all 1=None, 2=A few, 3= Some, 4=Mo	?	

Revi	sion of <mark>10/MAR/2006</mark> ID	Date//	Form #223 Page 5 of 5
45.	1=Excellent, 2=Very good 3=Good 4=Fair	our health during the past week? 5=Poor 8=Don't know 9=Refused	
QOI	L Center Only		
100.	Language used to complete this f	form? (1=English, 2=Spanish)	
101.		r location	
102.	0=N/A, instrument was comple	nt logistics (phone disconnected, on vacation) completed - patient too sick completed - patient in hospital	
201.	Username of person completing i	interview	

## Frequent Hemodialysis Network CENTRAL SPECIAL STUDY QUESTIONS – FORM #224

Instructions: Schedule:		This fo Questic and F12 also as	ons are <mark>2/F14</mark> i	asked in the I	at Bas	eline a nal Tr	and ial u	F12 f inless	for the	rwi	ise ii	ndica	ated.	No	te Q	uesti	ion 1	2 is	
	1. Participant ID# 2. Alpha 3a.Visit 3b. Visit Number 4a. Date of Assessment: dd/mon/yyyy Code Type																		
4b.	Time	of in	terview'	?(hh:m	ım:ss)			•••••	• • • • • • •	• • • • • • • • • • • • • • • • • • • •	••••	•••••	•••••	• • • • • • •	•• —	:_		_:	
Im	pact (	of Tre	<u>eatment</u>																
5. a. How long does it take you to recover from a dialysis session and resume your normal, usual activities? (Record the participant's actual response)																			
	b.	Units	s of mea	sure in	n Q5a:	(1=Mi	inutes	, 2=	Hour	s, 3=1	Day	ys)	•••••	• • • • • • •	•••••	•••••	•••••		
6.			from 0 ence," ho															·	
Me	edicat	ion C	omplia	nce															
7.	a.		you mi Io, go to		• •					••••••	•••••	•••••	••••••	•••••	•••••	•••••	•••••	•••••	
	b. <u>EXCEPT</u> for your phosphate binders, have you missed any pills in the last week? (0=No, 1=Yes) ( <i>Note: phosphate binders include, but are not limited to: Tums, calcium carbonate, Renagel, etc</i> )																		
Se:		three	questio	ns are	nerson	al and	relate	to s	zour (	sevija	1 ac	rtivit	v h	ut ve	nir a	new	erc a	re	
			nderstan		-			•					•	•	our a	115 W (	.15 a	iic	
8.		-	nad any s , skip to			-	_							• • • • • • •	•••••	•••••	•••••	•••••	
			a proble sex? 1=Not: 2=A lit 3=Som 4=Very 5=Seve 9=Refu	a probl tle pro ewhat much ere prol	lem blem of a pr	oblem												•••••	

For items 5-12, possible responses may include: 8=Don't know, 9=Refused to answer (these responses will be considered as missing data.)

If the patient is under 18 years old, questions 8, 9, and 10 will not be asked and the questions will appear blank in the database.

Revisio	n of 10/FEB/2007	PID:	Date:	/	/	Form #224 Page 2 of 3
10. Bec	1=Not a pro 2=A little p 3=Somewh	roblem at of a problem ch a problem				
Modali at F14)	•	ese questions are a	sked at the end	l of the	study (Dai	ly at F12, Nocturnal
11. a.	There are a numb failure. If you we you rank as your 1= Peritone 2=In-center 3=In-center 4=Home 6	3 times weekly here 6 times weekly here times weekly daily times weekly noctu	modialysis modialysis hemodialysis	treatme	nts, which	would
b.	1= Peritone 2=In-center 3=In-center 4=Home 6	3 times weekly here 6 times weekly here times weekly daily times weekly noctu	modialysis modialysis hemodialysis			
c.	1= Peritone 2=In-center 3=In-center 4=Home 6	3 times weekly here 6 times weekly here times weekly daily times weekly noctu	modialysis modialysis hemodialysis			
<u>Dai</u> <u>Noc</u>	patients at: ly: Baseline, F4 a eturnal: Baseline,		ast dialysis sess	ion:		

For items 5-12, possible responses may include: 8=Don't know, 9=Refused to answer (these responses will be considered as missing data.)

If the patient is under 18 years old, questions 8, 9, and 10 will not be asked and the questions will appear blank in the database.

Revi	sion of 10/FEB/2007					Page 3 of 3
QOI	Center Only					
100.	Language used to con	mplete this form? (1	=English, 2=Sp	oanish)		<u> </u>
101.	Setting where this for 1=Telephoned perso 2=Telephoned perso 3=Telephoned perso 4=Patient phone in a	n at home (or patie n when he or she w n at another locatio	nt returned QOI vas at the dialysion	L phone		
102.	Identify reason this Q	OL instrument was	s not completed	?		<u> </u>
	0=N/A, instrument 1=Not completed d 2=Attempted but un 3=Attempted but un 4=Unable. Patient v 5=Study Staff logis	ue to patient logistinable to be complet nable to be complet withdrew consent.	ed - patient too	sick	on vacati	on)
201.	Username of person c	ompleting interviev	V		·····	

For items 5-12, possible responses may include: 8=Don't know, 9=Refused to answer (these responses will be considered as missing data.)

If the patient is under 18 years old, questions 8, 9, and 10 will not be asked and the questions will appear blank in the database.

responses will be considered as missing data.)

#### Frequent Hemodialysis Network MOS SLEEP SCALE - FORM #225

Instructions: This form is completed by Central Interview.  Schedule: Daily: Completed at Baseline, F4 and F12  Nocturnal: Completed at Baseline, F5 and F14.									
1. Participant ID # 2. Alpha 3a. Visit 3b. Visit Number 4a. Date of Questionnaire: dd/mon/yyyy									
Code Type									
4b. Time of interview?(hh:mm:ss):::::									
5. How long did it usually take for you to fall asleep <u>during the past 4 weeks</u> ?									
6. On the average, how many hours did you sleep each night <u>during the past</u> <u>4 weeks</u> ? (Write in the number of hours per night)									
Use the following codes to answer questions 7-16:  1=All of the time 4=Some of the time 2=Most of the time 5=A little of the time 3=A good bit of the time 6=None of the time									
7. How often <u>during the past 4 weeks</u> did you feel that your sleep was not quiet?(moving restlessly, feeling tense, speaking, etc., while sleeping)									
8. How often <u>during the past 4 weeks</u> did you get enough sleep to feel rested upon waking in the morning?									
9. How often during the past 4 weeks did you awaken short of breath or with a headache?									
10. How often <u>during the past 4 weeks</u> did you feel drowsy or sleepy during the day?									
11. How often <u>during the past 4 weeks</u> did you have trouble falling asleep?									
12. How often <u>during the past 4 weeks</u> did you awaken during your sleep time and have trouble falling asleep again?									
13. How often <u>during the past 4 weeks</u> did you have trouble staying awake during the day?									
14. How often <u>during the past 4 weeks</u> did you snore during your sleep?									
15. How often <u>during the past 4 weeks</u> did you take naps (5 minutes or longer) during the day?									
16. How often <u>during the past 4 weeks</u> did you get the amount of sleep you needed?									


Revi	ision of <mark>10/JAN/2006</mark>	PID:	Date (dd/mor	n/yyyy)/_	/	Form 225 Page 2 of 2
QO	L Center Only					
100	. Language used to	complete this f	form? (1=English, 2=S	panish)		
101	1=Telephoned pe	rson at home ( rson when he or rson at another		L phone call s		<u> </u>
102	0=N/A, instrume 1=Not completed 2=Attempted but	ent was compled due to patient unable to be out unable to be out withdrew co	t logistics (phone discompleted - patient too completed - patient in l	onnected, on v		
201	. Username of person	n completing i	nterview			

## Frequent Hemodialysis Network FEELING THERMOMETER RESULTS – FORM #230

**Instructions**: This form is completed by Study Staff based on the rating provided by the patient. This rating a scale from 0 to 100 with 0 = "Worst imaginable health state" and 100 = "Best imaginable health state". The patient is to use the form provided to answer the question, "How good or bad is your health today."


It is recommended that the patient complete this test before the other physical function tests. It is also recommended that test be done greater than 6 hours following the end of hemodialysis.


Schedule: Daily: Baseline, F-4 and F-12.  Nocturnal v3.0: Baseline, F-4 and F-12. ( <i>Nocturnal v2.1: Baseline, F-5 and F-14</i> ).								
1. Participant ID # 2. Alpha Code Type 3a. Visit Number 4a. Date of Test: dd/mon/yyyy								
4b. Time of interview? (24 hr clock)								
5. What rating did the patient record on the worksheet? (000 to 100)								
For Center Use:								
100. Language used to complete this form? (1=English, 2=Spanish)								
101. Identify reason this instrument was not completed?								
200. Date this form completed (dd/mon/yyyy)								
201. Username of certified person who performed this test								
For Clinical Center Use Only: 202. Username of person entering this form:								
203. Date Entered: (dd/mon/yyyy)///								



To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the *best* state you can imagine is marked by 100, and the *worst* state you can imagine is marked by 0.

We would like you to indicate on this scale how good or bad your health is today. Please do this by drawing a straight line from the black dot to whichever point on the scale that indicates how good or bad your health is currently.





Best Imaginable Health State

Worst Imaginable Health State

#### Frequent Hemodialysis Network MODIFIED MINI-MENTAL STATUS QUESTIONNAIRE - FORM #231

**Instructions**: Review all instructions in MOP on how to properly administer this test. It is strongly recommended that this test be done pre-dialysis or should not be done within the 1st six hours from end of hemodialysis. The study coordinator should conduct the test with the patient first and then go back later to score it.

<b>Schedule:</b> Daily: Baseline, F-4 and F-12. Nocturnal v3.0: Baseline, F-4 and F-12. ( <i>Nocturnal v2.1: Baseline, F-5 and F-14</i> ).									
1. Participant ID # 2. Alpha Sa. Visit Number 4a. Date of Test: dd/mon/yyyy Code Type									
4b. Time of test? (24-hr clock)									
Items 4c and d can be patient reported:									
c. Date of last dialysis treatment (dd/mon/yyyy)									
d. End time of last dialysis treatment? (24-hr clock)									
Examiner: "Are you comfortable? I would like to ask you a few questions that require concentration and memory. Some are a little bit more difficult than others. Some questions will be asked more than once."									
5. Examiner: "When were you born?" (For 5a-c: Record 0=Incorrect, 1=Correct)									
a. Month:									
b. Day:									
c. Year:									
6. Examiner: "Where were you born?" (For 6a-b: Record 0=Incorrect, 1=Correct)									
a. City/town:									
b. State/country:									

Re	Revision of 26/FEB/2008 PID: D	ate:	_/	/	
Ex	Examiner: "I am going to say three words for you to	) remen	ıber. Ro	eneat thei	Page 2 of 11
	all three words: Shirt, Blue, Honesty"	7 1 0111011		peut the	11 u1001 1 11u ( 0 5u1u
	Examiner note: Do not repeat the words for the pa The participant may give the words in any order. If repeat the items up to six times until they are learne attempt.	there a	e error.	s on the fit	rst trial,
Fo					
7.	7. a. Shirt:	•••••	•••••		
	b. Blue:	•••••	• • • • • • • • • • • • • • • • • • • •	••••	·····
	c. Honesty:		•••••		
	d. Number of presentations necessary for the partici	ipant to	repeat tl	ne present	ation:
	Examiner: "I would like you to count from 1 - 5. If a say 1-2-3-4-5."	unable to	o count	forward co	orrectly:
8.	8. a. Counting from 1-5:(0=Unable to count forward, 1=Able to count forward,	 rward)			
Ex	Examiner: "Now I would like you to count backward	s from	5 to 1."		
	b. Counting backwards from 5 to 1: (write in participant is use the series, fill in the rest of the dashes with asterisk will allow you to enter the asterisks and will score once the participant's responses are entered.)	nable to	comple databas	ete e	
Ex	Examiner: "Spell the word, 'world'." Record letters	in the o	der giv	en.	
9.	9. a. Spelling "world":	ard)			<u> </u>
Ex	Examiner: "Now spell 'world' backwards."				
b.	b. Spelling "world" backwards: (write in participant's (Record the first five letters in the order given start first dash. If participant is unable to complete the s the rest of the dashes with asterisks. The database you to enter the asterisks and will score this item at once the participant's responses are entered.)	ing with series, fi will alle	the ll in ow		

Revision of <mark>26/FEB/2008</mark> PID:	Date:	/	/	
			au.	Page 3 of 11
Examiner: "What three words did I ask Examiner note: The words may be rep the correct answer after a category con still cannot give the correct answer from and provide the correct answer. Exam	peated in any order. we, provide the three om the three choices	If the choice, recore	participar es listed. I d "Unable	If the participant to recall/refused"
10. a. Shirt:0=Unable to recall/refused (provide 1=Spontaneous recall 2=Correct word/incorrect form 3=After "Something to wear" 4=After "Was it shirt, shoes, or so				<u> </u>
b. Blue:				<u> </u>
c. Honesty:	the correct answer)			<u> </u>
Examiner: "What is today's date?" (mo	• •	ise, ent	er '9'.	
11 a. Month:				
b. Day:				

Revision of 26/FEB/2008	PID:	Date:/_	/	
Examiner: "What day of	the week is it?"			Page 4 of 11
11d. Day of the week: 0=Incorrect 1=Correct				<u> </u>
Examiner: "What season	of the year is it?"	(see MOP for instru	uctions on 'seas	on')
e. Season: 0=Incorrect 1=Correct				<u> </u>
Examiner: "What state (p	province) are we in	n?''		
12 a. State: 0=Incorrect 1=Correct				
Examiner: "What county	(parish) are we in	ı?''		
b. County: 0=Incorrect 1=Correct				<u> </u>
Examiner: "What city/tov	wn are we in?''			
c. City/town: 0=Incorrect 1=Correct				
Examiner: "Are we in a c	linic, store or hon	ne?" (substitute act	ual location, if 1	needed)
d. Clinic, store, home: 0=Incorrect 1=Correct	:			<u> </u>
Examiner: Point to forehea	ad: "What do you	call this part of the	face?"	
13. a. Forehead: 0=Incorrect 1=Correct		·		<u> </u>
Examiner: Point to chin: "	And this part of t	he body?''		
b. Chin: 0=Incorrect 1=Correct		····		<u> </u>
Examiner: Point to should c. Response to shoulde 0=Incorrect 1=Correct	_	-		<u> </u>

Revision of 26/FEB/2008	PID:	Date:	_ /	/	_ Form #231 Page 5 of 11
Examiner: Point to elbow: d. Elbow:	•	•			J
0=Incorrect 1=Correct					
Examiner: Point to knuckl	e: "And this part of the	he hand?''			
e. Knuckle: 0=Incorrect 1=Correct					
Examiner: "What animal Examiner Note: Discortine participant gives not gently remind them (on The first time an incorr	ntinue after 30 seconds. response in 10 second ce only) " <b>What other a</b>	. Record the 's and there a nimals have	total na ure still <b>four le</b>	umber of corn at least 10 se gs?"	econds remaining,
The first time an incorr	ect answer is proviaea, 	say 1 wani	Jour le	eggea anımal	<b>S.</b>
	<del></del>				
					<u></u>
					<del></del>
14. Participant's total corre	ct responses to animals	:			<u></u> _
Examiner Note: If the participant by saying: answer. Coach only for	"An arm and a leg are	both limbs of	r extren	nities" to rein	force the correct
Examiner: "In what way	are an arm and leg ali	ke?''			
15 a. Arm/leg: 0=Error (states differe	ences, gives unrelated a	ınswer)		•••••	
1=Lesser correct resp	onse (e.g., body parts, limbs, extremities, appe	both bend, ha	ave join	its)	

Revision of 26/FEB/2008 P	'ID:	Date:	_ /	Form #231
				Page 6 of 11
Examiner: "In what way ar	0 0	• 0		
b: Laughing/crying:				
0=Error (states differen				
1=Lesser correct respon		omer similar res	ponses)	
2=Expressions or feeling	gs, emotions			
Examiner: "In what way ar	e eating and slee	ning alike?''		
c.Eating/sleeping:	e caring and sice	ping unit		
0=Error (states differen	ces, gives unrelate	ed answer)		
1=Lesser correct respon	_		g, "good for you")	
2=Necessary bodily fur			, ,	
•				
Examiner: "Repeat what I s	•	_	1	
Examiner Note: Pronoun	ce tne inaiviauai v	woras aistinctiy	but with normal temp	00
of a spoken sentence.				
16. Participant's response:				
0=3 or more words mis				
1=1 or 2 words missed	3 <b>S</b>			
2=Correct				
- IDV				
Examiner: "Now repeat: "			1 . • .1 . 1 .	
Examiner Note: Pronoun		•		00
of a spoken sentence. Gi	ve no creatt if the j	participant miss	ses the 's.	
17. a. 'No ifs':				
0=Incorrect				
1=Correct				
b. 'Ands':			•••••	
0=Incorrect				
1=Correct				
c. 'Or buts':				
0=Incorrect		·····	•••••	·····
1=Correct				
1–Conce				

Examiner: Hold up Card#1 (card says: CLOSE YOUR EYES) and say: "Please do this."

Examiner note: If the subject does not close their eyes within five seconds, prompt by pointing to the sentence and saying: "Read and do what this says." If the subject has already read the sentence aloud spontaneously, simply say "Do what this says."

Allow five seconds for the response. Record "1" if the subject reads the sentence aloud, either spontaneously or after your request, but does not close their eyes. As soon as the subject closes their eyes, say "Open."

Revision of 26/FEB/2008 PID:	Date:/ Form #231 Page 7 of 11
18. Participant response:  0=Does not read aloud or closes eye 1=Reads aloud, but does not close eye 2=Obeys with prompting 3=Obeys without prompting	s/refuses
Examiner: "Please write the following	sentence: 'I would like to go out.'"
participant uses to write. Allow a m the scored response. Assign 1 for ed "0" if there are spelling errors. Do	t a piece of paper and a pencil. Note which hand the aximum of 1 minute after the first reading of the sentence for ach correct word, but no credit for "I". For each word, mark not penalize self-corrected errors. If this task is not done, ask ft handed {for use in Questions 20 and 21}.
19. a. 'would': 0=Incorrect 1=Correct	
b. 'like': 0=Incorrect 1=Correct	
c. ' <b>to</b> ': 0=Incorrect 1=Correct	
d. 'go': 0=Incorrect 1=Correct	
e.'out': 0=Incorrect 1=Correct	
f. What hand did the participant use 1=Right 2=Left	to write the sentence?

Examiner: "Here is a drawing. Please copy the drawing onto this piece of paper."

Examiner's Note: Hand the participant Card #2 (pentagon drawing) and a blank piece of paper. Allow 1 minute for copying. For right-handed participants, present the sample on the left side; the left-handed participants present the sample on the right side. Do not penalize for self-corrected errors, tremors, minor gaps, or overshoots. Do not allow patient to trace drawing.


Revision of 26/FEB/2008 F					Page 8 of 11
20. a. Pentagon 1:	efused it is not an enclosed to sed figure shortest side>2:1				
b. Pentagon 2:	efused it is not an enclosed to sed figure shortest side>2:1				······
c. Intersection of pentage 0=No enclosure / refus 1=Other than 4-corned 2=4-cornered enclosur	sed l enclosure				
Examiner: Refer back to piece of white paper in pi	. –	-	-		nand. Hold up a
"Take this paper with your hands, and hand it back to		anded persoi	ı) hand,	fold it in ha	lf using both
21. a. Takes paper in correct 0=Incorrect 1=Correct	hand:				<u> </u>
b. Fold paper in half correct 0=Incorrect 1=Correct	ectly:				
c. Hands paper back: 0=Incorrect 1=Correct					

#### Examiner: "What three words did I ask you to remember earlier?

Examiner note: The words may be repeated in any order. If the participant cannot give the correct answer after a category cue, provide the three choices listed. If the participant still cannot give the correct answer from the three choices, record "0" and provide the correct answer.

Revision	n of <mark>26/FEB/2008</mark>	PID:	Date:	_//	
22. a. Sł	nirt:				Page 9 of 11
		efused (provide the c			<u> </u>
	Spontaneous recal				
	=Correct word/inco				
	After "Something		•		
4=	=After "Was it shii	rt, shoes, or socks?'	,		
b. Bl					
		efused (provide the c	correct answer)		
	Spontaneous recal				
	=Correct word/inco =After <b>"A color"</b>	rrect form			
		e, black or brown?	,,		
		,			
c. H	onesty:	efused (provide the c	enrect answer)		······ <u> </u>
	=Spontaneous recal	· <u>-</u>	offect allswer)		
	=Correct word/inco				
	After "A good per				
4=	After <b>"Was it hor</b>	nesty, charity or mo	desty?"		
Exar				ches the ans	swer given in Items 6a & b,
If physical	al/functional disabili			•	pant difficulty in completing codes.
		ve any physical/function go to Q200; 1=Yes, c		as stated abov	ve?
	-	abilities: Use codes:			<u> </u>
c. He	earing:				······—
d. W	riting problems due t	to injury or illness or a	amputation:		······
e. Ill	iteracy or lack of edu	acation:			······
f. La	anguage:				
100. La	nguage used to comp	plete this form? (1=En	glish, 2=Spanish	)	
200. Da	te this form complete	ed (dd/mon/yyyy)			/
201. Us	ername of certified p	erson who performed	this test		······
	ical Center Use Onl	•			
	_	ntering this form: _		_	
203 Da	te Entered: (dd/ma	n/vvvv) /	1		

# **CLOSE YOUR EYES**



## Frequent Hemodialysis Network TRAILMAKING B SCORE SHEET - FORM #232

Instructions: Review all instructions in MOP/Forms Manual on how to properly administer this test. It is recommended that test be done more than 6 hours following the end of hemodialysis.


Note: Time allowed for test has been extended from 4 to 10 minutes; maximum score for the FHN Trial is 23 connecting lines.

<b>Schedule:</b> Daily: Baseline, F-4 and F-12. Nocturnal v3.0: Baseline, F-4 and F-12. ( <i>Nocturnal v2.1: Baseline, F-5 and F-14</i> ).
1. Participant ID # 2. Alpha 3a. Visit 3b. Visit Number 4a. Date of Test: dd/mon/yyyy
Code Type
4b. Time of test? (24 hr clock)
TRIALMAKING B: Number to Letter Test  Sample test: "You will notice that this page has both numbers and letters. Begin at number one, and draw a line from number one to the letter A, A to two, two to B, B to three, three to C, and so on, until you reach the end. Draw the lines as fast as you can. Go."
<u>Test</u> : "Good. Now do this test the same way. Begin at number one, and draw a line from number one to the letter A, A to two, two to B, B to three, three to C, and so on, until you have reached the end. Remember, first you have a number, then a letter, and so on. Draw the lines as fast as you can. Go."
Scoring:  5. Time required for patient to complete Trailmaking Test B:
6. Number of correct responses:
100. Language used to complete this form? (1=English, 2=Spanish)
101. Identify reason this instrument was not completed?
102. Did test administrator catch an error too late? (0=No, 1=Yes)
200. Date this form completed (dd/mon/yyyy)
201. Username of certified person who performed this test
For Clinical Center Use Only:
202. Username of person entering this form:


Date entered: (dd/mon/yyyy) \_\_\_/\_ \_\_/\_ \_\_\_/\_\_\_\_\_\_\_

203.

#### Trail Making (Part B) – SAMPLE



#### Trail Making (Part B)



Ι **10** D B H **12** G  $\mathbf{E}$ 11 K

## Frequent Hemodialysis Network CLINICAL CENTER MISCELLANEOUS QUESTIONS - FORM #233

Instructions: Clinical Center staff completes these questions at intervals specified in each section.

Follow-up Extension Study: For all patients cons	enting to the Follow-up Extension Study, only	r			
complete Questions 12a - 13b at the end of this form	n.				
1. Participant ID# 2. Alpha 3a.Visit	3b. Visit Number 4a. Date: dd/mon/yyyy				
1. Participant 1D# 2. Alpha 3a. Visit  Code Type	36. Visit Number 4a. Date: dd/mon/yyyy				
For all U.S. patients at baseline:					
4b. Did patient agree to provide health insurance id	entification numbers for future linkage				
with USRDS?		-			
0=No, patient refused ( <i>Do not complete Form 1</i>	08)				
1=Yes, patient agreed. (Complete Form 108)					
8=Not applicable					
For Daily Trial: skip questions 5 and 6.					
Nocturnal Trial Blood Pressure - at baseline only					
5. Mid-arm circumference for BP cuff (in cm)					
6. a. Cuff size provided to the patient for the OMI	<del></del>	-			
1=Pediatric 3=Lar					
2=Regular 4=X-large (thigh sized)					
b. How much is patient's electric bill per month?\$\$					
c. How much is patient's water bill per month?	?\$	_			
d. What currency are Items 6b & c reported in	?	_			
(1=American, 2=Canadian, 3=Australian)					
Items 7 - 11 For All Patients At End of Trial					
Employment Status Change					
7. Current work status:	07-N-4	-			
01=Student, not employed 02=Student, employed	0/=Not working, seeking work, not disabled 08=Employed full-time				
03=Homemaker	09=Employed fun-time				
04=Not working, not seeking work, disabled	10=Retired				
05=Not working, not seeking work, not disabled	10 Retired				
06=Not working, seeking work, disabled	99=Unknown				
8. Has there been a change in employment status s	since baseline?	_			
(0=No, skip to Q10, 1=Yes, complete Q9)					

Revision of 07/MAY/2010 PID:	Date:	/	/		Form #233
					Page 2 of 3
0 Primary for any 1-states along the	4	1:			_
9. Primary reason for work status change (bet			current).	<i>!</i>	
1=Due to time constraints of chronic kidney		ent			
2=Due to complications of chronic kidney					
3=Due to illness other than chronic kidney	iaiiure				
4=Due to retirement					
5=Patient now working more hours.					
6=Due to other reasons	on and and DC	C C			
If other reason for change in work statu	is, contact DC	_ jor nev	v coae.		
For All Dationts At The End of the Candy					
For All Patients At The End of the Study	h. 0-No. 1-V	aa <b>9-N</b> Ia	at Amalia	abla)	
Patient Health Insurance: (For questions 10a				able)	
10. <b>Column A:</b> What type of health insurance <b>Column B:</b> Are any of the insurance plant					
an HMO (Health Maintenance	-				
an fino (fleath maintenance	Organization)	!		<b>A</b>	В
				A Have?	HMO?
a Madiegra:					
<ul><li>a. Medicare:</li><li>b. Medicaid or State Medical Assistance:</li></ul>	• • • • • • • • • • • • • • • • • • • •	•••••	•••••		····· <u> </u>
c. State or county program other than Med	 licaid:				
d. Employer-sponsored or retiree health pl					
e. Privately-purchased policy (e.g., Medig					
f. Veterans benefit, TriCare or military he					
g. Canadian health care benefits:					
h. None:					
11. 140110	• • • • • • • • • • • • • • • • • • • •		•••••		
11. a. Is Medicare paying for this patient's	hemodialysis?				
0=No, answer Question 11b	iioiiiodidiy 515.	•••••	••••••	••••••	······ <u>—</u>
1=Yes, skip to Question 200.					
(Note: This question may need to be con	nnleted by you	r Billing	Denartn	nent.)	
(France 111111 question 11111) incom to co con	inprocess of you	2,,,,,	z cp w w		
b. If no to Question 11a, why not?					
1=Patient recently started hemodialysis					
2=Patient is Canadian					
3=U.S. Patient has alternative insurance					
4=Patient is Australian					
************	********	*****	*****	*****	*****
Follow-up Extension Study Final Visit	t Only: Mod	lality P	referen	ce.	
12. a. There are a number of different treatme					
failure. If you (patient) were eligible				•	l
would you rank as your 1st preference					
1= Peritoneal dialysis					
2=In-center 3 times weekly hem	odialysis				
3=In-center 6 times weekly hem	•				
4=Home 6 times weekly daily h	-				
5=Home 6 times weekly nocture		is			
6=Kidney transplant	<i>y</i>				
7=Home 3 times weekly hemod	<mark>ialysis</mark>				
8=Home 3 times weekly nocture		<mark>is</mark>			

# Frequent Hemodialysis Network CLINICAL CENTER MISCELLANEOUS QUESTIONS - FORM #233

b. Which would be your 2nd preference?

1= Peritoneal dialysis	
2=In-center 3 times weekly hemodialysis	
3=In-center 6 times weekly hemodialysis	
4=Home 6 times weekly daily hemodialysis	
5=Home 6 times weekly nocturnal hemodialysis	
6=Kidney transplant 7=Home 3 times weekly hemodialysis	
8=Home 3 times weekly nocturnal hemodialysis	
o Trome a united weekly meetarian nemediaryons	
c. Which would be your 3rd preference?	
1= Peritoneal dialysis	
2=In-center 3 times weekly hemodialysis	
3=In-center 6 times weekly hemodialysis	
4=Home 6 times weekly daily hemodialysis	
5=Home 6 times weekly nocturnal hemodialysis	
6=Kidney transplant 7=Home 3 times weekly hemodialysis	
8=Home 3 times weekly nocturnal hemodialysis	
o frome 3 times weekly noctarial nemodiarysis	
13. a. What is <u>primary</u> reason patient would prefer <u>dialysis modality indicated in Q12a?</u>	
1=Convenience for patient's schedule	
2=Convenience for caregiver's schedule	
3=Pt feels best using this modality	
4=Pt believes he/she will feels feel better using this modality	
5=Pt concern for access	
8=Other reason (complete Q13b)	
h If 012a=8 prayida athar rassan in commant section:	
b. If Q13a=8, provide other reason in comment section:	
200 Data this form completed (dd/mon/yww)	
200. Date this form completed (dd/mon/yyyy)	
201. Username of person completing this form	
For Clinical Center Use Only:	
202. Username of person entering this form:	
203. Date Entered: (dd/mon/yyyy)//	

## Frequent Hemodialysis Network PHYSICAL FUNCTION MEASURES QUESTIONS - FORM #234

**Instructions:** Review detailed instructions in MOP on how to conduct these physical function tests. A stopwatch is needed. The computer will calculate the number of points assigned to each test and report the scores in items 13a-e.

**Schedule:** Daily: Baseline, F-4 and F-12.

Nocturnal v3.0: Baseline, F-4 and F-12. (Nocturnal v2.1: Baseline, F-5 and F-14).

	<ol> <li>Participant ID #</li> </ol>	2. Alpha	3a.Visit	3b. Visit Number	<ol><li>Date of</li></ol>	assessment:	dd/mon/y	ууу	
		Code	Type						
4b. Time of assessment? (24 hr clock)									
c. How does this patient ambulate/move around?(1=Unassisted, 2=Walker, 3=Cane, 4=Wheelchair)									

All of the tests should be performed in the same order as they are presented. Instructions to the participant are shown in bold italic and should be given exactly as they are written in this script.

#### **BALANCE TESTS** (Record number of seconds each position is held.)

The participant must be able to stand <u>unassisted</u> without the use of a cane or walker. You may help the participant to get up.

<u>Examiner</u>: "Now let's begin the evaluation. I would now like you to try to move your body in different movements. I will first describe and show each movement to you. Then I'd like you to try to do it. If you cannot do a particular movement, or if you feel it would be unsafe to try to do it, tell me and we'll move on to the next one. Let me emphasize that I do not want you to try to do any exercise that you feel might be unsafe"

"Do you have any questions before we begin?"

- "Now I will show you the first movement" (Demonstrate) "I want you to try to stand with your feet together, side-by-side, for about 10 seconds."
- ''You may use your arms, bend your knees, or move your body to maintain your balance, but try not to move your feet. Try to hold this position until I tell you to stop.''
- Stand next to the participant to help him/her into the side-by-side position. Supply just enough support to the participant's arm to prevent loss of balance.
- When the participant has his/her feet together, ask "Are you ready?
- Then let go and begin timing as you say, "Ready, begin."

Re	vision of <mark>01/MAY/2007</mark> ID Date / Form #23 Page 2 of
	• Stop the stopwatch and say "Stop" after 10 seconds or when the participant steps out of position or grabs your arm.
	• If participant is unable to hold the position for 10 seconds, record result in Item #5 and go to the gait speed test.
5.	Results: Side-by-side stand (seconds)
	• "Now I will show you the second movement. (Demonstrate) I want you to try to stand with the side of the heel of one foot touching the big toe of the other foot for about 10 seconds. You may put either foot in front, whichever is more comfortable for you."
	• ''You may use your arms, bend your knees, or move your body to maintain your balance, but try not to move your feet. Try to hold this position until I tell you to stop.''
	• Stand next to the participant to help him/her into the semi-tandem position. Supply just enough support to the participant's arm to prevent loss of balance.
	• When the participant has his/her feet together, ask "Are you ready?"
	• Then let go and begin timing as you "Ready, begin."
	• Stop the stopwatch and say "Stop" after 10 seconds or when the participant steps out of position or grabs your arm.
	• If participant is unable to hold the position for 10 seconds, record result in Item #6 and go to the gait speed test.
6.	Results: Semi-tandem stand (seconds)
	• "Now I will show you the third movement". (Demonstrate) "I want you to try to stand we heel of one foot in front of and touching the toes of the other foot for about 10 seconds. You may put either foot in front, whichever is more comfortable for you."
	• ''You may use your arms, bend your knees, or move your body to maintain your balance, but try not to move your feet. Try to hold this position until I tell you to stop.''
	• Stand next to the participant to help him/her into the tandem position. Supply just enough support to the participant's arm to prevent loss of balance.

- When the participant has his/her feet together, ask "Are you ready?"
- Then let go and begin timing as you say, "Ready, begin."

Re	vision of <mark>01/MAY/2007</mark>	ID	Date	/	/	Form #234 Page 3 of 7
	• Stop the stopwatch as position or grabs you		" after 10 seconds	or when	the participan	at steps out of
	• Record the number of	f seconds in i	item #7.			
7.	Results: Tandem stand ( (Ideal is to hold position record '99.99' and answer	for 10 second	ds. If balance test	is not at		
8.	If participant did not atto 0=N/A, patient complete 1=Tried but unable to per 2=Participant could not 3=Not attempted, you (present the second	ed test. erform test hold position person condu ipant felt uns	n unassisted cting test) felt unsa afe	·	on why:	<u> </u>

**GAIT SPEED TEST** Observe participant's normal walk. A cane or other walking aid may be used, if needed.

- "Now I am going to observe how you normally walk. If you use a cane or other walking aid and you feel you need it to walk a short distance, then you may use it."
- "This is our walking course. I want you to walk to the other end of the course at your usual speed, just as if you were walking down the street to go to the store.
- Demonstrate the walk for the participant.

- "Walk all the way past the other end of the tape before you stop. I will walk with you. Do you feel this would be safe?"
- Have the participant stand with both feet touching the starting line.
- "When I want you to start, I will say: Ready, begin." When the participant acknowledges this instruction say: "Ready, begin."
- Press the start/stop button to start the stopwatch as the participant begins walking. Walk behind and to the side of the participant.
- Stop timing when one of the participant's feet is completely across the end line and record the number of seconds in Item 9a.

Revis	ion of <mark>01/MAY/2007</mark>	ID	Date/	/ Form #234 Page 4 of 7
First	Gait Test			
9. a	. Results: Time (in second to complete		<del>-</del> -	ers
b	o. Did patient not attem	pt or failed to	est? (0=No, 1=Yes)	
c	. Why did patient not a 0=N/A, patient com 1=Tried but unable	-	led test?	
	2=Participant could 3=Not attempted, you			
	4=Not attempted, pa	articipant felt	unsafe	
	5=Participant unable 6=Participant refuse		d instructions	
d.		alk?		
	0=None		3=Other, specify:	
	1=Cane 2=Walker		4=N/A, patient did not a	ittempt test
e.	Does examiner have	any commen	ts? (0=No, 1=Yes)	
	Specify:			
Secor	nd Gait Speed Test			
•	_			our usual pace, and go all the
•	Have the participant	stand with bo	th feet touching the starting	g line.
•	"When I want you to this instruction say: "		• • •	the participant acknowledges
•	Press the start/stop behind and to side of			pant begins walking. Walk
•	Stop timing when on results in Item 10a.	e of the partic	cipant's feet is completely a	cross the end line. Record
10. a.	Results: time (in sec If unable to complete			neters
b.	Did patient not attem	pt or failed to	est? (0=No, 1=Yes)	<u> </u>

Kev1s:	ion of <mark>01/MAY/2007</mark>	ID	Date/	_/ Form #234 Page 5 of 7
c.	Why did patient not a 0=N/A, patient con 1=Tried but unab 2=Participant con 3=Not attempted 4=Not attempted 5=Participant una 6=Participant ref	ompleted test ble ald not walk u , you (examin , participant f able to unders	er) felt unsafe elt unsafe	
d.	Aids used for second	l walk?		<u> </u>
	0=None		3=Other, specify:	
	1=Cane 2=Walker		4=N/A, patient did not atter	npt test
e.	Does examiner have	any comment	s? (0=No, 1=Yes)	
	Specify:			
reasor	ns for discontinuing tes		ise without using arms, the tes	et is finished. See also other
Single	e Chair Stand "Let's do the last mo from a chair withou		Do you think it would be safe rms?''	for you to try to stand up
•	"The next test meas	ures the stren	gth in your legs."	
•	•		edure.) "First, fold your arms n stand up keeping your arms	•
•	"Please stand up kee	eping your ar	ns folded across your chest.''	(Record result).
•			sing arms, say "Okay, try to st d result in item #11a and to the	
_	e Chair Stand Test Ro Did participant feel s		ithout help? (0=No, 1=Yes)	<u> </u>

b. Results of single chair stand test.....\_\_\_

1=Participant stood without using arms (continue with repeated chair stand test)

2=Participant used arms to stand (end test)
3=Participant could not complete test (end test)

Revisi	on of 01/MAY/2007	ID	Date	_/	/	Form #234 Page 6 of 7
c.	Why did patient not a 0=N/A, patient co 1=Tried but unab 2=Participant cou 3=Not attempted, 4=Not attempted, 5=Participant una 6=Participant refu	ompleted test, go le, go to question ld not walk unas you (examiner) participant felt lble to understan	to question 12 in 103 ssisted, go to que felt unsafe, go to unsafe, go to que d instructions, g	estion 10 o questio estion 10	3 on 103 3	······
Repea	nted Chair Stand Test	Į				
•	"Do you think it wou using your arms?"	ld be safe for yo	ou to try to stand	l up from	a chair fi	ve times without
•	(Demonstrate and exp can five times, without stand up again. Keep stopwatch"	ut stopping in bo	etween. After si	tanding u	ıp each tim	e, sit down and then
•	When the participant	is properly seate	ed, say: " <b>Ready</b> ?	Stand"	and begin	iming.
•	Count out loud as the	participant arise	es each time, up	to five ti	mes.	
•	Stop if participant bed	comes tired or sh	nort of breath du	ring repe	eated chair	stands.
•	Stop the stopwatch w	hen he/she has s	traightened up c	completel	y for the fi	fth time.
•		ses his/her arms , if participant hation, if concerned	as not completed			
•	If the participant stop this by asking "Can y		be fatigued befo	ore comp	leting the f	ive stands, confirm
•	If participant says "Y stopwatch.	es," continue tin	ning. If particip	ant says	"no", stop a	and reset the
12. a.	Did participant feel sa	afe to stand five	times? (0=No, 1	=Yes)		······ <u> </u>
b.	Results: time (in second If unable to complete	-				······
c.l	Results of repeated cha 1=Participant stood w 2=Participant used ar 3=Participant could n	vithout using arn ms to stand (end	ns l test. go to ques	tion 103)	)	<u> </u>

Revis	ion of <mark>01/MAY/2007</mark>	ID	_ Date	_/	_/	Form #234 Page 7 of 7
	1=Tried but unable 2=Participant course 3=Not attempted, 4=Not attempted, 5=Participant una	mpleted test, go to que, go to question 103 ld not walk unassisted you (examiner) felt un participant felt unsafe ble to understand instructed, go to question 10	estion 103 l, go to que nsafe, go to e, go to que ructions, go	estion 103 o question estion 103	3 n 103 3	
Stud	y Staff continue:					
100.	Language used to comp	olete this form? (1=Eng	glish, 2=Sp	oanish)		
103. \$	Setting where this form 1=Patient was tested a 2=Patient was tested a 3=Patient was tested in	t home t the dialysis unit				
104. I	dentify reason this entine 1=N/A, instrument wa 2=See reasons describe 3=Attempted but unab 4=Attempted but unab 5=Unable. Patient in h 6=Unable. Patient with 7=Staff logistics 8=Pt. disabled, uses well as the second se	s completed. ed in sections above. le to be completed - pale to be completed - pale ospital. eddrew consent.	atient too s	ick.		
200.	Date this form comple	ted (dd/mon/yyyy)	•••••		/	/
201.	Username of certified	person who performed	d this test			· — — — —
For C	Clinical Center Use On	ly:				
202.	Username of person of	entering this form: _			_	
203.	Date entered: (dd/mo	on/yyyy)/	_/			

# Frequent Hemodialysis Network SINGLE FREQUENCY BIOELECTRIC IMPEDANCE (BIA) ASSESSMENT - FORM #242

**Instructions:** Prior to the measurement, **the patient should lie flat for 15-20 minutes to equilibrate fluid distribution**. See MOP for specific instructions on how to take the measurements. You will need to ask the patient whether he/she has an implanted defibrillator or pacemaker, and if he does, do not do the test. Do not do the test if the patient is a bilateral amputee.

It is preferable, but not mandatory, that all measurements be conducted in the supine position, if at all possible, and should be performed immediately prior to a mid-week HD treatment (i.e., Wednesday or Thursday).

Recommended Schedule:	Daily Study: Base		l F12 ( <mark>BIA is n</mark>	iot required f	or										
	randomization as of 2		1.510	0.1 175	1.774.4										
Nocturnal Study v3.0: Baseline, F4, and F12. (v2.1: F5 and F14)															
I Participant ID#	1. Participant ID#  2. Alpha Code Type  Type  3a.Visit 3b. Visit Number  4a. Date of Measurement: dd/mon/yyyy														
1. I articipant 1D #	Code Type		4a. Date of f	ivicasurement. C	id/iiioii/yyyy										
4b. Time of test? (24 hr clock):::															
5. Height (measure supine length in those unable to stand) (cm)															
6. a. Current weight (kg)															
b. Estimated dry weight (	(kg)		•••••												
7. Body position (1=Supine	[preferred], 2=Seated	l, 3=Semi-recum	lbent)	••••••											
8. Side measured (1=Right,	2=Left)			•••••											
<ul><li>9. Measured resistance (R) (</li><li>10. Measured reactance (Xc)</li></ul>															
10. Measured reactance (AC)	(onms)	•••••	••••••	••••••											
200. Date this form completed (	(dd/mon/yyyy)			/											
201. Username of certified person	on who performed th	is test													
For Clinical Center Use Only: 202. Username of person en			_												
203. Date Entered: (dd/mor	n/yyyy)/	_/													

## Frequent Hemodialysis Network LAST DIALYSIS SESSION BEFORE THE MRI FORM - # 250

This form is completed after the study coordinator knows the date that an MRI was performed. The Study Coordinator goes back to the patient's dialysis data and obtains data on last dialysis session that was done prior to the MRI. This form is completed in conjunction with the MRI based on the following schedule.

Schedule: Daily: Baseline and F-12.  Nocturnal v3.0: Baseline and F-12. (Nocturnal v2.1: Baseline and F-14)														
Nocturnal v3.0: Baseline and F-12. ( <i>Nocturnal v2.1: Baseline and F-14</i> ).														
1 Participant ID # 2 Alpha 3a Visit 3b Visit Number 4 Date of MRI: dd/mon/yyyy														
1. Participant ID # 2. Alpha 3a.Visit 3b. Visit Number 4. Date of MRI: dd/mon/yyyy Code Type														
5. Date of this patient's last dialysis session before the MRI														
6. End time of this patient's last dialysis session (24-hour clock) : : :														
7. Post weight after this patient's last dialysis session (kg)														
200. Date this form completed (dd/mon/yyyy)														
201. Username of person reviewing this form														
For Clinical Center Use Only:														
202. Username of person entering this form:														
203. Date entered: (dd/mon/yyyy) / /														

## Frequent Hemodialysis Network MRI Mailing Form # 251

No technician may do an MRI on an FHN study patient until they have submitted two test case MRI's to the Cardiac MRI Core Laboratory (CICL) and received feedback that the test MRI's were performed and processed correctly. MRI's are assumed to have been done at the MRI site associated with the patient's participating dialysis unit as recorded in the study database. This form should be completed at the time of the MRI or (*if the MRI is not done*) at the end of the visit window for the MRI (*if the MRI is not done*, use the end date of the visit window as Date of MRI - Item #4). If an MRI is done but is clearly of inadequate quality, repeat the MRI. Do not submit the MRI to the CICL and/or enter a mailing form.

It is preferable, but not mandatory, that the MRI be obtained either on a non-dialysis day or on the same day but after an HD session.

When this form has been completed, it should be photocopied. The copy should be sent with the MRI images to the CICL; make sure it is a clear, clean copy. The original should be entered by a Clinical Center and kept with the patient's other completed study forms. Be sure to make an extra copy of the patient's MRI scan. Ship the MRI and copy of Form 251 to the attention of:

#### Tam Tran, Mbabazi Kariisa

110 Davis Heart and Lung Institute 473 W 12th Ave Columbus OH 43210 Phone: 614-366-6434

On shipping day, send an email message to: *fhn-mricore@bio.ri.ccf.org*. For the e-mail message, use the following template:

"Please be advised that the Cardiac MRI for patient xxxxxx-xx has been shipped by Fed-ex today, (dd/mmm/yy). Tracking number is xxxx-xxxx. Please confirm with us upon receipt."

Items #1 - 6 are to be completed by the Study Coordinator.

									1					7							-		_
																				1	1		
	1	. Parti	cipant	ID#			2. Al <sub>1</sub>	pha		3a.Visi	t	3b. Vis	it Numl	ber		4. D	ate of	MRI:	dd/m	on/yy	уу		
			•				Cd	ode		Type													
5.	Was 1=Y		MRI (	done	durin	he vis	sit wii		v? 5=No,											•••••			
	2=N	o. na	tient	refus	ed				ť	6=No,	109	ristic	probl	em	relat	ed to	the	MR	I site	;			
						പ്പ	ted to	the p			302	,10010	proor	· · · · ·	10141	.cu ic	, 1110	1,11	1 5100				
			-	•				_				1		\(()			C 11		1	`			
	4=N	o, me	eaica	ı prot	oiem	(1.e	., pac	emak	er, r	netall	1C 11	mpiar	it, etc	.)(1	or us	e in	IOHO	w-uj	oni	y)			
	If MRI done, continue. If not done, skip to item 200.  6. Type of study																						
Iten	ns #7	-35 a	ire to	be c	ompl	ete	d by t	he M	RI T	<i><b>Techn</b></i>	icia	n.											
Hea	ırt R	ate																					
7	Hear	t rate	mea	sured	at th	e ti	ime o	f MR	I (hr	om)													
, .	Hour	ı ruic	incu	burcu	ut tii			1 1/110	1(0)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•••••	•••••	••••••		•••••	•••••	• • • • • • •	••••••	•••••				
MR	I																						
8.	Tiı	me of	f MR	I		••••					•••••	•••••		• • • •		• • • • • • •		(n	nilita	(y) _		:	
9	W	as the	ere re	onlar	·rhvt	hm	? (0=	No 1	=Ye	(25													

Re	vision of 16/JAN/2009	PID:		Date:	_//	Form #251 Page 2 of 3
10.	a. What was the gating	? (1= ECG	, 2=Pulse)			·······
	b. What gating method 1=Retrospective, as 2=Prospective					
	t Ventricular Function - e: Items 11 - 34 are not re			ie database	?.	
11.	Position: 4-chamber view	v:a. Sei	ries Number	b.	Slice position	
12.	Position: Proximal to base	e:a. Ser	ries Number	b.	Slice position	
13.	Position: Base:	a. Ser	ries Number	b.	Slice position	
14.	Next:	a. Sei	ries Number	b.	Slice position	
15.	Next:	a. Ser	ries Number	b.	Slice position	
16.	Next:	a. Ser	ries Number	b.	Slice position	
17.	Next:	a. Ser	ries Number	b.	Slice position	
18.	Next:	a. Ser	ries Number	b.	Slice position	
19.	Next:	a. Ser	ries Number	b.	Slice position	
20.	Next:	a. Ser	ries Number	b.	Slice position	
21.	Next:	a. Ser	ries Number	b.	Slice position	
22.	Next:	a. Ser	ries Number	b.	Slice position	
23.	Next:	a. Ser	ries Number	b.	Slice position	
24.	Next:	a. Ser	ries Number	b.	Slice position	
25.	Next:	a. Ser	ries Number	b.	Slice position	
26.	Next:	a. Ser	ries Number	b.	Slice position	
27.	Next:	a. Ser	ries Number	b.	Slice position	
28.	Next:	a. Sei	ries Number	b.	Slice position	
29.	Position: Apex:	a. Sei	ries Number	b.	Slice position	
30.	Position: Distal to Apex:	a. Ser	ries Number	b.	Slice position	
Cin	e Long Axis					
31.	Position: 3-Chamber View	wa. Sei	ries Number	b.	Slice position	
32.	Position: 2-Chamber view	va. Sei	ries Number	b.	Slice position	
Aoı	tic Stiffness					
33.	Position: LV outflow tra	act: a. Sei	ries Number	b.	Slice position	
34.	Position: Ascending aor	rta: a. Sei	ries Number	b.	Slice position	

35. Username of certified MRI tech who did this MRI. .....\_\_\_\_\_\_\_\_\_\_\_

Revision of 16/JAN/2009 PID:	Date:/	Form #251 Page 3 of 3
Items #36, 200-201 are to be completed by the Study Coo. 36. Date shipped to Central MRI Facility		//
For DCC Use Only: 199. MRI unreadable per core?	<u> </u>	
200. Date DCC notified	/	
200. Date this form completed (dd/mon/yyyy)		/
201. Username of person reviewing this form prior to data	entry	
For Clinical Center Use Only:		
202. Username of person entering this form:	· —— —— ——	
203. Date Entered: (dd/mon/yyyy)///		

## Frequent Hemodialysis Network MRI CENTRAL DATA ENTRY - FORM # 252A

This form is completed at the Cardiac MRI Core Laboratory (CICL). A staff member from the CICL will enter this into the study database. Many values will be calculated automatically and reported back to the Clinical Centers.

						r			1		i			, ,				1	1			
	1	. Partic	cipant 1	ID#			2. Alp		•	3a.Visit Type		3b. Vis	it Num	ber		4a. Da	ate of 1	MRI:	dd/mo	on/yyyy	V	•
4h	Date	this	MR	Lread	d (dd.	/m	on/vv	/VV)									/	,		/		
He	4b. Date this MRI read (dd/mon/yyyy)																					
Global Left Ventricular Function  6. Left ventricular end-diastolic volume: (ml)																						
7.	Left	vent	ricul	ar en	d-sys	sto	lic vo	olume	e: (n	nl)				• • • •	• • • • • •	•••••		••••				
			cular ricul			gr)	)						•••••		••••						•_	
					cular end-d			<b>on</b> volui	ne:	(ml).	•••••		•••••	••••	•••••	•••••		••••	··		•_	
10.	Righ	nt vei	ntricı	ılar e	end-s	yst	olic v	volun	ne: (	(ml)	•••••			• • • • •	•••••			•••••			<b>·</b> _	
_								ction (mm)			•••••			••••	••••					···		•
12.	Rel	ative	syste	olic t	hicke	eni	ng: (	%)			•••••		•••••	• • • •	• • • • • •	•••••		••••				
	(Wa	<mark>ll mo</mark>	tion	scor	e ind	ex i	<mark>move</mark>	ed to I	Fori	n 252	2 <mark>B a</mark>	is Itei	m #5.	.)								
<ul><li>14.</li><li>15.</li><li>16.</li></ul>	Mar Mir Mar	nimal xima	l area area l dia:	ı:(cm mete	<sup>2</sup> )	 n²) .					•••••		•••••								·_ ·	
201	. Us	ernar	ne of	f CIC	CL sta	ıff	mem	lber re	eadi	ng th	e M	IRI	•••••	••••	•••••	•••••						
202	. Us	serna	ame (	of pe	rson	en	terir	ng thi	s fo	rm:												
203	. Da	ate e	ntere	ed: (c	dd/m	on	/yyy	y)	/	/		/			_							

## Frequent Hemodialysis Network MRI WALL MOTION SCORE INDEX DATA ENTRY - FORM # 252B

This form is completed by the Cardiac MRI Core Laboratory (CICL) physician who reviews the MRI scan for the wall motion score index and clinical alerts. A staff member from the CICL will enter this into the study database.

1. Participant ID#  2. Alpha Sa.Visit Sumber 4a. Date of MRI: dd/mon/yyyy Code Type	<u> </u>
The Data wall motion score index masswed (dd/mon/www)	
4b. Date wall motion score index measured (dd/mon/yyyy)	
Segmental Left Ventricular Function  5. Wall motion score index:	
5. Wall motion score index:	_
201. Username of CICL staff member measuring wall motion score index	_
202. Username of person entering this form:	
203. Date entered: (dd/mon/yyyy)/ / /	

10.

### Frequent Hemodialysis Network HEART RATE VARIABILITY MAILING FORM - FORM # 253

This form is to be completed for the Daily Study only. Review MOP for instructions on how to complete the Holter testing. When this form has been completed, it should be photocopied. The copy should be sent with the Holter CD to the Central Holter Lab; make sure it is a clear, clean copy. The original should be entered by a Clinical Center and kept with the patient's other completed study forms. Be sure to make an extra copy of the patient's Holter CD. Ship by overnight courier, the CD and completed copy of Form 253 to the attention of:

Christopher T. Chan, M.D.

Division of Nephrology Toronto General Hospital
Eaton North 8N-842
200 Elizabeth Street
Toronto, Ontario M5G 2C4
Phone: 416-340-3073

On shipping day, send an email message to: holtercore@bio.ri.ccf.org (christopher.chan@uhn.on.ca and margaret.mcgrath-chong@uhn.on.ca). For the e-mail message, use the following template: "Please be advised that the Holter for patient xxxxxx-xx has been shipped by (overnight courier) today, (dd/mmm/yy). The tracking number is xxxx-xxxx. Please confirm with us upon receipt."

	1. Participant ID#	2. Alpha Code	3a.Visit Type	3b. Visit Number	4. Start Date of Holter: dd/mon/yyyy (Use target date if not done)	
5.	Was the Holter (hea 1=Yes, Holter comp 2=No, patient refuse 3=No, logistic probl to the patient	oleted ed	4=No, lo 5=No, m	gistic problem	n related to the FHN site n (i.e., sustained atrial fib-must review emaker, etc.)	
If H	olter done, continue. If	not done, ski	ip to item	200.		
6.		 ow)				
7.	Start time of Holter:	(use 24-hour	r clock)		:::	
8.	Stop time of Holter:	(use 24-hour	clock)		::	
9.	Username of person	placing the H	Holter			

Date shipped to the Central Reading Facility (dd/mon/yyyy) \_\_ \_\_ /\_ \_ \_ \_ /\_ \_ \_ \_ \_

Revis	ion <mark>5/SEPT/2008</mark> PID:	Date:	/	_/	Form #253
					Page 2 of 2
11.	a. Name of person completing thi	s form:			
	b. Telephone Number: /	<u>ex</u>	kt		
	c. E-Mail Address:				
	d. Name of FHN Clinical Center:				
	a. Holter unreadable per core? b. Date DCC notified: /_		_		
200. I	Date this form completed (dd/mon/y	уууу)	/_	/	′ <u> </u>
201. U	Username of person completing or i	reviewing this form		·	
	Clinical Center Use Only: Username of person entering th	nis form:			
203.	Date Entered: (dd/mon/yyyy) _	/			

# Frequent Hemodialysis Network CENTRAL HOLTER READING FACILITY DATA TRANSMISSION - FORM #254

Data are entered by the Central Holter Reading Facility. 2. Alpha Code 4. Date received at central facility: ...... (dd/mon/yyyy) \_\_\_ \_\_ /\_\_ \_\_ /\_\_ \_\_ \_\_ 5. Date read at central facility:......(dd/mon/yyyy) \_\_\_ \_\_ /\_\_ \_ \_\_ /\_\_ \_\_ \_\_ **Mean RR:** pNN50: 8. The proportion of differences in successive RR intervals >50ms (in percent): .....\_\_\_\_\_. \_\_\_. SDNN: 9. The standard deviation of RR intervals: (milliseconds):.....\_\_\_\_\_\_\_\_\_\_\_ VLF: LF: HF: LF/HF Ratio 200. User name of person entering this form: \_\_\_\_\_\_\_\_ 201. Date entered (dd/mon/yyyy): \_\_\_/\_ \_\_/\_ \_\_\_\_\_

8.

## Frequent Hemodialysis Network (FHN) <a href="U.S.">U.S.</a> BIOLOGICAL SPECIMEN REPOSITORY MAILING FORM - #255

NIDDK BioRepository Contact Information Address: Fisher BioServices Attn: Lab Manager NIDDK Repository 20301 Century Blvd. Building 6, Suite 400 Germantown, MD 20874		Bio-NIDDKRepository@ther (240) 686-4703 (Heather Higg (240) 686-4702 (Sandra Ke) (301) 515-4049						
You will need to complete one Form 255 for each PID in the shipment. Ship samples to the address above in the mailer provided. Spin tubes and ship them on cold packs. Mondays through Thursdays, notify the repository of shipments by e-mail* or by facsimile on the day the package is picked up by FedEx. Refer to Chapter 22 for details on how to process vacutainers for shipment. <i>Do not ship on Fridays</i> . Enclose this original form in the mailer. Keep a copy of this form. <i>Enter items 1 to 9a only into the FHN database</i> .								
On shipping day, send an email message to: <i>Bio-NIDDKRepository@thermofisher.com</i> . For the e-mail message, use the following template: "Please be advised that biorepository samples for patient(s) xxxxxx-xx has/have been shipped by Fed-ex today, (dd/mmm/yy). Tracking number is xxxx-xxxx. Please confirm with us upon receipt."								
Section A: To be completed at the FHN site	:							
4. Date specimen collected	ected will be		Number _/					
5. a. Time of <u>pre-dialysis</u> blood draw		(24 hour clock	·) :					
b. Time of post-dialysis blood draw								
<u>Serum</u>			DCC Use # Hemolyzed?					
6.a. Number of <u>pre-dialysis</u> 7.5 mL SST tubes (ser	rum) sent	to Repository						
b. Number of post-dialysis 7.5 mL SST tubes (see	erum) sen	t to Repository						
<u>Plasma</u>								
7.a. Number of <u>pre-dialysis</u> 8 mL PST tubes (plass	ma) sent t	o Repository	<del></del>					
b. Number of post-dialysis 8 mL PST tubes (plas	sma) sent	to Repository						

		Page 2 of 2						
9. a. Username of person completing this form	<u> </u>							
Items 9 b, c, & d are required by NIDDK Bio will not be entered into the database.								
b. Telephone number:	/							
c. E-mail address:								
d. Name of FHN Clinical Center:								
Items contained in the boxes are for individual cen		nto the database.						
BioRepository notified via  Email Fax	Date of Notification:	Time:						
		•						
Fed Ex Tracking #:	(dd/mon/yyyy)	(24 hour clock						
Do the PID's on this form correspond with the l	PID's on the vacutainer labels?	Yes No						
Completed by Date of	or Receipt (dd/mon/yyyy)	_/						
-								
	Vere any of the samples hemolyzed? (Notify DCC)							
If not, describe the error as well as any other discrepancies and notify a supervisor								
,								
For Clinical Center Use Only:								

**NIDDK BioRepository Contact Information** 

# Frequent Hemodialysis Network (FHN) INTERNATIONAL BIOLOGICAL SPECIMEN REPOSITORY MAILING FORM - #256

Addre		ss: Fisher BioServices Attn: Lab Manager				]	Email: Bio-NIDDKReposi				sitory@thermofisher.com							
	I	NIDDK R	epositor	y					one:				-			ggins)	)	
		20301 Cer Building 6	•					Pho Faz	one:	(240)				Sandra	ı Ke)	)		
		Germanto			74			гах	х:	(301)	) 31.	3-4U	49					
You v	vill n	eed to cor	nplete o	ne fo	rm F2	256 fc	or each	ı PID	) in th	e shipn	nent	. Sh	ip sa	mples	s to t	he ado	lress at	ove in
the ma	ailer	provided.	See spe	ecific	detai	ls in t	the FH	IN M	IOP C	hapter	22,	for d	letail	ed ins	struct	tions f	or whe	
•		ow to com of shipme	•		•				•						_			ocony
all for	ms a	nd save co																
FHN o	datal	pase.																
		ng day, se				ige to	: <mark>Bio-</mark>	NIDI	DKRe <sub>j</sub>	<mark>positor</mark>	y@ <i>t</i>	hern	nofis.	her.co	<mark>om</mark> . ]	For th	e e-ma	il
	_	se the foll advised the	_	-		omple	os for 1	notio	nt(c) s	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	vv.	hoc/l	howo	haan	chin	nad br	, End o	w
		mmm/yy)																X
Section	on A.	To be co	mpleted	l by (	Clinic	al Ce	enter											
				1														
				-														
	1a.	Repository II	<b>D</b> #		1b. Pa	articipa	int ID#				2	. Alpl Cod		3a.Vi Typ		Bb. Visit	Number	
4.	Date	specimen	collecte	ed						(d	ld/m	on/y	уууу)		/	/	, 	
5.	a. Time of pre-dialysis blood draw				(24 hour clock)::													
	b. T	ime of <u>po</u>	st-dialys	sis bl	ood di	raw								(24 h	our c	lock)_	:	
												_						
6. S	Serum	Products S	Sent/Rec	eived										ber Se HN Si			nber R <u>Fisher</u>	ec'd at
	0	<u>Serum</u> Number (	of 0.2 ml	olian	ota of	nro di	iolymia		n cont									
	a. b.	Number of		-		•	•											
	υ.																	
	c.	Number		_		_	-											
	d.	Number	of other of	quanti	ty of <u>p</u>	ost-di	ialysis	serun	n sent:		•••••	•••••						
			2 2		·									ber Se				ec'd at
7. F	Plasma Products Sent/Received: Plasma									by F	HN Si	<u>te</u>	<u>at</u>	<u>Fisher</u>				
	a.	Number	of .0.2 m	l aliqı	ots of	pre-d	<u>lialysis</u>	plası	<u>ma</u> ser	ıt:								
	b.	Number	er of other quantity ml aliquots of <u>pre-dialysis plasma</u> sent:															
	c.	Number	of 0.2 ml	aliqu	ots of	post-c	dialysis	s plas	<u>ma</u> sei	nt:								

# Frequent Hemodialysis Network (FHN) INTERNATIONAL BIOLOGICAL SPECIMEN REPOSITORY MAILING FORM - #256

d.	Number of other qua	antity ml aliquots of	post-dialysis plasma sent:	
----	---------------------	-----------------------	----------------------------	--

Re	vision 29/NOV/2006	PID:	Date:/	FHN Form #256 Page 3 of 3						
8.	Date shipped to Repo	sitory	(dd/mon/yyyy)/	_/						
9.	a. Username of pers	on completing this f								
	Items 9 b, c, & d are will not be entered in		K BioRepository at Fisher but							
	b. Telephone number	er:	_/							
	c. E-mail address:	c. E-mail address:								
	d. Name of FHN Cl	inical Center:								
			center use only. They will not be entered in							
BioRe Email	pository notified via Fax	Notified by:	Date of Notification:	Time:						
	<del></del>		/	(24 hour clock)						
T Cu L	Tracking #:		(dd/mon/yyyy)	(2 : 11001 010011)						
	-	•	e of Receipt (dd/mon/yyyy)//							
Do	the PID's on this form c	orrespond with the F	PID's on the cryovial labels?	Yes No						
We	re any of the samples he	molyzed? (Notify D	CC)	Yes No						
If n	ot, describe the error as	well as any other dis	crepancies and notify a supervisor							
_										
	Clinical Center Use	v								
200	). Username of perso	n entering this fo	rm:							
201	. Date Entered: (dd/	mon/yyyy)	/ /							

## Frequent Hemodialysis Network CANADIAN REPOSITORY COLLECTION DATE – FORM #257

Instructions: For Canadian Center Use Only. Follow instructions in Chapter 22 of MOP for blood processing and freezing instructions. Complete and enter this Form 257 into database (Complete and enter Form 256 when shipping to the Repository).

1. Participant ID #	2. Alpha Code	3a. Visit Type	3b. Visit #			
4. Date blood collected for Repository (dd/r	non/vvvv)		/	/		
				-'		
200. Date this form completed (dd/mon/yyyy)		······ <u> </u>	/	_/		
201. Username of person completing this form						
For Clinical Center Use Only:						
202. Username of person entering this form	ı:					
203. Date Entered: (dd/mon/yyyy)/_	/					

## Frequent Hemodialysis Network ACCESS USED FOR CHRONIC HEMODIALYSIS - FORM 271

#### **Instructions:**

**Trial:** This form is completed at baseline and whenever the patient's access currently being used for chronic hemodialysis changes.

**Extended Follow-up Study:** Complete this form at time of final Extended Follow-up Study visit to identify what access is currently being used (even if it is the same access used throughout the trial).

***	at access is carrently being as	ba (even ii it is the same access a	ased un oughout the triar).				
		1. Participant ID #	2. Alpha Code				
4.	1=AV fistula 2=AV graft (note: if any pa 3=Tunneled catheter	tient is currently using for chronic rt of an access is a graft, then it it te: use of non-tunneled catheter it					
5.		) was placed? (dd/mon/yyyy) cess and placement date is unknown					
Foi	r Grafts or Fistulas:						
6.			<u> </u>				
	1=Forearm	3=Leg	8=Not applicable				
	2=Upperarm	4=Chest (be sure to comp	plete Q7)				
_		3=Not applicable)					
	<u>r Tunneled Catheters:</u>						
/.			O_Disht artamal incular				
	0=None	•	9=Right external jugular				
	1=Right internal jugular 2=Left internal jugular						
	3=Right subclavian	8=Right translumbar inferior	vena cava				
	4=Left subclavian	(if other codes are needed, email					
8.	3. Date that access first used for chronic HD therapy: (mon/yyyy)/						
9.		nd, different type of access that h	nas been placed				
	0=No	2=Yes, a fistula					
	1=Yes, a graft	3=Yes, a catheter					
200	Date this form completed (dd	/mon/yyyy)	///				
201	. Username of person reviewin	g completeness of this form					
For 202	Clinical Center Use Only: . Username of person entering the	his form:					
203	. Date Entered: (dd/mon/yyyy)	//					

## Frequent Hemodialysis Network KINETIC MODELING FORM - FORM #273

**Instructions**: This form is to be completed by the study coordinator and the dialysis unit technician on the FHN Trial kinetic modeling day sessions that occur during baseline, and monthly during follow-up. Kinetic modeling should not be performed at sessions with isolated ultrafiltration. However, kinetic modeling should be performed at a session designated for collection of kinetic modeling irrespective of any interruption time. A Form 274 must be completed with each kinetic modeling session to document information from the dialysis run sheet during the week preceding the kinetic modeling session. In nocturnal protocol version 3.0, two kinetic modeling sessions must be completed during baseline.

con	npieted during baseline.								
	1. Participant ID#  2. Alpha 3a.Visit 3b. Visit Number 4. Date of Kinetic Modeling: dd/mon/yyyy Code Type								
Que	estions 5–16 refer to specific dialysis treatment at which kinetic modeling is performed.								
5.	a. Type of session								
	b. Where was the dialysis conducted? (1=In-center dialysis unit, 2=At home)								
6.	Dialysis membrane type (from code list at end of document)								
7.	Reuse number (enter 0 if this is the first use of the dialyzer)								
<b>We</b> 8.	a. Patient target weight (estimated dry weight) (kg)								
	b. Pre-dialysis weight (kg)								
	c. Post-dialysis weight (kg)								
Acc	cess								
9.	a. Current type of vascular access								
	<ul> <li>b. Has there been a surgical or radiological intervention to improve access function or a change in the type of access since the previous kinetic modeling session?</li></ul>								
	[If the answer to Q9b is "2", please answer questions 9b1-9b2 below. Otherwise skip to Q9c if on Nocturnal Trial.]								
	b1. Has there been a surgical or radiological intervention to improve access function since the previous kinetic modeling session?								

Rev		orm #2' age 2 of
9.	b2. Did the access fail (access removed or can no longer be used) since the previous kinetic modeling session?  0=No (no access failure)  1=Yes (complete F277 for each instance)	
	(Note: if a new access was placed since the last KM session, complete F278. And if a different access is being used for HD, be sure to complete F271.)	
9.	c. For Nocturnal Trial Only: Was a buttonhole access used? (0=No, 1=Yes)	
10.	What kind of needle was used for this patient's hemodialysis?	
11.	Prescribed treatment time (minutes) for this session:	
12.	a. Start time of dialysis treatment (24-hour time):	:
	b. End time of dialysis treatment (24-hour time):	:
	er the start and end time to reflect actual dialysis (in which the blood pump is on), and not count the time period with isolated ultrafiltration.	
13.	Was there a serious interruption during this session? (0=No, 1=Yes)	
14.	Machine readout of actual dialysis treatment time (minutes)	
15.	Average blood flow achieved during session (ml/min)	
16.	Recorded dialysate flow (ml/min)	
<b>Con</b> 17.	nplications: Complications experienced in the current dialysis treatment - use the following codes: 0=No 1=Yes, but not requiring saline, lowering of UF rate, or reduced blood flow 2=Yes, requiring either saline, lowering of UF rate, or reduced blood flow (nocturnal: need to give back saline at the end of dialysis due to hypotension or symptoms)	:
	a. Cramping?	
	b. Nausea or vomiting?	
	c. Chest pain?	
Blo	od Pressures:	
18.	a. <u>Pre</u> -dialysis blood pressure (mmHg) (systolic/diastolic)//	
	b. Post-dialysis blood pressure (mmHg) (systolic/diastolic)	

ision of <mark>09/OCT/2009</mark> PID:	Date:	/	/	Form #273 Page 3 of 9				
ysate: Based on the dialysis run sheet, indicate the concentrations of the following substances in the dialysate:								
dialysis. If these concentrations are not more concentrations for magnesium, calcium, and	dified, leave the fin d bicarbonate are p	al conce resumed	ntrations blank	. Only single				
a. Initial Sodium (mEq/L)				······				
or in SI units (mmol/L)								
b. Final Sodium (mEa/L)								
c Initial Potassium (mFq/L)								
· • •								
	_							
	in decimal field if	not avai	lable)					
or in SI units (mmol/L)		•••••						
c. Pre-dialysis serum creatinine (mg/	/dL)		•••••	······				
or in SI units (µmol/L)								
d. Post-dialysis serum creatinine (mg	g/dL)			······				
e Pre-dialysis serum phosphate (mg	/dI )							
	Based on the dialysis run sheet, indices substances in the dialysate:  Separate items for initial and final sodium is dialysis. If these concentrations are not mo concentrations for magnesium, calcium, and modified during dialysis, please enter the interest a. Initial Sodium (mEq/L)	Based on the dialysis run sheet, indicate the concent substances in the dialysate:  Separate items for initial and final sodium in the dialysate are dialysis. If these concentrations are not modified, leave the fin concentrations for magnesium, calcium, and bicarbonate are p modified during dialysis, please enter the initial concentration.  a. Initial Sodium (mEq/L)	Based on the dialysis run sheet, indicate the concentrations substances in the dialysate:  Separate items for initial and final sodium in the dialysate are provided dialysis. If these concentrations are not modified, leave the final conce concentrations for magnesium, calcium, and bicarbonate are presumed modified during dialysis, please enter the initial concentration.  a. Initial Sodium (mEq/L)	Based on the dialysis run sheet, indicate the concentrations of the follow substances in the dialysate:  Separate items for initial and final sodium in the dialysate are provided in case these of dialysis. If these concentrations are not modified, leave the final concentrations blank concentrations for magnesium, calcium, and bicarbonate are presumed. If one of these modified during dialysis, please enter the initial concentration.  a. Initial Sodium (mEq/L)				

Revision of 09/OCT/2009 PID:\_\_\_\_\_ Date:\_\_\_/\_\_\_\_

Rev	rision of <mark>09/OCT/2009</mark> PID: Date:/	Form #273 Page 4 of 9
<i>Pati</i> f.	ient's Lab Measurements continued:  Post-dialysis serum phosphate (mg/dL)	•_
	or in SI units (mmol/L)	·
	Note: The date pre-samples are drawn is the date of the kinetic modeling session (see Q4). Enter the date the post-samples are drawn below in Q20h.	
	h. Date post-dialysis samples drawn (dd/mon/yyyy)///	
21.	a. Monthly serum albumin (g/dL)	
	or in SI units (g/L)	
	b. Date monthly serum albumin drawn (dd/mon/yyyy)///	
Noc	cturnal Trial Only:	
poss to w Pati	e study coordinator should obtain the response to this question from the patient sible to the day of this kinetic modeling session. (It is recommended that patient write this down on a log sheet.)  ient response to the question "When you drew your blood just before this kinetic deling session, what was the date and time of your last medium or large meal?"	
22.	a. Date when closest medium/large meal eaten (not including snacks)  just before this dialysis session (dd/mon/yyyy)//////	
	b. Time of day when meal eaten (use 24-hour clock):	:
	c. Did patient eat a medium/large meal <u>during</u> this dialysis session? (0=No, 1=Ye Note: If you or the patient is not sure whether food eaten was a meal or a snaw or whether the meal was small, medium, or large, ask your center's Principal Investigator to decide.	
200	Date this form completed (dd/mon/yyyy)	
201	. Username of person reviewing completeness of this form	
For	Center Use Only:	
202	. Username of person entering this form:	
203	. Date entered: (dd/mon/yyyy)//	
***	*************************	******

Use the four-digit codes numbers on the following pages to answer Question #6. The list is in order by dialyzer membrane name, then model.

CODE	BRAND	MODEL	1136 Asahi	AMR 75U	CODE	BRAND	MODEL	1406	Bellco	BLS 517 SD
1001	Allmed	Opal 110 S	1137 Asahi	AMR 90U	1226	B. Braun Medtech	Diacap SMC 1.5	1407	Bellco	BLS 714 G
1002	Allmed	Opal 130 S	1138 Asahi	APS 1050	1227	B. Braun Medtech	Diacap SMC 1.5 SD	1408	Bellco	BLS 714 SD
1003	Allmed	Opal 160 S	1139 Asahi	APS 1050 MD		B. Braun Medtech	Diacap SMC 1.8	1409	Bellco	BLS 716 G
1004	Allmed	Opal 180 S	1140 Asahi	APS 1050S		B. Braun Medtech	Diacap SMC 1.8 SD	1410	Bellco	BLS 716 SD
1005	Allmed	Opal 200 S	1141 Asahi	APS 13 U		Di Diddii iiiodiooii	Slasap Silie III GB	1411	Bellco	BLS 719 G
1006	Allmed	Opal 220 S	1142 Asahi	APS 15 U	1301	Baxter	CA 110 G	1412	Bellco	BLS 719 SD
1007	Allmed	Quartz 100 S	1143 Asahi	APS 18 U	1302	Baxter	CA 130 G	1413	Bellco	BLS 803
1007	Allmed	Quartz 130 S	1144 Asahi	APS 21 U	1303	Baxter	CA 150 G	1414	Bellco	BLS 805
1009	Allmed	Quartz 160 S	1145 Asahi	APS 550	1304	Baxter	CA 170 G	1415	Bellco	BLS 807
1010	Allmed	Quartz 180 S	1146 Asahi	APS 550S	1305	Baxter	CA 210 G	1416	Bellco	BLS 809
1010	Allmed		1147 Asahi	APS 650	1305	Baxter	CA 50 G	1417	Bellco	BLS 812 G
1011		Ruby 130 S		APS 650 MD	1300		CA 50 G CA 70 G	1417	Bellco	BLS 812 SD
1012	Allmed Allmed	Ruby 160 S	1148 Asahi 1149 Asahi	APS 650S	1307	Baxter	CA 70 G CA 90 G	1419		BLS 814 G
		Ruby 180 S				Baxter			Bellco	
1014	Allmed	Topaz 100 S	1150 Asahi	APS 900	1309	Baxter	CA-HP 110	1420	Bellco	BLS 814 SD
1015	Allmed	Topaz 130 S	1151 Asahi	APS 900 MD	1310	Baxter	CA-HP 130	1421	Bellco	BLS 816 G
1016	Allmed	Topaz 160 S	1152 Asahi	APS 900S	1311	Baxter	CA-HP 150	1422	Bellco	BLS 816 SD
1017	Allmed	Topaz 180 S	1153 Asahi	PAN 03	1312	Baxter	CA-HP 170	1423	Bellco	BLS 819 G
			1154 Asahi	PAN 06	1313	Baxter	CA-HP 210	1424	Bellco	BLS 819 SD
1101	Asahi	AM 500H SD	1155 Asahi	PAN 10	1314	Baxter	CA-HP 90	1425	Bellco	NC 1285
1102	Asahi	AM 50H SD	1156 Asahi	PAN 1000 SF	1315	Baxter	CT 110 G	1426	Bellco	NC 1285 G
1103	Asahi	AM 650H SD	1157 Asahi	PAN 110 DX	1316	Baxter	CT 150 G	1427	Bellco	NC 1285 SD
1104	Asahi	AM 65H SD	1158 Asahi	PAN 65 DX	1317	Baxter	CT 190 G	1428	Bellco	NC 1485
1105	Asahi	AM 750U SD	1159 Asahi	PAN 650 SF	1318	Baxter	CT 90 G	1429	Bellco	NC 1485 G
1106	Asahi	AM 75U SD	1160 Asahi	PAN 85 DX	1319	Baxter	Dicea 110 G	1430	Bellco	NC 1485 SD
1107	Asahi	AM BIO 100	1161 Asahi	PAN 900 SF	1320	Baxter	Dicea 130 G	1431	Bellco	NC 1785
1108	Asahi	AM BIO 1000	1162 Asahi	PAN HFD 30	1321	Baxter	Dicea 150 G	1432	Bellco	NC 1785 G
1109	Asahi	AM BIO 1000 WET	1163 Asahi	REXEED-25	1322	Baxter	Dicea 170 G	1433	Bellco	NC 1785 SD
1110	Asahi	AM BIO 50	1164 Asahi	REXEED-18R	1323	Baxter	Dicea 210 G	1434	Bellco	NC 2085
1111	Asahi	AM BIO 500 WET			1324	Baxter	Dicea 90 G	1435	Bellco	NC 2085 G
1112	Asahi	AM BIO 65	1201 B. Braun Medtech	Diacap CE 1100	1325	Baxter	Exeltra 150	1436	Bellco	NC 2085 SD
1113	Asahi	AM BIO 650	1202 B. Braun Medtech		1326	Baxter	Exeltra 170	1437	Bellco	NC 2285 G
1114	Asahi	AM BIO 650 WET	1203 B. Braun Medtech		1327	Baxter	Exeltra 190	1438	Bellco	NT 1175
1115	Asahi	AM BIO 75	1204 B. Braun Medtech		1328	Baxter	Exeltra Plus 210	1439	Bellco	NT 1208 H
1116	Asahi	AM BIO 750	1205 B. Braun Medtech		1329	Baxter	PSN 120	1440	Bellco	NT 1208 HG
1117	Asahi	AM BIO 750 WET	1206 B. Braun Medtech	•	1330	Baxter	PSN 140	1441	Bellco	NT 1208 SD
1118	Asahi	AM BIO HX 1000	1207 B. Braun Medtech		1331	Baxter	PSN 150	1442	Bellco	NT 1265 H
1119	Asahi	AM BIO HX 650	1207 B. Braun Medtech	•	1332	Baxter	PSN 170	1443	Bellco	NT 1265 HG
1117	Asahi	AM BIO HX 750	1209 B. Braun Medtech		1333	Baxter	PSN 210	1443	Bellco	NT 1375
1120	Asahi	AM BIO UP 650	1210 B. Braun Medtech		1334	Baxter	Syntra 120	1445	Bellco	NT 1408 H
1121	Asahi	AM BIO UP 750	1210 B. Braun Medtech		1335	Baxter	Syntra 160	1445	Bellco	NT 1408 HG
1122	Asahi	AM SD 1000 U	1211 B. Braun Medtech		1336		Tricea 110 G	1440		NT 1408 FIG NT 1408 SD
					1337	Baxter			Bellco	
1124	Asahi	AM SD 300	1213 B. Braun Medtech			Baxter	Tricea 130 G	1448	Bellco	NT 1665 H
1125	Asahi	AM SD 400 M	1214 B. Braun Medtech		1338	Baxter	Tricea 150 G	1449	Bellco	NT 1665 HG
1126	Asahi	AM SD 400 U	1215 B. Braun Medtech		1339	Baxter	Tricea 170 G	1450	Bellco	NT 1675
1127	Asahi	AM SD 500 H	1216 B. Braun Medtech		1340	Baxter	Tricea 190 G	1451	Bellco	NT 1808 H
1128	Asahi	AM SD 500 M	1217 B. Braun Medtech		1341	Baxter	Tricea 210 G	1452	Bellco	NT 1808 HG
1129	Asahi	AM SD 500 U	1218 B. Braun Medtech		1342	Baxter	Xenium 170	1453	Bellco	NT 1808 SD
1130	Asahi	AM SD 650 H	1219 B. Braun Medtech			D II	DI 0 540 C	1454	Bellco	NT 1975
1131	Asahi	AM SD 650 U	1220 B. Braun Medtech	•	1401	Bellco	BLS 512 G	1455	Bellco	SG 30 Plus
1132	Asahi	AM SD 750 U	1221 B. Braun Medtech		1402	Bellco	BLS 512 SD	1456	Bellco	SG 40 Plus
1133	Asahi	AM UP 75 WET	1222 B. Braun Medtech		1403	Bellco	BLS 514 G	1457	Bellco	SG 8 Plus
1134	Asahi	AMR 50U	1223 B. Braun Medtech		1404	Bellco	BLS 514 SD			
1135	Asahi	AMR 65U	1224 B. Braun Medtech		1405	Bellco	BLS 517 G	CODE	BRAND	MODEL
			1225 B. Braun Medtech	Diacap SMC 1.2 SD				1501	Even	EBM 100
CODE	BRAND	MODEL	1		CODE	BRAND	MODEL	1502	Even	EBM 120

											Page 6 of 9
1503	Even	EBM 140	1704	Fresenius	E 2 DS	1759	Fresenius	Optiflux 180 B	1852	Gambro	Revaclear-Max
1504	Even	EBM 160	1705	Fresenius	E 2 S	1760	Fresenius	Optiflux 200 B			
1505	Even	EBM 180	1706	Fresenius	E 3				1901	Gross-O-Pharm	Future 1.0
1506	Even	EBM 200	1707	Fresenius	E 3 DS	1801	Gambro	100 HG	1902	Gross-O-Pharm	Future 1.2
1507	Even	EC 100	1708	Fresenius	E3S	1802	Gambro	Alwall GFE 09	1903	Gross-O-Pharm	Future 1.4
1508	Even	EC 120	1709	Fresenius	E 4	1803	Gambro	Alwall GFE 11	1904	Gross-O-Pharm	Future 1.6
1509	Even	EC 140	1710	Fresenius	E 4 DS	1804	Gambro	Alwall GFE 12	1905	Gross-O-Pharm	Present 1.0
1510	Even	EC 160	1711	Fresenius	E4S	1805	Gambro	Alwall GFE 15	1906	Gross-O-Pharm	Present 1.2
1511	Even	EC 190	1712	Fresenius	F 10 HPS	1806	Gambro	Alwall GFE 18	1907	Gross-O-Pharm	Present 1.4
1512	Even	EC 210	1713	Fresenius	F 3	1807	Gambro	Alwall GFS 12	1908	Gross-O-Pharm	Present 1.6
1513	Even	EC 260	1714	Fresenius	F 4	1808	Gambro	Alwall GFS 16	1909	Gross-O-Pharm	Synergie 0.61
1514	Even	EH 100	1715	Fresenius	F 4 HPS	1809	Gambro	Alwall GFS Plus 11	1910	Gross-O-Pharm	Synergie 0.9
1515	Even	EH 120	1716	Fresenius	F 40	1810	Gambro	Alwall GFS Plus 12	1911	Gross-O-Pharm	Synergie 1.21
1516	Even	EH 140	1717	Fresenius	F 40 S	1811	Gambro	Alwall GFS Plus 16	1912	Gross-O-Pharm	Synergie 1.5
1517	Even	EH 160	1718	Fresenius	F 5	1812	Gambro	Alwall GFS Plus 20			, ,
1518	Even	EH 190	1719	Fresenius	F 5 HPS	1813	Gambro	Aria 550 *	2001	Haidylena	HL 100
1519	Even	EH 210	1720	Fresenius	F 50	1814	Gambro	Aria 700 *		Haidylena	HL 100 B
1520	Even	EH 260	1721	Fresenius	F 50 S	1815	Gambro	Lundia Alpha 400 *		Haidylena	HL 100 H
			1722	Fresenius	F 6	1816	Gambro	Lundia Alpha 500 *		Haidylena	HL 110
1601	Fidia	Diadema 110 HF	1723	Fresenius	F 6 HPS	1817	Gambro	Lundia Alpha 600 *		Haidylena	HL 110 H
1602	Fidia	Diadema 110 LF	1724	Fresenius	F 60	1818	Gambro	Lundia Alpha 700 *		Haidylena	HL 120
1603	Fidia	Diadema 110 MF	1725	Fresenius	F 60 Light	1819	Gambro	Lundia Pro 100		Haidylena	HL 120 H
1604	Fidia	Diadema 130 HF	1726	Fresenius	F 60 S	1820	Gambro	Lundia Pro 200		Haidylena	HL 130
1605	Fidia	Diadema 130 LF	1727	Fresenius	F 7	1821	Gambro	Lundia Pro 500		Haidylena	HL 130 B
1606	Fidia	Diadema 130 MF	1728	Fresenius	F 7 HPS	1822	Gambro	Lundia Pro 500 G		Haidylena	HL 130 H
1607	Fidia	Diadema 150 HF	1729	Fresenius	F 70 S	1823	Gambro	Lundia Pro 600		Haidylena	HL 130 HS
1608	Fidia	Diadema 150 LF	1730	Fresenius	F 8	1824	Gambro	Lundia Pro 600 G		Haidylena	HL 130 S
1609	Fidia	Diadema 150 MF	1731	Fresenius	F 8 HPS	1825	Gambro	Lundia Pro 800		Haidylena	HL 140 H
1610	Fidia	Diadema 170 HF	1732	Fresenius	FX 10	1826	Gambro	Lundia Pro 800 G		Haidylena	HL 160
1611	Fidia	Diadema 170 LF	1733	Fresenius	FX 100	1827	Gambro	Polyflux 10 L		Haidylena	HL 160 B
1612	Fidia	Diadema 170 MF	1734	Fresenius	FX 40	1828	Gambro	Polyflux 11		Haidylena	HL 160 H
1613	Fidia	Diadema 190 HF	1735	Fresenius	FX 50	1829	Gambro	Polyflux 11 S		Haidylena	HL 180 H
1614	Fidia	Diadema 190 LF	1736	Fresenius	FX 60	1830	Gambro	Polyflux 14		Haidylena	HL 200 H
1615	Fidia	Diadema 190 MF	1737	Fresenius	FX 60 M	1831	Gambro	Polyflux 14 L		Haidylena	HL 220 H
1616	Fidia	Diadema 210 HF	1738	Fresenius	FX 8	1832	Gambro	Polyflux 14 S		Haidylena	HL 90
1617	Fidia	Diadema 210 LF	1739	Fresenius	FX 80	1833	Gambro	Polyflux 140H		Haidylena	HP 100
1618	Fidia	Diadema 210 MF	1740	Fresenius	FX 80 M	1834	Gambro	Polyflux 17		Haidylena	HP 100 S
1619	Fidia	Even 110 H	1741	Fresenius	HDF 100 S	1835	Gambro	Polyflux 17 L		Haidylena	HP 120
1620	Fidia	Even 130 H	1742	Fresenius	HF 60 LS	1836	Gambro	Polyflux 17 S		Haidylena	HP 120 S
1621	Fidia	Even 150 H	1743	Fresenius	HF 80	1837	Gambro	Polyflux 170 H		Haidylena	HP 130
1622	Fidia	Even 180 H	1744	Fresenius	HF 80 LS	1838	Gambro	Polyflux 21		Haidylena	HP 130 S
1623	Fidia	Even 200 H	1745	Fresenius	HF 80 Light	1839	Gambro	Polyflux 21 L		Haidylena	HP 160
1624	Fidia	Syntex 110 S	1746	Fresenius	HF 80 S	1840	Gambro	Polyflux 21 S		Haidylena	HP 160 S
1625	Fidia	Syntex 130 S	1747	Fresenius	Hemaflo 1.0	1841	Gambro	Polyflux 210 H		Haidylena	HP 180
1626	Fidia	Syntex 150 S	1748	Fresenius	Hemaflo 1.3	1842	Gambro	Polyflux 24 S		Haidylena	HP 180 S
1627	Fidia	Syntex 170 S	1749	Fresenius	Hemaflo 1.8	1843	Gambro	Polyflux 6 L		Haidylena	HP 200
1628	Fidia	Syntex 190 S	1750	Fresenius	Optiflux F 160 NR	1844	Gambro	Polyflux 6 S		Haidylena	HP 200 S
1629	Fidia	Syntex 210 S	1751	Fresenius	Optiflux F 180 A	1845	Gambro	Polyflux 6B		Haidylena	HPH 130S
.027	. raia	- J 2.10 G	1752	Fresenius	Optiflux F 180 NR	1846	Gambro	Polyflux 8 L		Haidylena	HPH 160S
			1753	Fresenius	Optiflux F 200 A		Cambro	. o.yax o z		Haidylena	HPH 180H
			1754	Fresenius	Optiflux F 200 NR	CODE	BRAND	MODEL			
			CODE		MODEL	1847	Gambro	Polyflux 8B	COD	E BRAND	MODEL
CODE	BRAND	MODEL	1755	Fresenius	Primaflo 1.0 E	1848	Gambro	Polyflux 24 R		Haidylena	HPH 180S
1701	Fresenius	E 1	1756	Fresenius	Primaflo 1.3 E	1849	Gambro	Polyflux 21 R		Haidylena	HPM 100S
1702	Fresenius	E1S	1757	Fresenius	Primaflo 1.8 E	1850	Gambro	Polyflux 17 R		Haidylena	HPM 130S
1703	Fresenius	E 2	1758	Fresenius	HF 80 A	1851	Gambro	Revaclear		Haidylena	HPM 160S
									. 2007		

								Page / or 9
2040 Haidylena	HPM 180S	2211 Hemofarm	F 5	2418 Idemsa	1400		JMS	BF 170
		2212 Hemofarm	F 5 HPS	2419 Idemsa	1400 HF		JMS	JC 1080
2101 Helbio	Ac 10	2213 Hemofarm	F 50	2420 Idemsa	15		JMS	JC 1280
2102 Helbio	Ac 13	2214 Hemofarm	F 50 S	2422 Idemsa	15 H		JMS	JC 1480
2103 Helbio	Ac 15	2215 Hemofarm	F 6	2424 Idemsa	160		JMS	JC 1680
2104 Helbio	Ac 18	2216 Hemofarm	F 6 HPS	2426 Idemsa	160 MHP	2509	JMS	JH 1080
2105 Helbio	Ac 22	2217 Hemofarm	F 60	2427 Idemsa	1600	2510	JMS	JH 1280
2106 Helbio	Bio 100	2218 Hemofarm	F 60 S	2428 Idemsa	1600 HF	2511	JMS	JH 1480
2107 Helbio	Bio 1000			2429 Idemsa	180		JMS	JH 1680
2108 Helbio	Bio 120	2301 Hospal	Crystal 2800 ST *	2431 Idemsa	180 MHP	2513	JMS	SM 110
2109 Helbio	Bio 1200	2302 Hospal	Crystal 3400 ST *	2432 Idemsa	1800		JMS	SM 130
2110 Helbio	Bio 140	2303 Hospal	Crystal 4000 ST *	2433 Idemsa	1800 HF		JMS	SM 150
2111 Helbio	Bio 1400	2304 Hospal	Diacepal DA 12	2434 Idemsa	20		JMS	SM 170
2112 Helbio	Bio 160	2305 Hospal	Diacepal DA 14	2436 Idemsa	20 H	2010	SIVIO	SIVI 170
2113 Helbio	Bio 1600	2306 Hospal	Diacepal DA 16	2438 Idemsa	200	2601	Kawasumi	Diapes R 12
2114 Helbio	Bio 180	2307 Hospal	Diacepal DA 20	2440 Idemsa	200 MHP		Kawasumi	Diapes R 15
2115 Helbio	Bio 1800	2308 Hospal	Disscap 120 SE	2441 Idemsa	2000		Kawasumi	Diapes R 18
2116 Helbio	Bio 200	2309 Hospal	Disscap 150 SE	2442 Idemsa	2000 2000 HF		Kawasumi	MA 08 H
2117 Helbio	Bio 2000	2310 Hospal	Disscap 180 SE	2443 Idemsa	23		Kawasumi	MA 08 U
2117 Helbio	Dia 10		Disscap 2100 SE	2445 Idemsa	23 23 H		Kawasumi	MA 10 H
		2311 Hospal						
2119 Helbio	Dia 100	2312 Hospal	Filtral 10	2447 Idemsa	25		Kawasumi	MA 10 U
2120 Helbio	Dia 13	2313 Hospal	Filtral 12	2449 Idemsa	25 H		Kawasumi	MA 12 H
2121 Helbio	Dia 130	2314 Hospal	Filtral 16	2451 Idemsa	28		Kawasumi	MA 12 U
2122 Helbio	Dia 15	2315 Hospal	Filtral 20	2453 Idemsa	28 H		Kawasumi	MA 15 H
2123 Helbio	Dia 150	2316 Hospal	Filtral 6	2455 Idemsa	30		Kawasumi	MA 15 U
2124 Helbio	Dia 18	2317 Hospal	H 1	2457 Idemsa	30 H		Kawasumi	MA 18 H
2125 Helbio	Dia 180	2318 Hospal	H 4	2459 Idemsa	32		Kawasumi	MA 18 U
2126 Helbio	Dia 22	2319 Hospal	H 6	2461 Idemsa	32 H		Kawasumi	ME 08 H
2127 Helbio	Dia 220	2320 Hospal	H 9	2463 Idemsa	34		Kawasumi	ME 08 U
2128 Helbio	SYN+100	2321 Hospal	HG 100	2465 Idemsa	34 H		Kawasumi	ME 10 H
2129 Helbio	SYN+120	2322 Hospal	HG 400	2467 Idemsa	36	2617	Kawasumi	ME 10 U
2130 Helbio	SYN+140	2323 Hospal	HG 500	2469 Idemsa	36 H	2618	Kawasumi	ME 12 H
2131 Helbio	SYN+160	2324 Hospal	HG 600	2471 Idemsa	H 1100	2619	Kawasumi	ME 12 U
2132 Helbio	SYN+180	2325 Hospal	HG 700	2473 Idemsa	H 1300	2620	Kawasumi	ME 15 H
2133 Helbio	SYN+200	2326 Hospal	M 4	2475 Idemsa	H 1500	2621	Kawasumi	ME 15 U
2134 Helbio	Tria 130	2327 Hospal	M 6	2477 Idemsa	H 1800	2622	Kawasumi	ME 18 H
2135 Helbio	Tria 1300	2328 Hospal	M 9	2479 Idemsa	H 2000	2623	Kawasumi	ME 18 U
2136 Helbio	Tria 150	2329 Hospal	Nephral ST 200	2481 Idemsa	H 900	2624	Kawasumi	RA 08 H
2137 Helbio	Tria 1500	2330 Hospal	Nephral ST 300	2483 Idemsa	LP 100	2625	Kawasumi	RA 08 M
2138 Helbio	Tria 180	2331 Hospal	Nephral ST 400	2484 Idemsa	LP 120	2626	Kawasumi	RA 08 U
2139 Helbio	Tria 1800	2332 Hospal	Nephral ST 500	2485 Idemsa	LP 140	2627	Kawasumi	RA 1.0 SH
2140 Helbio	Tria 210	· ·	•	2486 Idemsa	LP 160	2628	Kawasumi	RA 1.25 SH
2141 Helbio	Tria 2100	2401 Idemsa	100	2487 Idemsa	LP 180		Kawasumi	RA 1.55 SH
		2403 Idemsa	100 MHP	2488 Idemsa	LP 200		Kawasumi	RA 10 H
2201 Hemofarm	E 2	2404 Idemsa	1000	2489 Idemsa	P 100	2000	ranaoa	
2202 Hemofarm	E 2 H	2405 Idemsa	1000 HF	2490 Idemsa	P 120	COD	E BRAND	MODEL
2203 Hemofarm	E 3	2100 14011104		2170 14011104	20	2631		RA 10 M
2204 Hemofarm	E 3 H	CODE BRAND	MODEL	CODE BRAND	MODEL	2632		RA 10 U
2201 Homolaini	2011	2406 Idemsa	12	2491 Idemsa	P 140	2633		RA 12 H
CODE BRAND	MODEL	2408 Idemsa	12 H	2492 Idemsa	P 160	2634		RA 12 M
2205 Hemofarm	E 4	2400 Idemsa	120	2493 Idemsa	P 180	2635		RA 12 U
2206 Hemofarm	E 4 H	2410 Idemsa	120 MHP	2494 Idemsa	P 200	2636		RA 15 H
2207 Hemofarm	F 4	2412 Idemsa	1200	ZT/T IUCIIISU	1 200	2637		RA 15 M
2207 Hemofarm	F 4 HPS	2413 Idemsa	1200 1200 HF	2501 JMS	BF 110	2638		RA 15 U
2209 Hemofarm 2210 Hemofarm	F 40 F 40 S	2415 Idemsa 2417 Idemsa	140 140 MHP	2502 JMS 2503 JMS	BF 130 BF 150	2639		RA 18 H RA 18 M
ZZIV HEIIIVIAIIII	F 40 3	2417 IUEIIISA	14U IVINT	2003 JIVIS	DE 100	2640	NawaSuill	KH 10 IVI

					_			rage o or 9
2641	Kawasumi	RA 18 U	2819 Kuraray	kf 201 1.6 m	3122 Nephro System	MO 18 U	3232 Nikkiso	FLY 15 GWS
2642	Kawasumi	RE 08 H	2820 Kuraray	kf 201 1.8 m	3123 Nephro System	MO 18 UA	3233 Nikkiso	FLY 18 GWS
2643	Kawasumi	RE 08 M			3124 Nephro System	NP 08 A	3234 Nikkiso	FLY 21 GWS
2644	Kawasumi	RE 08 U	2901 Meditech	BioF 10	3125 Nephro System	NP 08 E		
2645	Kawasumi	RE 10 H	2903 Meditech	BioF 12	3126 Nephro System	NP 08 U	3301 Nipro	FB 110 A
2646	Kawasumi	RE 10 M	2905 Meditech	BioF 15	3127 Nephro System	NP 08 UA	3302 Nipro	FB 110 H
2647	Kawasumi	RE 10 U	2907 Meditech	MF 4	3128 Nephro System	NP 10 A	3303 Nipro	FB 110 T
2648		RE 12 H	2908 Meditech	MF 40	3129 Nephro System	NP 10 E	3304 Nipro	FB 110 U
	Kawasumi			MF 6		NP 10 U		FB 110 UH
2649	Kawasumi	RE 12 M	2909 Meditech		3130 Nephro System		3305 Nipro	
2650	Kawasumi	RE 12 U	2910 Meditech	MF 60	3131 Nephro System	NP 10 UA	3306 Nipro	FB 130 A
2651	Kawasumi	RE 15 H	2911 Meditech	MO 08 EO	3132 Nephro System	NP 12 A	3307 Nipro	FB 130 H
2652	Kawasumi	RE 15 M	2912 Meditech	MO 08 R	3133 Nephro System	NP 12 E	3308 Nipro	FB 130 T
2653	Kawasumi	RE 15 U	2913 Meditech	MO 10 EO	3134 Nephro System	NP 12 U	3309 Nipro	FB 130 U
2654	Kawasumi	RE 18 H	2914 Meditech	MO 10 R	3135 Nephro System	NP 12 UA	3310 Nipro	FB 130 UH
2655	Kawasumi	RE 18 M	2915 Meditech	MO 12 EO	3136 Nephro System	NP 15 A	3311 Nipro	FB 150 A
2656	Kawasumi	RE 18 U	2916 Meditech	MO 12 R	3137 Nephro System	NP 15 E	3312 Nipro	FB 150 H
2657	Kawasumi	SMC A 10	2917 Meditech	MO 15	3138 Nephro System	NP 15 U	3313 Nipro	FB 150 T
2658	Kawasumi	SMC A 13	2919 Meditech	MO 16 EO	3139 Nephro System	NP 15 UA	3314 Nipro	FB 150 U
2659	Kawasumi	SMC A 16	2920 Meditech	MO 16 R	3140 Nephro System	NP 18 A	3315 Nipro	FB 150 UH
2660	Kawasumi	SMC A 19	2921 Meditech	MO 18 EO	3141 Nephro System	NP 18 E	3316 Nipro	FB 170 A
2661	Kawasumi	SMC R 10	2922 Meditech	MO 18 R	3142 Nephro System	NP 18 U	3317 Nipro	FB 170 H
2662	Kawasumi	SMC R 13	2923 Meditech	MO 20 EO	3143 Nephro System	NP 18 UA	3318 Nipro	FB 170 T
2663	Kawasumi	SMC R 16	2924 Meditech	MO 20 EO	3143 Nephilo System	INF TO UA	3319 Nipro	FB 170 U
					2201 Nikking	ALE 100		
2664	Kawasumi	SPAN 1.0	2925 Meditech	NP 08	3201 Nikkiso	ALF 100	3320 Nipro	FB 170 UH
2665	Kawasumi	SPAN 1.3	2927 Meditech	NP 10	3202 Nikkiso	ALF 120	3321 Nipro	FB 190 A
2666	Kawasumi	SPAN 1.6	2929 Meditech	NP 12	3203 Nikkiso	ALF 120 A	3322 Nipro	FB 190 H
2667	Kawasumi	SPAN E 20	2931 Meditech	NP 15	3204 Nikkiso	ALF 160	3323 Nipro	FB 190 T
			2933 Meditech	NP 18	3205 Nikkiso	ALF 160 A	3324 Nipro	FB 190 U
2701	Kimal	KF 1000			3206 Nikkiso	ALF 180	3325 Nipro	FB 190 UH
2702	Kimal	KF 1200	3001 Minntech	Primus 1350	3207 Nikkiso	ALF 180 A	3326 Nipro	FB 210 A
2703	Kimal	KF 1400	3002 Minntech	Primus 2000	3208 Nikkiso	ALF 80	3327 Nipro	FB 210 H
2704	Kimal	KF 1600			3209 Nikkiso	ALH-08 GW	3328 Nipro	FB 210 T
2705	Kimal	KF 1800			3210 Nikkiso	ALH-10 GW	3329 Nipro	FB 210 U
2706	Kimal	KF 2000	3101 Nephro System	HFP 10	3211 Nikkiso	ALH-12 GW	3330 Nipro	FB 210 UH
			3102 Nephro System	HFP 14	3212 Nikkiso	ALH-16 GW	3331 Nipro	FB 50 A
			3103 Nephro System	HFP 20	3213 Nikkiso	BLF-08 GW	3332 Nipro	FB 50 H
2801	Kuraray	KF 201 0.8	3104 Nephro System	MO 08 A	3214 Nikkiso	BLF-10 GW	3333 Nipro	FB 50 T
2802	Kuraray	KF 201 0.8 C	3105 Nephro System	MO 08 E	3215 Nikkiso	BLF-12 GW	3334 Nipro	FB 50 U
2803	Kuraray	KF 201 1.0 C	3106 Nephro System	MO 08 U	3216 Nikkiso	BLF-16 AW	3334 Nipro	FB 70 A
2804	,	KF 201 1.0 D			3217 Nikkiso		3330 Mpi0	1 D 70 A
	Kuraray	KF 201 1.0 D KF 201 1.3 C	3107 Nephro System	MO 08 UA	3217 IVIKKISU	BLF-16 GW	CODE BRAND	MODEL
2805	Kuraray		3108 Nephro System	MO 10 A	CODE DDAND	MODEL		
2806	Kuraray	KF 201 1.3 D	OODE DRAND	MODEL	CODE BRAND	MODEL	3337 Nipro	FB 70 H
2807	Kuraray	KF 201 1.6 C	CODE BRAND	MODEL	3218 Nikkiso	BLF-18 GW	3338 Nipro	FB 70 T
			3109 Nephro System	MO 10 E	3219 Nikkiso	BLH 16 AW	3339 Nipro	FB 70 U
CODE	BRAND	MODEL	3110 Nephro System	MO 10 U	3220 Nikkiso	BLH-08 GW	3340 Nipro	FB 70 UH
					3221 Nikkiso		22.41 Nipro	FB 90 A
2000	Kuraray	KF 201 1.6 D	3111 Nephro System	MO 10 UA		BLH-10 GW	3341 Nipro	
∠009	Kuraray Kuraray	KF 201 1.6 D KF 201 1.8 C	3112 Nephro System	MO 12 A	3222 Nikkiso	BLH-10 GW BLH-12 GW	3342 Nipro	FB 90 H
2810	Kuraray	KF 201 1.8 C	3112 Nephro System	MO 12 A	3222 Nikkiso	BLH-12 GW	3342 Nipro	FB 90 H
2810 2811	Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH	3112 Nephro System 3113 Nephro System	MO 12 A MO 12 E	3222 Nikkiso 3223 Nikkiso	BLH-12 GW BLH-16 GW	3342 Nipro 3343 Nipro	FB 90 H FB 90 T
2810 2811 2812	Kuraray Kuraray Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH KF 201 13 CH	3112 Nephro System 3113 Nephro System 3114 Nephro System	MO 12 A MO 12 E MO 12 U	3222 Nikkiso 3223 Nikkiso 3224 Nikkiso	BLH-12 GW BLH-16 GW FLX 10 GWS	3342 Nipro 3343 Nipro 3344 Nipro	FB 90 H FB 90 T FB 90 U
2810 2811 2812 2813	Kuraray Kuraray Kuraray Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH KF 201 13 CH KF 201 CH 1.6 KF 201 N 0.7	3112 Nephro System 3113 Nephro System 3114 Nephro System 3115 Nephro System 3116 Nephro System	MO 12 A MO 12 E MO 12 U MO 12 UA MO 15 A	3222 Nikkiso 3223 Nikkiso 3224 Nikkiso 3225 Nikkiso 3226 Nikkiso	BLH-12 GW BLH-16 GW FLX 10 GWS FLX 12 GWS FLX 15 GWS	3342 Nipro 3343 Nipro 3344 Nipro 3345 Nipro 3346 Nipro	FB 90 H FB 90 T FB 90 U FB 90 UH Sureflux 110 E
2810 2811 2812 2813 2814	Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH KF 201 13 CH KF 201 CH 1.6 KF 201 N 0.7 KF 201 N 1.0	3112 Nephro System 3113 Nephro System 3114 Nephro System 3115 Nephro System 3116 Nephro System 3117 Nephro System	MO 12 A MO 12 E MO 12 U MO 12 UA MO 15 A MO 15 E	3222 Nikkiso 3223 Nikkiso 3224 Nikkiso 3225 Nikkiso 3226 Nikkiso 3227 Nikkiso	BLH-12 GW BLH-16 GW FLX 10 GWS FLX 12 GWS FLX 15 GWS FLX 18 GWS	3342 Nipro 3343 Nipro 3344 Nipro 3345 Nipro 3346 Nipro 3347 Nipro	FB 90 H FB 90 T FB 90 U FB 90 UH Sureflux 110 E Sureflux 110 FH
2810 2811 2812 2813 2814 2815	Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH KF 201 13 CH KF 201 CH 1.6 KF 201 N 0.7 KF 201 N 1.0 KF 201 N 1.3	3112 Nephro System 3113 Nephro System 3114 Nephro System 3115 Nephro System 3116 Nephro System 3117 Nephro System 3118 Nephro System	MO 12 A MO 12 E MO 12 U MO 12 UA MO 15 A MO 15 E MO 15 U	3222 Nikkiso 3223 Nikkiso 3224 Nikkiso 3225 Nikkiso 3226 Nikkiso 3227 Nikkiso 3228 Nikkiso	BLH-12 GW BLH-16 GW FLX 10 GWS FLX 12 GWS FLX 15 GWS FLX 18 GWS FLX 21 GWS	3342 Nipro 3343 Nipro 3344 Nipro 3345 Nipro 3346 Nipro 3347 Nipro 3348 Nipro	FB 90 H FB 90 T FB 90 U FB 90 UH Sureflux 110 E Sureflux 110 FH Sureflux 110 G
2810 2811 2812 2813 2814 2815 2816	Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH KF 201 13 CH KF 201 CH 1.6 KF 201 N 0.7 KF 201 N 1.0 KF 201 N 1.3 KF 201 N 1.6	3112 Nephro System 3113 Nephro System 3114 Nephro System 3115 Nephro System 3116 Nephro System 3117 Nephro System 3118 Nephro System 3119 Nephro System	MO 12 A MO 12 E MO 12 U MO 12 UA MO 15 A MO 15 E MO 15 U MO 15 UA	3222 Nikkiso 3223 Nikkiso 3224 Nikkiso 3225 Nikkiso 3226 Nikkiso 3227 Nikkiso 3228 Nikkiso 3229 Nikkiso	BLH-12 GW BLH-16 GW FLX 10 GWS FLX 12 GWS FLX 15 GWS FLX 18 GWS FLX 21 GWS FLX 8 GWS	3342 Nipro 3343 Nipro 3344 Nipro 3345 Nipro 3346 Nipro 3347 Nipro 3348 Nipro 3349 Nipro	FB 90 H FB 90 T FB 90 U FB 90 UH Sureflux 110 E Sureflux 110 FH Sureflux 110 G Sureflux 110 L
2810 2811 2812 2813 2814 2815 2816 2817	Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray Kuraray	KF 201 1.8 C KF 201 10 CH KF 201 13 CH KF 201 CH 1.6 KF 201 N 0.7 KF 201 N 1.0 KF 201 N 1.3	3112 Nephro System 3113 Nephro System 3114 Nephro System 3115 Nephro System 3116 Nephro System 3117 Nephro System 3118 Nephro System	MO 12 A MO 12 E MO 12 U MO 12 UA MO 15 A MO 15 E MO 15 U	3222 Nikkiso 3223 Nikkiso 3224 Nikkiso 3225 Nikkiso 3226 Nikkiso 3227 Nikkiso 3228 Nikkiso	BLH-12 GW BLH-16 GW FLX 10 GWS FLX 12 GWS FLX 15 GWS FLX 18 GWS FLX 21 GWS	3342 Nipro 3343 Nipro 3344 Nipro 3345 Nipro 3346 Nipro 3347 Nipro 3348 Nipro	FB 90 H FB 90 T FB 90 U FB 90 UH Sureflux 110 E Sureflux 110 FH Sureflux 110 G

Revision of 09/OC	T/2009						Form #273
		1		1		1	Page 9 of 9
3352 Nipro	Sureflux 130 L	3601 Riggers	Altair 10	3912 Terumo	Clirans C 121 L	4017 Toray	Filtryzer B2 0.8
3353 Nipro	Sureflux 150 E	3602 Riggers	Altair 12	3913 Terumo	Clirans C 15 L	4018 Toray	Filtryzer B2 1.0
3354 Nipro	Sureflux 150 FH	3603 Riggers	Altair 16	3914 Terumo	Clirans C 15 NL	4019 Toray	Filtryzer B2 1.0 H
3355 Nipro 3356 Nipro	Sureflux 150 G Sureflux 150 L	3604 Riggers	Nouvelle 10 Nouvelle 12	3915 Terumo 3916 Terumo	Clirans C 151 Clirans C 151 L	4020 Toray 4021 Toray	Filtryzer B2 1.2 H Filtryzer B2 1.5 H
3357 Nipro	Sureflux 170 E	3605 Riggers 3606 Riggers	Nouvelle 16	3917 Terumo	Clirans E 12 NL	4021 Toray 4022 Toray	Filtryzer B2 2.0
3358 Nipro	Sureflux 170 G	3607 Riggers	Orion 10	3918 Terumo	Clirans E 12 NLA	4022 Toray	Filtryzer B3 0.5 A
3359 Nipro	Sureflux 170 L	3608 Riggers	Orion 12	3919 Terumo	Clirans E 15 NL	4024 Toray	Filtryzer B3 0.8 A
3360 Nipro	Sureflux 190 E	3609 Riggers	Orion 16	3920 Terumo	Clirans E 15 NLA	4025 Toray	Filtryzer B3 1.0 A
3361 Nipro	Sureflux 190 FH	3610 Riggers	Synergie 1.0	3921 Terumo	Clirans E 18 NL	4026 Toray	Filtryzer B3 1.3 A
3362 Nipro	Sureflux 190 G	3611 Riggers	Synergie 1.2	3922 Terumo	Clirans E 18 NLA	4027 Toray	Filtryzer B3 1.6 A
3363 Nipro	Sureflux 190 L	3612 Riggers	Synergie 1.6	3923 Terumo	Clirans EE 12 NL	4028 Toray	Filtryzer B3 2.0 A
3364 Nipro	Sureflux 210 E		, ,	3924 Terumo	Clirans EE 12 NLA	4029 Toray	Filtryzer BK 1.0 F
3365 Nipro	Sureflux 210 FH	3701 Saxonia	DC 09 2 1	3925 Terumo	Clirans EE 15 NL	4030 Toray	Filtryzer BK 1.0 P
3366 Nipro	Sureflux 210 G	3702 Saxonia	DC 11 2 1	3926 Terumo	Clirans EE 15 NLA	4031 Toray	Filtryzer BK 1.0 U
3367 Nipro	Sureflux 210 L	3703 Saxonia	DC 12 2 1	3927 Terumo	Clirans EE 18 NL	4032 Toray	Filtryzer BK 1.3 F
3368 Nipro	Sureflux 30 L	3704 Saxonia	DC 16 2 1	3928 Terumo	Clirans EE 18 NLA	4033 Toray	Filtryzer BK 1.3 P
3369 Nipro	Sureflux 50 E	3705 Saxonia	DH 09 2 1	3929 Terumo	Clirans EE 20 NL	4034 Toray	Filtryzer BK 1.3 U
3370 Nipro	Sureflux 50 G	3706 Saxonia	DH 11 2 1	3930 Terumo	Clirans M 081	4035 Toray	Filtryzer BK 1.6 F
3371 Nipro	Sureflux 50 L	3707 Saxonia	DH 13 2 1	3931 Terumo	Clirans M 101	4036 Toray	Filtryzer BK 1.6 P
3372 Nipro	Sureflux 70 E	3708 Saxonia	DH 16 2 1	3932 Terumo	Clirans M 121	4037 Toray	Filtryzer BK 1.6 U
3373 Nipro	Sureflux 70 G	3709 Saxonia	Saxon 1030 E	3933 Terumo	Clirans M 151	4038 Toray	Filtryzer BK 2.1 F
3374 Nipro	Sureflux 70 L	3710 Saxonia	Saxon 1065 H	3934 Terumo	Clirans NT 120 L	4039 Toray	Filtryzer BK 2.1 P
3375 Nipro	Sureflux 90 E	3711 Saxonia	Saxon 1080 C	3935 Terumo	Clirans NT 150 L	4040 Toray	Filtryzer BK 2.1 U
3376 Nipro	Sureflux 90 G	3712 Saxonia	Saxon 1080 H	3936 Terumo	Clirans NT 175 L	44.04 1/04/5	AUE 40
3377 Nipro	Sureflux 90 L	3713 Saxonia	Saxon 1265 H	3937 Terumo	Clirans S 12 NL	4101 VMP	AHF 10
3378 Nipro	Sureflux FB 210 U	3714 Saxonia	Saxon 1280 C	3938 Terumo	Clirans S 15 NL	4102 VMP	AHF 14
3379 Nipro	Surelyzer PES 110 DH	3715 Saxonia	Saxon 1280 H	3939 Terumo	Clirans S 18 NL	4103 VMP	CDF 100
3380 Nipro	Surelyzer PES 150 DH	3716 Saxonia	Saxon 1330 E	3940 Terumo	Clirans SE 12 NL	4104 VMP	CDF 120
3381 Nipro	Surelyzer PES 190 DH	3717 Saxonia 3718 Saxonia	Saxon 1465 H	3941 Terumo 3942 Terumo	Clirans SE 15 NL Clirans SE 18 NL	4105 VMP 4106 VMP	CDF 140 CDF 160
3401 Pierrel Medical Ca	are Opal 110 S	3719 Saxonia	Saxon 1480 C Saxon 1480 H	3942 Terumo 3943 Terumo	Clirans T 150 L	4100 VMP	CDF 180
3402 Pierrel Medical Ca		3719 Saxonia	Saxon 1665 H	3944 Terumo	Clirans T 150 LM	4107 VMP	CDF 200
3403 Pierrel Medical Ca	•	3720 Saxonia	Saxon 1680 C	3945 Terumo	Clirans T 175 L	4100 VIVII	GDI 200
3404 Pierrel Medical Ca	•	3721 Saxonia	Saxon 1680 H	3946 Terumo	Clirans T 175 LM		
3405 Pierrel Medical Ca	•	3722 Saxonia	30X011 1000 11	3740 Terumo	Omans i 173 EW		
3406 Pierrel Medical Ca	•	CODE BRAND	MODEL	CODE BRAND	MODEL		
3407 Pierrel Medical Co	•	3801 Schiwa	Basicflux 1.0	3947 Terumo	Clirans T 220 L		
		3802 Schiwa	Basicflux 1.3	3948 Terumo	Clirans T 220 LM		
CODE BRAND	MODEL	3803 Schiwa	Basicflux 1.8				
3408 Pierrel Medical Ca	are Ruby 160 S	3804 Schiwa	Perflux SD 1.0	4001 Toray	BS 1.3		
3409 Pierrel Medical Ca	are Ruby 180 S	3805 Schiwa	Perflux SD 1.3	4002 Toray	BS 1.3 U		
3410 Pierrel Medical Ca		3806 Schiwa	Perflux SD 1.8	4003 Toray	BS 1.6		
3411 Pierrel Medical Ca	are Topaz 130 S			4004 Toray	BS 1.6 UL		
3412 Pierrel Medical Ca				4005 Toray	BS 1.8		
3413 Pierrel Medical Ca	are Topaz 180 S	3901 Terumo	Clirans C 061	4006 Toray	BS 1.8 UL		
		3902 Terumo	Clirans C 08 L	4007 Toray	BS 2.1 UL		
3501 RenaSelect	Altair 10	3903 Terumo	Clirans C 081	4008 Toray	Filtryzer B1 0.6		
3502 RenaSelect	Altair 12	3904 Terumo	Clirans C 081 L	4009 Toray	Filtryzer B1 0.8		
3503 RenaSelect	Altair 14	3905 Terumo	Clirans C 10 L	4010 Toray	Filtryzer B1 1.0		
3504 RenaSelect	Altair 16	3906 Terumo	Clirans C 10 NL	4011 Toray	Filtryzer B1 1.0 H		
3505 RenaSelect 3506 RenaSelect	Nouvelle 10 Nouvelle 12	3907 Terumo 3908 Terumo	Clirans C 101 Clirans C 101 L	4012 Toray 4013 Toray	Filtryzer B1 1.3 H Filtryzer B1 1.6 H		
3500 RenaSelect	Nouvelle 12 Nouvelle 14	3908 Terumo 3909 Terumo	Clirans C 101 L	4013 Totay 4014 Toray	Filtryzer B1 1.6 U		
3508 RenaSelect	Nouvelle 14 Nouvelle 16	3910 Terumo	Clirans C 12 NL	4014 Totay 4015 Toray	Filtryzer B1 2.1 U		
JJUU IVEHAJEIEUL	Nouvelle 10	3911 Terumo	Clirans C 121	4016 Toray	Filtryzer B2 0.5		

p. Was this a dialysis session?

(0=No, isolated ultrafiltration; 1=Yes)

#### Frequent Hemodialysis Network **RETROSPECTIVE KINETIC MODELING DATA - FORM #274**

**Instructions:** This table is completed every month, using dialysis flow sheets to look at the past week excluding the reference day. Although the table accommodates up to 6 sessions, use only as many columns as needed (starting from the left) to cover all treatments in the preceding week, including dialysis sessions and treatments with isolated ultrafiltration only.

1. Participant ID#	2. Alpha Code	3a.Visit 3b. Visit Number Type	
4. a. Was kinetic modeling done this	month? (0=No; 1=Yes)		
b. If yes, date of KM (if no, use las	t date within visit window):	(dd/mon/yyyy)	//
	<u> </u>		
Data Item	5. Session – #1	6. <b>Session – #2</b>	7. <b>Session – #3</b>
a. Treatment Date (dd/mon/yyyy)	/	//	/
b. Start Time (24 hr clock)	:	:	:
c. End Time (24 hr clock)	:	:	:
d. Predialysis weight (kg)			
e. Minimum intradialytic systolic BP <sup>2</sup>			
f. Minimum intradialytic diastolic BP			
g. Hypotensive episode? <sup>1</sup>	_	_	_
h. Significant interruption? <sup>3</sup>	_	_	
i. Pre-dialysis systolic BP			
j. Pre-dialysis diastolic BP			
k. Post-dialysis systolic BP			
1. Post-dialysis diastolic BP			
m. Post-dialysis weight (kg)			

<sup>&</sup>lt;sup>1</sup>For Item 4g, hypotensive episode, enter 0=No, 1=Symptoms of hypotension led to lowering of UF rate or reduced blood flow, 2=Symptoms of hypotension led to administration of saline, 3=Symptoms of hypotension led to lowering of UF rate and administration of saline.

<sup>&</sup>lt;sup>2</sup>For Item e: specify systolic and diastolic blood pressure at time of minimum systolic blood pressure.

<sup>&</sup>lt;sup>3</sup>For Item h, significant interruption, enter 0=No, 1=Yes. For an in-center dialysis treatment, a significant interruption is any interruption of 15 minutes or greater. For a home dialysis treatment, a significant interruption is any interruption of 30 minutes or greater.

Revision of 27/JUL/2007 PID:	Date:	//	Form #274 Page 2 of 2
Data Item	8. Session – #4	9. <b>Session</b> – #5	10. <b>Session</b> – #6
a. Treatment Date (dd/mon/yyyy)	//	//	//
b. Start Time (24 hr clock)	:	:	:
c. End Time (24 hr clock)	:	:	:
d. Predialysis weight (kg)			
e. Minimum intradialytic systolic BP			
f. Minimum intradialytic diastolic BP			
g. Hypotensive episode? <sup>1</sup>	_	_	_
h. Significant interruption? <sup>2</sup>	_	_	_
i. Pre-dialysis systolic BP	———		
j. Pre-dialysis diastolic BP	———		
k. Post-dialysis systolic BP			
l. Post-dialysis diastolic BP			
m. Post-dialysis weight (kg)	<u>-</u> -		<del>`</del> _
p. Was this a dialysis session? (0=No, isolated ultrafiltration; 1=Yes)	_	_	_

200.	Date this form completed (dd/mon/yyyy)
201.	Username of person reviewing completeness of this form
For Cl	linical Center Use Only:
202.	Username of person entering this form:
203.	Date entered: (dd/mon/yyyy) / /

<sup>&</sup>lt;sup>1</sup>For Item 4g, hypotensive episode, enter 0=No, 1=Symptoms of hypotension led to lowering of UF rate or reduced blood flow, 2=Symptoms of hypotension led to administration of saline, 3=Symptoms of hypotension led to lowering of UF rate and administration of saline.

<sup>2</sup>For Item e: specify systolic and diastolic blood pressure at time of minimum systolic blood pressure.

<sup>&</sup>lt;sup>3</sup>For Item h, significant interruption, enter 0=No, 1=Yes. For an in-center dialysis treatment, a significant interruption is any interruption of 15 minutes or greater. For a home dialysis treatment, a significant interruption is any interruption of 30 minutes or greater.

## Frequent Hemodialysis Network ATTENDANCE AT IN-CENTER DIALYSIS SESSIONS - FORM#275

This form is completed during follow-up for all Daily Trial patients (and those in the Nocturnal Trial who are receiving dialysis in-center. Use Form 279 for Nocturnal Trial patients dialyzing at home). Form 275 is to be completed by the study coordinator or dialysis unit technician at the start of each calendar month following randomization in order to document missed dialysis treatments during the prior calendar month. Do not count those treatments completed for ultrafiltration only.

Cai	endar month. Do not count those treatments completed for ditramitation only.						
	1. Participant ID#  2. Alpha Code  Type  3a. Visit Number (of the calendar month listed below)						
4.	Indicate calendar month to which this form applies: (mon/yyyy):/						
5.	Did this patient avoid continual care of your FHN hemodialysis unit through the calendar month for any of the reasons listed below: (For questions 5a-d: 0=No, 1=Yes)						
	a. Patient was admitted to a rehabilitation unit or nursing home						
	b. Patient was hospitalized on some of the days that patient should have been dialyzed at your unit						
	(Be sure to fill out hospitalization forms 302 and 303.) c. Patient was out of town part of the time						
	d. Patient was being cared for by some other dialysis unit than yours for some other reason						
	r Questions 6-8: <u>EXCLUDE</u> the time that the patient was not under the care of eFHN dialysis unit:						
6.	What was the number of treatments that the patient should have had <u>at your dialysis unit</u> under the protocol?						
7.	How many treatments at your unit were missed during the designated calendar month?						
8.	. How many treatments did the patient actually have <u>at your unit</u> ?						
	Note: The responses to questions 7 and 8 should add up to the response in question 6.						
200	0. Date form completed(dd/mon/yyyy)///						
20	1. Username of person reviewing completeness of this form						
Fo	r Clinical Center Use Only:						
202	2. Username of person entering this form:						
20	3. Date entered: (dd/mon/yyyy) / /						

## Frequent Hemodialysis Network ACCESS REPAIR PROCEDURE - FORM #276

Instructions: This form is completed whenever an access procedure is done to help maintain or restore function of the access that is currently being used for HD. For access failure or removal, complete Form 277. For placement of a new access, complete Form 278. If you only wish to indicate that a new access is being used for hemodialysis, fill out Form 271.

The following do not count as FHN access repair procedures and do not merit a Form 276, so do NOT complete this form if:

- the patient only had diagnostic venogram without any other procedures.
- the patient only had one or more dwells of tPA
- the only procedure done was banding
- the procedures was done within a dialysis unit. This form is intended for procedures done in a vascular access center or in a hospital
- there is angioplasty of a central vein or stent placement on a central vein

Wait until at least one dialysis procedure is done after the access placement before you complete this form (Otherwise you will never be able to answer "yes" to the question about the success of the repair.)

	1. Participant ID #  2. Alpha Code  3. Date of Access Procedure: dd/mon/yyyy
4.	Type of access that the procedure was carried out on:  1=Arteriovenous fistula 2=Arteriovenous graft 3=Tunneled (permanent) catheter 4=Non-tunneled (temporary) catheter
5.	Date access (identified in Q4) was placed? (dd/mon/yyyy)/

#### Type of Procedure(s) Performed

6. For patients with <u>fistulas and grafts</u> indicated in item 4 above: For items 6a-e: Use 0=No, 1=Yes, to identify whether the procedure was performed by a non-physician(Non-MD) or physician(MD).

	Non-MD? MD
a.	Angioplasty:
b.	Stent placement:
c.	Thrombolysis (pharmacologic removal of a clot):
d.	Thrombectomy (physical or mechanical removal of a clot):
e	Surgical revision (not handing)

7.	Fo	r patients with <u>catheters</u> indicated in item 4 above For items 7a-c: Use 0=No, 1=Yes, to identify whether the procedure									
		was performed by a non-physician(Non-MD) or physician(MD).									
	a.	Repair of catheter by stripping of fibrin sheath:	D?								
	b.										
		Thrombolysis:									
	c.	Repair of broken catheter component:	-								
8.	Was this procedure successful?										
		(If the patient was using a different access before this repair and a Form 271 was completed, fill out another Form 271 to indicate that the patient is now using the repaired access. If there was no interruption in the use of the repaired access,									
	2=	there is no need to fill out Form 271 again.) 2=It appears to have been successful, but a week or more has passed and the access cannot yet be used or the access has not been used.									
		(Complete Forms 278 and 271 if a new access was placed and is being used to dialyze the patient in the meanwhile. When the repaired access is able to be used again, then complete 271 again.)									
	3=No, the access required further salvage procedures. Complete a new Form 276										
	for each additional procedure. 4=No, the access can no longer be used. Complete Form 277 access failure form and 278 if a new access was placed.										
Fo	r D	CC Use Only:									
199	9.	a. Event reason:									
		b. Date updated:									
200	).	Date this form completed (dd/mon/yyyy)	_								
20	1.	Username of person reviewing completeness of this form	_								
Fo	r C	linical Center Use Only:									
202	2.	Username of person entering this form:									
203	3.	Date Entered: (dd/mon/yyyy)///									

203.

# Frequent Hemodialysis Network PERMANENT ACCESS FAILURE OR ACCESS REMOVAL FORM #277

Instructions: This form is completed whenever an access that is currently being used for HD is
removed or otherwise can no longer be used (defined as "permanent failure.") Do not use this form if
the access is still being used. Access repair procedures are recorded on form 276. New access
placement is recorded on Form 278. If you only wish to indicate that a new access is being used for
hemodialysis, fill out Form 271.
1. Participant ID # 2. Alpha 3. Date of Access failure: dd/mon/yyyy
4. Type of access that permanently failed:
1=Arteriovenous fistula
2=Arteriovenous ristura 2=Arteriovenous graft
3=Tunneled catheter
4=Non-tunneled catheter
4=Non-tuimeled cameter
5 Data agges (identified in O4) was placed? (dd/mon/www)
5. Date access (identified in Q4) was placed? (dd/mon/yyyy)//
the date of the first known use)
the dute of the first known use)
6. Primary Reason for permanent failure
For Fistulas and Grafts (designated in item 4 above), use these codes:
01=Irreparable stenosis or thrombosis (clot)
02=Ligated for Aneurysm
03=Ligated for Steal syndrome
04=Ligated for Ischemic neuropathy
05=Ligated for Congestive heart failure
06=Infection
07=Severe swelling/hematoma formation
08=Other irreparable condition/problem (i.e., laceration)
For Catheters (designated in item 4 above, use these codes:
20=Removed because of infection
21=Removed because of mechanical failure or poor flows or thrombosis
22=Removed electively because another access such as a fistula or graft is now
being used
If the reason for permanent failure is not on the above code list, email fhn-dcc@bio.ri.ccf.org
7. Was the access removed? (0=No, 1=Yes)
For DCC Use Only:
199. a. Event reason:
b. Date updated:
200. Date this form completed (dd/mon/yyyy)
Username of person reviewing completeness of this form
For Clinical Center Use Only:
202 Usarnama of parson entaring this form:

### Frequent Hemodialysis Network NEW ACCESS PLACEMENT - FORM #278

Instructions: This form is completed at any time during baseline or follow up, whenever a new access is <u>placed</u>. Access repair procedures are recorded on Form 276. Access failure or removal is reported on Form 277. New access placement is recorded on Form 278. To indicate that a new access is being <u>used</u> for hemodialysis, fill out Form 271.

If two accesses are placed on one day, complete this form twice, once for each access that was placed.

Wait until at least one dialysis procedure is done after the access placement before you complete this form. (Otherwise you will never be able to answer "yes" to the question about whether the access is currently being used.) 2. Alpha 1. Participant ID # 3. Date of Access Placement: dd/mon/yyyy **New Access Placement** 4. What was the type of access that was placed: 1=Arteriovenous fistula 2=Arteriovenous graft 3=Tunneled (permanent) catheter 4=Non-tunneled (permanent) catheter 5. Is this the access currently being used for HD?.....\_\_\_\_\_ 0=No. Remember to complete Form 271 once this access is actively used as the patient's main access. 1=Yes. Fill out Form 271 now. 200. 201. For Clinical Center Use Only: Username of person entering this form: \_\_\_\_\_\_\_\_\_ 202. 203.

# Frequent Hemodialysis Network CLINICAL CENTER HOSPITALIZATION NOTIFICATION FORM #302

**Baseline:** If a patient is hospitalized during baseline, complete this Form 302 only as soon as the Clinical Center becomes aware that a patient has been hospitalized. *If the trial caused the hospitalization, then a Form 303 must be completed along with a Form 308.* 

	<b>ow-Up:</b> This form is completed as soon as the Clinical Center becomes aware that a patient has hospitalized. A Form 303 and Form 308 must be completed and entered.
	1. Participant ID #  2. Alpha Code  3. Hospital admission date: dd/mon/yyyy
4.	Is the patient still in the hospital?(0=No-discharged, 1=No-died (enter Form 305/306), 2=Yes-still in hospital)
	Remember to complete a Clinical Center Detailed Hospitalization Form #303, SAE Form #308. Send/fax the hospitalization packet to the DCC within three months after the patient was discharged.
5.	Primary reason for this hospitalization
6.	Secondary reason for this hospitalization(see code list from Form 303)
	Date this form completed (dd/mmm/yyyy)
	Username of person completing this form
	Clinical Center Use Only:
202. 203	Username of person entering this form:
<b>∠</b> UJ.	Date Entered. (uu/mmm/yyyy)/ / /

### Frequent Hemodialysis Network CLINICAL CENTER HOSPITALIZATION FORM #303

**Baseline:** If a patient is hospitalized during baseline and it was identified that *the trial caused the hospitalization, then this Form 303 must be completed and entered along with a Form 308.* 

**Follow-Up:** A Form 303 must be completed for all hospitalizations that required an overnight stay. A Form 308 must be completed and entered. Detailed documentation regarding the patient's hospitalization (i.e., discharge summaries, lab reports, etc.) must be submitted to the DCC within 6 weeks after the patient was discharged.

**Follow-up Extension Study:** A Form 303 must be completed for all hospitalizations that required an overnight stay for patients who consent to participate. In the Daily study, only hospitalizations that occurred during follow-up months F-12 through F-18. *In the Nocturnal study, all hospitalizations will be collected regardless of follow-up month?* All information regarding a patient's hospitalization and outcome should be detailed in Q15 since Form 308 is not completed (in the Extension Study only). Detailed documentation regarding the patient's hospitalization (i.e., discharge summaries, lab reports, etc.) should be submitted to the DCC. If no medical records are available, the PI should write a detailed summary letter for use by the Outcomes Committee.

Recall that hospitalizations for transplants will be reviewed by the Outcomes Committee but no other hospitalizations after the transplant are to be submitted. This also applies to patients who switch to peritoneal dialysis (PD) or regained kidney function.

1. Participant ID #		2	. Alph		3. D	ate of	f hosp	ital ac	lmissi	on: d	d/mor	1/уууу	7			

- 6. Billing category for economic analyses.....\_\_\_\_
  - 01 = Diseases & disorders of the nervous system
  - 02 = Diseases & disorders of the eye
  - 03 = Diseases & disorders of the ear / nose / mouth & throat
  - 04 = Diseases & disorders of the respiratory system
  - 05 = Diseases & disorders of the circulatory system
  - 06 = Diseases & disorders of the digestive system
  - 07 = Diseases & disorders of the hepatobiliary system & pancreas
  - 08 = Diseases & disorders of the musculoskeletal system & connective tissue
  - 09 = Diseases & disorders of the skin / subcutaneous tissue & breast
  - 10 = Endocrine / nutritional & metabolic diseases & disorders
  - 11 = Diseases & disorders of the kidney & urinary tract
  - 12 = Diseases & disorders of the male reproductive system
  - 13 = Diseases & disorders of the female reproductive system

Continued on next page...

Rev	ision of 10/SEPT/2010	PID:	Date:	/_		Form #303 Page 2 of 13
	14 = Pregnancy / child 15 = Newborns & othe 16 = Diseases & disordary 17 = Myeloproliferativa 18 = Infectious & para 19 = Mental diseases & 20 = Alcohol/drug use 21 = Injuries / poisona 22 = Burns 23 = Factors influencia 24 = Multiple signification	er neonates we ders of blood we diseases & sitic diseases & disorders & alcohol/dings & toxic ang health statent trauma	with condition original / blood forming to disorders / poor to s / systemic or unurug induced organeffects of drugs to the contacts to the contacts of the con	organs ly diffe specif nic me	s / immunol erentiated n ied sites ental disorde	ogical disorder eoplasm ers
7.a.	Did the patient have a si (0=No, 1=Yes, 9=Unkn					
b	. Was this an access-rela	ted surgical	procedure (0=No	, 1=Ye	es)?	
<b>Acc</b> 8.	ess Related Issues Access Hospitalization 1=This was a "Non-Acc 2=Admitted for an acce complications 3=Admitted for an acce	<u>cess</u> hospitali ss problem, '	zation" - admitte 'Access hospitali	d for a zation	problem ur without no	nrelated to access on-access
	complications that we 4=This was an "Access due to access problem	ere <u>not</u> due to hospitalizati	o access problem	S.		
9.	Was access repair or rei Code 0=No, 1=Yes, con	-				
10.	Was a new access place Code 0=No, 1=Yes, con					
	rdiovascular Disease (Co a. Was there new onset				ischemic he	art disease?
	b. Was there new onset (left ventricular d					
	c. Was there a myocard	lial infarction	1?		•••••	····· <u> </u>
	d. Was there new onset	of or worse	ning arrhythmias	?		
	e. Was there new onset (Note - if any of a		_			

Hos	pitalization for Infection (Code 0=No, 1=Yes)
12.	a. Was there bacteremia or sepsis?
	b. Was there organ or deep tissue infection (serious)?
	(Note – if either of the above are true, this was an infection hospitalization)
Pati	ent Status
13.	a. Current status of patient
13.	b. If item 13a = 3 or 4, date of discharge (dd/mon/yyyy)//
14.	If you know the DRG for this hospitalization, record it here:(Use 999 if unknown)
15.	<b>Required:</b> Comments. (For patients still in the trial follow-up period, Write in as much as you wish. For patients in the Follow-up Extension study, please provide detailed text as no Form 308 is required. Use back of sheet if necessary. Key enter text.)
200	
200.	Date this form completed (dd/mmm/yyyy)
201.	Username of person completing this form
	Clinical Center Use Only: Username of person entering this form:
203.	Date Entered: (dd/mmm/yyyy)//
For I	OCC Use Only:
204.	a. Falls outside of Ext. Follow-up Study reporting period (1=Yes) b. Date DCC reviewed://

### FHN STUDY: Hospitalizations - Code List of Diagnoses and Procedures (For Form 303, Q4 & 5)

Coding Instructions: When parentheses (\_) are next to the code, you need to add one of the

following: 1 = New, 2 = Worsening, 3 = Not a new condition

Note: A terminal code of 0 indicates a procedure and cannot be used as a

primary reason code in Q4.

An asterisk (\*) indicates that the disease or condition is also classified as an "infection outcome".

#### 1. ISCHEMIC HEART DISEASE (IHD)

Also see category: coronary heart disease (CHD) or coronary artery disease (CAD)

01AA(\_) Chest pain of non-cardiac or unclear etiology (R/O MI admission)

01AB(\_) CAD

01AC(\_) Angina

01AD0 Bypass surgery (CABG) 01AE0 Coronary angiographies

01AF0 Coronary angioplasty (PTCA) or atherectomy

01AG Myocardial infarction (acute)(MI)

01AH Cardiac arrest

#### 2. **CONGESTIVE HEART FAILURE (CHF)**

02AA(\_) CHF

02AB(\_) CHF due to volume overload 02AC(\_) Pulmonary edema (cardiogenic)

02AD( ) Pleural effusion(s)

02AE0 Thoracentesis (diagnostic or therapeutic)

02AF Cardiogenic shock

#### 3. ARRHYTHMIAS AND CONDUCTION PROBLEMS

O3AA(\_) Syncope (also presyncope and syncopal episode)

03AB(\_) Atrial fibrillation

03AC(\_) Ventricular tachycardia

03AD(\_) Supraventricular tachycardia

03AE(\_) Sick sinus (tachy-brady) syndrome

03AF(\_) Atrioventricular conduction block

03AG(\_) Hyperkalemia

O3AH( ) Other new or other arrhythmia and conduction problem

03AI0 Cardioversion

03AJ0 Electrophysiologic studies (EPS)

03AK0 Pacemaker placement

03AL0 Pacemaker malfunction/repair

03AM0 Implantable cardioverter-defibrillator (ICD)

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

#### 4. OTHER HEART DISEASES AND CONDITIONS (OHD)

)4AA(_)	Pericarditis
)4AB(_)	Endocarditis
)4AC(_)	Myocarditis
)4AD(_)	Cardiomyopathy (without IHD or CHF)
)4AE(_)	Pericardial effusion
)4AF(_)	Aortic valve stenosis or insufficiency
)4AG(_)	Mitral valve stenosis, regurgitation, or prolapse
)4AH(_)	Other valve defect
)4AI(_)	Other heart condition
)4AJ(_)	Cardiac tamponade
)4AK0	Pericardiocentesis
)4AL0	Aortic valve replacement
)4AM0	Mitral valve replacement
)4AN0	Balloon valvuloplasty
)4AP0	Pericardial Window

#### 5. **HYPERTENSION (HTN) / HYPOTENSION**

05AA(\_) Hypertensive crisis or accelerated HTN

05AB(\_) Hypotensive crisis or accelerated hypotension

#### 6. CEREBRAL VASCULAR DISEASE (CVD)

06AA(_)	Transient ischemic attack (TIA)
06AB(_)	Cerebral vascular accident (CVA)
06AC(_)	Carotid artery stenosis
06AD(_)	Cerebral artery aneurysm
06AE(_)	Subarachnoid or cerebral hemorrhage
06AF(_)	Other CVD condition
06AG0	Carotid endarterectomy (CEA)
06AH0	Carotid angiogram

#### 7. PERIPHERAL VASCULAR DISEASE (PVD)

07AA(_)	Deep vein thrombosis (DVT)
07AB(_)	Pulmonary embolism
07AC(_)	Peripheral vascular disease
07AD(_)	Ischemic foot ulcers
07AE(_)	Gangrene of toes or foot*
07AF(_)	Abdominal aortic aneurysm (AAA)
07AG(_)	Thoracic aortic aneurysm (TAA)

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

07AH(_)	Hemorrhage from ruptured vascular aneurysm
07AI(_)	Aortic aneurysm (not specified)
07AJ(_)	Other aneurysm
07AK(_)	Mesenteric ischemia or infarction (ischemic bowel)
07AL(_)	Cellulitis (non-access related)*
07AM(_)	Gangrene with septicemia-shock due to PVD
07AN(_)	Other condition due to PVD or other disorder of arteries
07AO(_)	Polyarteritis nodosa and other arteritides
07AP	Arterial embolism
07AQ0	AAA repair
07AR0	TAA repair
07AS0	Angioplasty for PVD
07AT0	Bypass graft for PVD
07AW0	Amputation site: toe(s) <sup>+</sup>
07AX0	Amputation site: transmetatarsal <sup>+</sup>
07BA0	Left below the knee amputation <sup>+</sup>
07BB0	Right below the knee amputation <sup>+</sup>
07BC0	Left above the knee amputation <sup>+</sup>
07BD0	Right above the knee amputation <sup>+</sup>
	<sup>+</sup> Be sure to complete Form 202 for any amputation

#### 8. DIABETES MELLITUS (DM) AND ENDOCRINE DISORDERS

08AA(_)	Diabetic foot infection*
08AB(_)	Gangrene of foot or toes (absence of PVD)*
08AC(_)	Hypothyroidism
08AD(_)	Other disorders of thyroid gland
08AE	Diabetes with ketoacidosis
08AF	Diabetes with hyperosmolar state or coma
08AG	Hypoglycemic coma
08AH0	Pancreatic transplant
08AI(_)	Other endocrine disorder
08AJ	Onset of diabetes
08AK0	Parathyroidectomy
08AL(_)	Hyperparathyroidism
08AM(_)	Hypoparathyroidism
08AN(_)	Other calcium-phosphorus disorder
08AO(_)	Hyperglycemia
08AP(_)	Diabetic foot ulcer
08AQ(_)	Hypoglycemia (without coma)

#### 9. **RESPIRATORY DISEASES**

09AA(\_) Asthma 09AB(\_) COPD

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

09AC(_)	Bronchitis
09AD(_)	Pneumothorax
09AE(_)	Empyema*
09AF(_)	Lung abscess*
09AG(_)	Pulmonary TB*
09AH(_)	Respiratory failure not requiring intubation and mechanical ventilation
09AI(_)	Respiratory failure requiring intubation and mechanical ventilation
09AJ(_)	Adult Respiratory Distress Syndrome (ARDS)
09AK	Respiratory failure of unknown cause
09AL(_)	Other respiratory disease
09AM(_)	Pulmonary hemorrhage
09AN(_)	Pneumonia (nosocomial)*
09AO(_)	Pneumonia (community acquired)*
09AP(_)	Pneumonia-sepsis*
09AQ(_)	Pneumonia (bacterial)*
09AR(_)	Pneumonia (fungal)*
09AS(_)	Pneumonia (viral)*
09AT(_)	Pneumocystis pneumonia*
09AU(_)	Aspiration pneumonia*
09AV(_)	Pneumonia (unspecified pathogen)*
09AW0	Open lung biopsy
09AX0	Lung lobectomy
09AY(_)	Upper respiratory tract disorders (including dyspnea, shortness of breath)
09AZ0	ENT procedures
09BA	Angioedema
09BB	Acute epiglottitis

#### 10. **MALIGNANCY**

10AA(_)	Hematologic malignancy (AML, ALL, CLL)
10AB(_)	Lymphoma (unspecified)
10AC(_)	Hodgkin's lymphoma
10AD(_)	Non-Hodgkin's lymphoma
10AE(_)	Multiple myeloma
10AF(_)	Colon cancer
10AG(_)	Breast cancer
10AH(_)	Prostatic cancer
10AI(_)	Ovarian cancer
10AJ(_)	Lung cancer
10AK(_)	Gastric cancer
10AL(_)	Pancreatic cancer
10AM(_)	Thyroid cancer
10AN(_)	Cervical cancer
10AO(_)	Endometrial cancer
10AP(_)	Primary cancer of liver

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

10AQ(_)	Head and neck squamous cell carcinoma
10AR(_)	Testicular cancer
10AS(_)	Renal cancer
10AT(_)	Bladder cancer
10AU(_)	Melanoma
10AV(_)	Other skin cancer
10AW(_)	Other malignancy or neoplasia
10AX(_)	Metastatic carcinoma unknown primary
10AY(_)	Complication(s) of pre-admission diagnosed cancer
10BA0	Diagnosis: surgical biopsy
10BB0	Other biopsy procedure
10BC0	Other diagnostic procedure
10BD0	Treatment: radiation therapy
10BE0	chemotherapy
10BF0	surgical excision
10BG0	other treatment
10BH0	Mastectomy (subtotal or total)
10BI0	Hysterectomy
11 1100 4	TODII IA DV DICE A CE
	TOBILIARY DISEASE
11AA(_)	Hepatitis B
11AB(_)	Hepatitis C
11AC(_)	Toxic/drug-induced hepatitis
11AD(_)	Hepatitis (other; unknown cause)

11AD(\_) 11AE( ) Cirrhosis

11AF(\_) Ascites Portal hypertension or esophageal varices

11AG(\_) Variceal bleed 11AH(\_)

Hepatic failure/severe dysfunction 11AI(\_)

Cholecystitis/cholangitis\* 11AJ(\_) Other hepatobiliary disease 11AK(\_)

11AL(\_) Biliary sepsis\* Cholecystectomy 11AM0 Liver transplant 11AN0 11AO0 Shunt procedure

11AP0 Paracentesis (diagnostic or therapeutic)

#### 12. MUSCULOSKELETAL AND CONNECTIVE TISSUE DISEASES

12AA(\_) Gout

12AB(\_) Wegener's granulomatosis

Systemic vasculitis 12AC(\_)

Systemic Lupus Erythematosus (SLE) 12AD(\_)

12AE(\_) Avascular necrosis

Osteomyelitis\* 12AF( )

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

12AG(_)	Septic arthritis*
12AH(_)	Back problems
12AI(_)	Other musculoskeletal or connective tissue disease
12AJ(_)	Bone fracture
12AK0	Carpal tunnel surgery
12AL0	Arthroscopy
12AM0	Hip replacement
12AN0	Knee replacement
12AO0	Knee procedures (other than replacement)
12AP0	Internal fixation or surgical reduction of bone fracture
12AQ0	Other orthopedic surgery
12AR0	Back and/or neck procedure
12AS(_)	Musculoskeletal pain
12AT0	Orthopedic related rehabilitation

### 13. GASTROINTESTINAL CONDITIONS (GI)

13AA(_)	Upper GI bleed
13AB(_)	Lower GI bleed
13AC(_)	GI bleeding, site unknown
13AD(_)	Peptic/duodenal ulcer disease
13AE(_)	Gastritis
13AF(_)	Reflux esophagitis (with or without hiatal hernia)
13AG(_)	Diverticulitis*
13AH(_)	Colonic polyps
13AI(_)	Ulcerative colitis (UC)
13AJ(_)	Enteritis (Crohn's disease)
13AK(_)	Septicemia due to peritonitis*
13AL(_)	Pancreatitis
13AM(_)	Necrotizing enterocolitis*
13AN(_)	C. difficile associated enterocolitis*
13AO(_)	Peritonitis*
13AP(_)	Fungal peritonitis*
13AQ(_)	Appendicitis*
13AR(_)	Ischemic bowel
13AS(_)	Intra-abdominal abscess*
13AT(_)	Abdominal pain, cause unknown
13AU(_)	Malabsorption
13AV(_)	Perforated viscus (peptic ulcer or bowel)*
13AX(_)	Gastroparesis
13BA0	Colectomy (partial or total)
13BB0	Gastrectomy
13BC0	Colostomy or ileostomy
13BD0	Gastrostomy/enterostomy
13BE0	Appendectomy

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

Laparotomy

13BF0

13BG0	Other GI procedure
13BH(_)	Other GI Condition
14. <b>NONV</b>	ASCULAR NERVOUS SYSTEM DISEASES
14AA(_)	Mental status change (acute)
14AB(_)	Seizure disorder
14AC(_)	Disequilibrium - syndrome
14AD(_)	Coma-stupor (traumatic cause)
14AE(_)	Coma-stupor (toxic-drug induced)
14AF(_)	Coma-stupor (metabolic cause, non-diabetic)
14AG(_)	Coma-stupor (anoxic encephalopathy)
14AH(_)	Coma-stupor (other unknown cause)
14AI(_)	Alcohol non-accidental
14AJ(_)	Drug overdose
14AK(_)	Head trauma
14AL(_)	Parkinson's disease
14AM(_)	Multiple sclerosis
14AN(_)	Subdural or epidural hematoma
14AO(_)	Depression
14AP(_)	Nervous system neoplasm
14AQ(_)	Alcohol/drug abuse related (detoxification included)
14AR(_)	Other psychiatric or mental disorder
14AS(_)	Viral meningitis*
14AT(_)	Meningitis (non-viral)
14AU(_)	Other CNS infection*
14AV(_)	Ataxia
14AW(_)	Cranial or peripheral nerve disorder
14AX(_)	Other nonvascular nervous system condition
14AY(_)	Suicide attempt
14AZ(_)	Neuropic pain in extremity

#### 15. URINARY TRACT CONDITIONS/RENAL CONDITIONS

15AA(_)	Urinary tract infection requiring antibiotics*
15AB(_)	Nephrolithiasis
15AC(_)	Benign prostatic hypertrophy (BPH)
15AD(_)	Prostatitis
15AE(_)	Orchitis
15AF(_)	Cystic kidney disease (PKD or acquired)
15AG(_)	Cyst-related hemorrhage
15AH(_)	Cyst-related infection
15AI(_)	Urinary tract hemorrhage
15AJ0	Nephrectomy unilateral

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

15AK0	Nephrectomy bilateral
15AL0	Prostatectomy (radical)
15AM0	Transurethral prostatectomy (TURP)
15AN0	Other transurethral procedures (cystoscopy included)
15AO0	Other urologic procedure
15AP(_)	Hematuria
15AQ0	Kidney transplant
15AR(_)	Acute transplant rejection
15AS(_)	Renal failure
15AT(_)	Uremia/acute renal insufficiency
15AU	Evaluation for transplant
15AV(_)	Urinary retention
15AW(_)	Chronic transplant rejection

#### 16. **HIV/AIDS**

16AA(_)	AIDS-related infection*
16AB(_)	Other AIDS-related condition (non-infection)
16AC(_)	HIV positive

#### 17. **OPHTHALMOLOGIC CONDITIONS**

17AA(_)	Retinal or vitreous hemorrhage
17AB(_)	Endophthalmitis*
17AC(_)	Other disorder of the eye
17AD0	Iris or lens procedure (cataract surgery included)
17AG0	Orbital procedure (vitrectomy included)
17AH0	Retina procedure (laser surgery included)
17AI0	Other ophthalmologic procedure

#### 18. **INFECTIONS**

18AA(_)	Abscess (lung, empyema, intra-abdominal, brain, soft tissuenot access-related)*
18AB(_)	Miliary TB*
18AC(_)	Extrapulmonary TB*
18AD(_)	Disseminated candidiasis*
18AE(_)	Other fungal infection**
18AF(_)	Viral infection (including CMV)*
18AG(_)	Other viral infection (not hepatitis)*
18AH(_)	Protozoan or parasitic infection (not PCP)*
18AI(_)	Other infection (not recorded in previous category)*
18AJ(_)	Septic shock*
18AK(_)	Bacteremia (known source, not access-related)*
18AL(_)	Bacteremia (unknown source, not access-related)*
18AM(_)	Bacteremia (known source, access-related)*

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

Bacteremia (unknown source, access-related)\* 18AN()

18AO(\_) Fever of unknown origin\*

#### 19. NON-MALIGNANT HEMATOLOGIC CONDITIONS

19AA() Coagulation disorders Thrombocytopenia (secondary) 19AB(\_) Thrombocytopenia (idiopathic) 19AC() 19AD(\_) Disseminated Intravascular Coagulation (DIC) Other consumption coagulopathy 19AE(\_) 19AF(\_) Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) Other, including peripheral hematoma 19AG(\_) 19AH(\_) Anemia 19AI Monitor anticoagulation status for elective surgery (ie., dental)

#### HEMODIALYSIS VASCULAR ACCESS COMPLICATIONS 20.

20AA0	Elective surgical access repair
20AB(_)	Soft tissue infection, cellulitis, abscess (access related)*
20AC(_)	Bacteremia or sepsis, access related*
20AD(_)	Clotted access
20AE(_)	Venous thrombosis, access related
20AF(_)	Arterial thrombosis or embolism, access related
20AG(_)	Steal syndrome, limb ischemia, access related
20AH(_)	Hemorrhage from vascular access
20AI(_)	Nerve entrapment, access related
20AJ0	Fistulogram, arteriogram, or other invasive imaging procedure
20AK0	Access declotting procedure
20AL0	Angioplasty or stent placement for vascular access
20AM0	Non-elective surgical access repair
20AN0	Temporary access placement
20AO(_)	Pneumothorax, hemothorax as result of temporary access placement
20AP(_)	Subclavian vein stenosis as result of temporary access
20AQ0	New access creation (AV-fistula)
20AR0	New access placement (AV-graft)
20AS(_)	Other access-related condition
20AT0	Other access-related procedure
20AU(_)	New vascular access needed
20AV0	New perm-cath placement

#### 21. OTHER HEMODIALYSIS COMPLICATIONS

21AA(\_) Uremia

21AB(\_) Hemorrhage from dialysis circuit

Air embolism 21AC(\_)

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

21AD(_)	Anaphylaxis, treatment related
21AE(_)	Hemolysis, treatment related
21AF(_)	Electrolyte and acid-base disorder (other than hyperkalemia),
	treatment related
21AG(_)	Dialysis-induced hypotension
21AH(_)	Other accident related to treatment
21AI(_)	Febrile reaction, not infection
21AJ0	Start of hemodialysis
21AK	Withdrawal from dialysis

#### 22. OTHER SURGICAL PROCEDURES

22AA(_)	Trauma
22AB(_)	Major hemorrhage (not GI or pulmonary)
22AC(_)	Hemorrhagic shock
22AD0	Skin graft/skin ulcer debridement
22AE0	Hernia procedure
22AF0	Other elective surgery procedure
22AG0	Removal of benign tumor
22AH0	Elective dental surgical procedure

#### 23. OTHER

23AA(_)	Other hemorrhage
23AB(_)	Other trauma
23AC(_)	Drug overdose (accidental)
23AD	Accident unrelated to treatment
23AE	Drug reaction (anaphylaxis)
23AF	Drug reaction (not anaphylaxis, not overdose)
23AG	Other electrolyte/acid-base disorder, not treatment related
23AH	Cachexia
23AI	Morbid Obesity
23AJ	Gynecologic or Obstetric condition

#### 24. UNKNOWN

24AA Unknown reason for hospitalization

++++If you have a condition not found on this listing, please contact the DCC (fhn-dcc@bio.ri.ccf.org) for a new code+++++

<sup>\*</sup>Disease or condition is also classified as an "infection outcome".

### Frequent Hemodialysis Network CLINICAL CENTER DEATH NOTIFICATION FORM #305

This form is completed as soon as the Clinical Center becomes aware that a patient has died.

**Baseline:** If it was identified that the trial caused the death during the baseline period, then Form 306 must be completed and entered along with a completed Form 308. If a death occurred during baseline and the trial did not cause the death then you only need enter this Form 305.

**Follow-Up:** A Form 306 must be completed for all deaths that occurred in the follow-up period in addition to a Form 308. Detailed documentation regarding the patient's death (if hospitalized at time of death: expiration summary, autopsy report, lab reports, etc., or, if not hospitalized at time of death: physician summary, autopsy, office notes, etc.) must be submitted to the DCC within 6 weeks after the patient expired. 4. Date of Death: dd/mmm/yyyy 2.Alpha Code Based on the information you have available to you now, what do you think is the: (for Causes of Death, use the Death Code List from Form 306.) 5. a. Primary cause of death.....\_\_\_\_\_\_\_\_\_\_\_ b. Secondary cause of death.....\_\_\_\_\_\_\_\_\_\_\_ c. Other cause of death.....\_\_\_\_\_\_\_\_\_\_ d. Other cause of death.....\_\_\_\_\_\_\_\_\_ For Clinical Center Use Only: 202. Username of person entering this form: \_\_\_\_\_\_\_

203. Date Entered: (dd/mmm/yyyy) \_\_\_/\_ \_\_/\_ \_\_\_/\_\_\_\_\_

# Frequent Hemodialysis Network DETAILED DEATH FORM - FORM #306

**Baseline:** If a death occurred during the baseline period, complete Form, 305, Form 306 and a Form 308. Detailed documentation\* will be required particularly if it was identified that the trial may have caused the patient's death.

**Follow-Up:** A Form 306 must be completed for all deaths that occurred in the follow-up period in addition to a Form 308.

	etailed documentation regarding the patient's death (if hospitalized at time of death: expiration mary, autopsy report, lab reports, etc., or, if not hospitalized at time of death: physician summary,
	opsy, office notes, etc.) must be submitted to the DCC within 6 weeks after the patient expired.
	1. Participant ID #  2. Alpha Code  3. Date of death: dd/mon/yyyy
Par	t 1: To be completed by the Study Coordinator:
4.	Date Death Review Packet submitted to DCC: (dd/mon/yyyy)
5.	Where did the death occur?
	1 = In a hospital, in the emergency room $5 = In the patient's home$
	2 = In a hospital, not in the emergency room 6 = Other known location
	3 = In the dialysis unit 7 = Location unknown 4 = In a nursing home or other skilled care facility
6.	Was an autopsy performed? (0=No, 1=Yes, 9=unknown)
Par	t 2: To be completed by the Principal Investigator:
7.	For causes of death, use the attached Death Code List starting on page 2.  a. Primary cause of death
	b. Secondary cause of death
	c. Other cause of death
	d.Other cause of death
	the that a narrative summary from the Principal Investigator of the events leading to the patient's death the circumstances surrounding the death will be recorded on the SAE form.
200	Date this form completed (dd/mon/yyyy)
201	. Username of person completing this form
For	· Clinical Center Use Only:
202	. Username of person entering this form:
203	. Date Entered: (dd/mon/yyyy)////

#### FHN TRIAL CODE LIST OF CAUSES OF DEATH

*Note*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

An asterisk (\*) indicates that the disease or condition is also classified as an infection outcome.

#### 1. ISCHEMIC HEART DISEASE (IHD)

- 01DA Sudden death (due to IHD)
- 01DB Myocardial infarction (acute) (MI)
- 01DC Angina:2
- 01DD Atherosclerotic heart disease (CAD):2
- 01DE Other acute and subacute forms of ischemic heart disease
- 01DF Old myocardial infarction:2
- 01DG Other forms of chronic ischemic heart disease:2

#### 2. CONGESTIVE HEART FAILURE (CHF)

- 02DA CHF
- 02DB CHF or pulmonary edema due to exogenous fluid (volume overload)
- 02DC Pulmonary edema (cardiogenic)
- 02DD Cardiogenic shock

#### 3. ARRHYTHMIAS AND CONDUCTION PROBLEMS

- 03DA Sudden death (due to arrhythmia, not due to IHD)
- 03DB Atrioventricular conduction block
- 03DC Sick sinus syndrome
- 03DD Atrial fibrillation
- 03DE Ventricular tachycardia
- 03DF Other cardiac arrhythmia and conduction disorder
- 03DG Hyperkalemia
- 03DH Ventricular fibrillation

#### 4. OTHER HEART DISEASES AND CONDITIONS (OHD)

- 04DA Sudden death (due to heart conditions other than IHD/arrhythmia)
- 04DB Pericarditis
- 04DC Endocarditis \*
- 04DD Myocarditis
- 04DE Pericardial effusion:2
- 04DF Cardiac tamponade
- 04DG Aortic valve stenosis or insufficiency:2
- 04DH Mitral valve stenosis, regurgitation, or prolapse:2
- 04DI Other valve defect:2
- 04DJ Prosthetic valve malfunction:2
- 04DK Cardiomyopathy (without IHD or CHF)

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

#### 5. HYPERTENSION (HTN)/HYPOTENSION

- 05DA Hypertensive crisis or accelerated HTN
- 05DB Hypotensive crisis or accelerated hypotension

#### 6. CEREBRAL VASCULAR DISEASE (CVD)

- 06DA Cerebral vascular accident (CVA)
- 06DB Carotid artery stenosis:2
- 06DC Cerebral artery aneurysm:2
- 06DD Subarachnoid or cerebral hemorrhage
- 06DE Other cerebrovascular disease

#### 7. PERIPHERAL VASCULAR DISEASE (PVD)

- 07DA Hemorrhage from ruptured vascular aneurysm
- 07DB Peripheral vascular disease (atherosclerotic):2
- 07DC Deep vein thrombosis (DVT):2
- 07DD Pulmonary embolism (PE)
- 07DE Abdominal aortic aneurysm (AAA):2
- 07DF Thoracic aortic aneurysm (TAA):2
- 07DG Aortic aneurysm (not specified as AAA or TAA):2
- 07DH Other aneurysm:2
- 07DI Arterial embolism and thrombosis
- 07DJ Mesenteric ischemia or infarction/ischemic bowel
- 07DK Gangrene with septicemia-shock due to PVD \*
- 07DL Polyarteritis nodosa and other arteritides:2
- 07DM Other disorders of arteries:2

#### 8. DIABETES MELLITUS (DM) AND ENDOCRINE DISORDERS

- 08DA Diabetes mellitus, Type I (insulin dependent):2
- 08DB Diabetes mellitus, Type II (non insulin dependent, could be insulin required):2
- 08DC Diabetes mellitus, type unclassified or unknown:2
- 08DD Diabetes with ketoacidosis
- 08DE Diabetes with hyperosmolar state or coma (hyperglycemia)
- 08DF Diabetes with other coma
- 08DG Hypoglycemia coma
- 08DH Diabetic foot infection \*
- 08DI Hypothyroidism:2
- 08DJ Disorders of the thyroid gland:2
- 08DK Other endocrine disorder:2
- 08DJ Hyperparathyroidism:2
- 08DK Hypoparathyroidism:2
- 08DL Other disorder of calcium and phosphorus metabolism

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

#### 9. RESPIRATORY DISEASES

- 09DA Asthma
- 09DB COPD exacerbation
- 09DC Bronchitis (chronic):2
- 09DD COPD:2
- 09DE Pneumonia (community acquired)\*
- 09DF Pneumonia (nosocomial)\*
- 09DG Pneumonia-sepsis\*
- 09DH Pneumonia (bacterial)\*
- 09DI Pneumonia (fungal)\*
- 09DJ Pneumonia (viral)\*
- 09DK Pneumocystic pneumonia\*
- 09DL Pneumonia (unspecified pathogen)\*
- 09DM Empyema\*
- 09DN Lung abscess\*
- 09DO Pneumothorax
- 09DP Pulmonary hemorrhage
- 09DQ Cor pulmonale:2
- 09DR Pulmonary TB\*
- 09DS Aspiration pneumonia
- 09DT Adult Respiratory Distress Syndrome (ARDS)
- 09DU Respiratory failure of unknown cause
- 09DV Sleep apnea:2
- 09DW Other respiratory cause

#### 10. MALIGNANCY

- 10DA Hematologic malignancy (AML, CML, ALL, CLL)
- 10DB Lymphoma (unspecified)
- 10DC Hodgkin's lymphoma
- 10DD Non-Hodgkin's lymphoma
- 10DE Multiple myeloma
- 10DF Colon cancer
- 10DG Breast cancer
- 10DH Prostate cancer
- 10DI Ovarian cancer
- 10DJ Lung cancer
- 10DK Gastric cancer
- 10DL Pancreatic cancer
- 10DM Thyroid cancer
- 10DN Cervical cancer
- 10DO Endometrial cancer
- 10DP Primary cancer of the liver
- 10DQ Head and neck squamous cell carcinoma
- 10DR Testicular cancer

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

- 10DU Melanoma
- 10DV Other skin cancer
- 10DW Other malignancy or neoplasia
- 10DX Metastatic cancer with unknown primary

#### 11. HEPATOBILIARY DISEASES

- 11DA Hepatitis B
- 11DB Hepatitis C
- 11DC Toxic/drug induced hepatitis
- 11DD Hepatitis (other unknown cause)
- 11DE Cirrhosis:2
- 11DF Ascites:2
- 11DG Portal hypertension or esophageal varices:2
- 11DH Hemorrhage from esophageal varices
- 11DI Hepatic (liver) failure/severe hepatic dysfunction
- 11DJ Polycystic liver disease:2
- 11DK Cholecystitis/cholangitis\*
- 11DL Biliary sepsis\*
- 11DM Other hepatobiliary disease

#### 12. MUSCULOSKELETAL AND CONNECTIVE TISSUE DISEASES

- 12DA Wegener's granulomatosis
- 12DB Systemic vasculitis
- 12DC Rheumatoid arthritis:2
- 12DD Systemic lupus erythematosus (SLE)
- 12DE Osteomyelitis\*
- 12DF Septic arthritis\*
- 12DG Osteoporosis:2
- 12DH Bone fracture(s):2
- 12DI Renal osteodystrophy:2

#### 13. GASTROINTESTINAL CONDITIONS (GI)

- 13DA Upper GI bleed
- 13DB Lower GI bleed
- 13DC GI bleeding, site unknown
- 13DD Peptic ulcer disease:2
- 13DE Gastritis:2
- 13DF Diverticulosis:2
- 13DG Ulcerative colitis (UC):2
- 13DH Enteritis (Crohn's disease):2
- 13DI Perforation of peptic ulcer
- 13DJ Perforation of bowel

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

- 15DB UTI-septicemia\*
- 15DC Nephrolithiasis:2
- 15DD Prostatitis\*
- 15DE Benign prostatic hypertrophy:2
- 15DF Orchitis\*
- 15DG Cystic kidney disease (PKD or acquired):2
- 15DH Cyst-related hemorrhage
- 15DI Cyst-related infection\*
- 15DJ Urinary tract hemorrhage

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

- 15DK Hemorrhage from renal transplant site
- 15DL Other renal and urologic condition (excluding ESRD)

#### 16. HIV/AIDS

- 16DA HIV positive (not AIDS)
- 16DB AIDS
- 16DC AIDS-related infection
- 16DD Other AIDS-related condition (not infection)

#### 17. OPHTHALMOLOGIC CONDITIONS

- 17DA Endophthalmitis\*
- 17DB Legally blind:2

#### 18. INFECTIONS (NOT ACCESS RELATED)

- 18DA Abscess (not recorded in previous category)\*
- 18DB Other infection (not recorded in previous category)\*
- 18DC Septic shock\*
- 18DD Septicemia (bacteremia) (known source, not access related)\*
- 18DE Septicemia (bacteremia) (unknown source, not access related)\*
- 18DF Extrapulmonary TB\*
- 18DG Miliary TB\*
- 18DH Disseminated candida infection\*
- 18DI Other fungal infection\*
- 18DJ Viral infection (CMV)\*
- 18DK Other viral infection (not hepatitis)\*
- 18DL Protozoan or parasitic infection (not PCP)\*

#### 19. NON-MALIGNANT HEMATOLOGIC CONDITIONS

- 19DA Anemia:2
- 19DB Bone marrow depression:2
- 19DC Leukocytopenia:2
- 19DD Coagulation disorder:2
- 19DE Thrombocytopenia:2
- 19DF Disseminated Intravascular Coagulation (DIC)
- 19DG Other consumption coagulopathy:2
- 19DH Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)
- 19DI Other non-malignant hematologic condition

#### 20. HEMODIALYSIS VASCULAR ACCESS COMPLICATIONS

- 20DA Septicemia (bacteremia) access related\*
- 20DB Hemorrhage from vascular access
- 20DC Venous thrombosis access related:2
- 20DD Arterial thrombosis or embolism access related

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

- 20DE Other access infection
- 20DF Other complication of temporary access placement

#### 21. OTHER HEMODIALYSIS COMPLICATIONS

- 21DA Hemorrhage from dialysis circuit
- 21DB Air embolism
- 21DC Anaphylaxis, treatment related
- 21DD Hemolysis, treatment related
- 21DE Electrolyte and acid-base disorder, treatment related (other than hyperkalemia)
- 21DF Dialysis-induced hypotension
- 21DG Other accident related to treatment

#### 22. OTHER SURGICAL COMPLICATIONS

- 22DA Hemorrhage from surgery
- 22DB Complications from surgery
- 22DC Complications from anesthesia

#### 23. OTHER

- 23DA Withdrawal from dialysis:2
- 23DB Other hemorrhage
- 23DC Cachexia
- 23DD Other trauma
- 23DE Drug overdose (accidental)
- 23DF Accident unrelated to treatment
- 23DG Drug reaction, anaphylaxis
- 23DH Drug reaction, not anaphylaxis, not overdose
- 23DI Other electrolyte and acid-base disorder (not related to hemodialysis treatment)
- 23DJ Homicide
- 23DK Refusal of lifesaving therapy
- 23DL Multi-organ system failure (pt. in ICU):2
- 23DM Multi-organ system failure (pt. not in ICU):2
- 23DN Multi-organ system failure (therapy induced):2
- 23DO Multi-organ system failure (not therapy induced):2
- 23DP Natural cause
- 23DQ Patient ever on immunosuppressive therapy

#### 24. UNKNOWN

- 24DA Sudden death, unknown cause
- 24DB Other death, unknown cause

#### 25. HYPERTENSIVE CARDIOVASCULAR DISEASE (HCVD)

25DA Hypertensive cardiovascular disease

*Notation*: A "2" indicates that the disease or condition could only be a secondary or other cause of death and not the primary cause.

### **Frequent Hemodialysis Network ADVERSE REACTION FORM - FORM #307**

Instructions: This form is completed for adverse events (AE) that do not meet the criteria for serious adverse events (SAE). For serious adverse events, complete Form 308.

It is up to the PI's clinical judgment to decide when an adverse event has occurred. You should file an adverse event form when the Clinical Center Study Team (PI and Study Coordinator) feels that the patient has had an event (such as, a sign, symptom or disease) that the Study Team feels is important. Each Clinical Center should follow its own local IRB's procedures for local reports of AE's and SAE's.

All adverse events occurring after randomization should be reported. During baseline, complete

Condition	MedDRA Code					
Adverse Event Description: Record diagnoses and/or signs and/or symptoms below. The atabase will allow as many other conditions and MedDRA code numbers as needed for the AE eport. Conditions and MedDRA codes you may see include, but are not limited to: hemorrhage MedDRA code 10019595), device leakage (MedDRA 10012587), infection (MedDRA code 0021789), air embolism (MedDRA code 10001526).						
l. Date of initial report	(dd/mon/yyyy) / /					
3. Date of onset:	(dd/mon/yyyy)//					
1. Participant ID #	2. Alpha Code					
and enter a Form 307 only if the AE was caused	by the FHN trial.					

Condition	MedDRA Code
5a.	
5b.	
5c.	

- 6. Has there been a prior history of similar event? 0=No, 1=Yes, 9=Unknown
- 7.a. In the Clinical Center PI's judgment, was this event caused by any device, procedure, or intervention that was done as part of the FHN Trial Protocol?..... 0=No, 1=Unlikely, 2=Possibly, 3=Probably, 4=Definitely

Note: If the answer to question 7a was possibly, probably, or definitely, indicate in your description of the AE (Item #9) if the AE was caused by the hemodialysis machine, blood tubing sets, dialyzers. dialysate, central venous catheters or enuresis alarms for detecting blood leaks.

If this event was possibly, probably, or definitely related to study device, write the model name and model number of the dialysis machine used in the text field.

Revision of 08/FEB/2008 ID Date/	FHN Form 307 Page 2 of 3
b. In the Clinical Center PI's judgment, was this event caused by the patie randomly assigned dialysis regimen?	
7. c. If the event was possibly, probably, or definitely caused by any device, or intervention that was done as part of the FHN Trial Protocol by the postional postio	patient's or nd accurately
8. Action taken	
9. Please write a brief summary of what happened and what action was taken	1.
10. Outcome of event (This can be updated later - weekly reports and routi will remind the physician/coordinator to complete this form)	_
11. Date of outcome	
12. Date clinical center became aware of the outcome (dd/mon/yyyy)	_/
13. Please write a brief summary of the outcome:	
200. Date this form completed (dd/mon/yyyy)	_//
201. Username of person completing/reviewing completeness of this form	
For Clinical Center Use Only:	
202. Username of person entering this form	···

Revis	ion of <mark>08/FEB/2008</mark>	ID	 Date	_/	_/		FHN Form 30 Page 3 of 3	07
203.	Date Entered: (dd/mo	on/yyyy)	 			/	/	

### Frequent Hemodialysis Network SERIOUS ADVERSE REACTION FORM - FORM #308

**Instructions:** This form is completed for serious adverse events (SAE). The definition of "serious" is that the event results in death, or is life threatening, or requires inpatient hospitalization or prolongation of existing hospitalization, or results in a persistent or significant/incapacity, or results in congenital anomaly/birth defect, or any medical event which requires treatment to prevent one of the medical outcomes listed above.

- For non-serious adverse events, complete Adverse Event Form 307 instead of this form.
- For hospitalizations, complete Forms 302 and 303 in addition to this form.
- In the event of a patient death, complete Forms 305 and 306 in addition to this form.

1. Participant ID # 2. Alpha
Code
3. a. Date of onset: (dd/mon/yyyy) / /
b. Date Clinical Center learned of the SAE (dd/mon/yyyy) / /
4. SAE Categorization: (Code 0=No, 1=Yes)
a. Did the patient die?
b. Was the event life threatening?
c. Was there a hospitalization?
c.1. Date of hospitalization: (dd/mon/yyyy) / / /
Be sure to complete and enter Forms 302 and 303.
d. Was there prolongation of existing hospitalization?
e. Did the event result in a persistent or significant incapacity?
f. Did the event result in a congenital anomaly/birth defect?
g. Was this a medical event which required treatment to prevent one of the medical outcomes listed above?
SAE Description: Record diagnoses and/or signs and/or symptoms below. The database will allow as many other conditions and MedDRA code numbers as needed for the SAE report  Conditions and MedDRA codes you may see include, but are not limited to: hemorrhage

(MedDRA code 10019595), device leakage (MedDRA 10012587), infection (MedDRA code 10021789), air embolism (MedDRA code 10001526).

Condition	MedDRA Code
5a.	
5b.	
5c.	

6.	Has there been a prior history of similar event?
	(0=No, 1=Yes, 9=Unknown)

Revis	sion	of <mark>15/APR/2009</mark>	ID	Date	/	_/	FHN Form 308 Page 2 of 3
7.	a.	or intervention the O=No, 1=Unlian Note: If the and description of the tubing sets, diablood leaks.  If this event was	ikely, 2=Possibly, nswer to question 7a	y done as p 3=Probably a was possib the SAE was entral venous y, or definitel	art of the v, 4=Defind v, probables caused in the caused i	e FHN Trial Initely oly, or definitely by the hemodi s or enuresis a	Protocol?ly, indicate in your falysis machine, blood falarms for detecting
	b.	randomly assign	enter PI's judgmented dialysis regimentikely, 2=Possibly,	n?			oatient's 
	c.	or intervention the by the patient's indescribed in the 1=Unexpected 2=Expected, but the control of the control	possibly, probably hat was done as parandomly assigned study consent? d – not mentioned but of greater sevend accurately described.	rt of the FF dialysis re in the conserity than me	IN Trial gimen, we sent centioned	Protocol by to as it expecte in the conser	he patient's or d and accurately
8.	Ac	0=None	discontinuation (If				d, complete F305, F306)
9. Pl	9. Please write a brief summary of what happened and what action was taken						

Revis	ion of 15/APR/2009	ID	Date	_/	_/	_	FHN Form 308 Page 3 of 3
10.	0=Recovered 1=Recovered 2=Event cont 3=Event cont 4=Event cont	without treatment with treatment inuing without treatment inuing and controlled inuing and not control died (Be sure to contail	nent I with trea olled with	itment treatmer			<u></u>
11.	Date of outcome			(dd/mon	/yyyy) <u> </u>	_/	_/
12.	Date clinical center	became aware of the	outcome	(dd/mon	/yyyy) <u> </u>	_/	_/
13.	Please write a brief	summary of the outc	ome				
200.	Date this form comp	leted (dd/mon/yyyy)		•••••		/	/
201.	Username of person	completing/reviewin	g complet	eness of	this form		
For (	Clinical Center Use	Only:					
202.	202. Username of person entering this form:						
203.	203. Date Entered: (dd/mon/yyyy)///						

# Frequent Hemodialysis Network PLANNED THERAPY DEVIATION - FORM #309

This form should be completed prior to planned <u>reductions</u> or <u>increases</u> in number of dialysis treatments or in treatment time: planned average time per session 30 minutes or different from prescribed time under the study protocol for a period of at least one week or received four or more treatments or greater as designated under the FHN protocol or for a nocturnal trial patient who dialyzed in-center rather than at home. Treatment deviations due to hospitalizations are not counted.

This form should be completed at the beginning of <u>each</u> month when the planned deviation will occur. Record the start date of the deviation in item #4.

		1. Participant ID# 2. Alpha Sa. Visit 3b. Visit Number 4. De Code Type	eviation Start Date: dd/mon/yyyy					
5.	Th		or 5a-d: use 0=No, 1=Yes)					
	a.							
	b.							
	c.	c. The patient will have 4 or more extra treatments in the next month						
	d.	d. Nocturnal Trial only: the patient will be receiving some dialysis to month instead of at home						
6.	a.	a. Anticipated length of time until correction of deviation:						
		1=1 month or less 2=1-2 months 3=2-4 months 4=Remainder of study 5=Indefinite						
	b.	b. During the period of planned deviation, how many dialysis treatmer per week will the patient be undergoing?						
7.	Is the planned deviation the result of a medical decision by a physician?							
8.		If Q7 is Yes, indicate which of the following apply: (For 8a-h: use 0=No, 1=Yes) a. Hypotension?						
	<b>b.</b> ]	b. Phosphate depletion?						
	c. l	c. Patient fatigue?						
	d. 3	d. Symptoms of under dialysis?						
	e. Problems controlling fluid intake and treating physician insists on additional dialysis sessions rather than hyperfiltration sessions							

Re	visi	on of <mark>16/OCT/2008</mark> PID:	Date:	_/	/	Form #309 Page 2 of 2
<b>Q</b> 8	(de	viation due to medical reason continued	: Code 0=No, 1=Yes	5)		
f. Vascular access problem made no hemodialysis possible						······
	g. Moderate vascular access problem was judged to make dialysis possible no more than 3x per week					
	h.	Other medical indication described in (Email the DCC at fhn-dcc@bio.ri.ccf.d.				
9.	Is	the planned deviation the result of pat	ient non-adherence	e?		······—
	(0=	=No, skip to Q11, 1=Yes, answer Q10	))			
10	. If	Q9 is Yes, indicate which of the follow	wing apply: (For 1	0a-g: u	ise 0=No, 1	=Yes)
	a.	Transportation difficulties?				······
	b.	Inadequate caregiver assistance?				······_
	c.	Employment constraints?				
	d.	Concern over vascular access?				······—
	e.	Other time commitments?				<u> </u>
	f.	Patient burn-out?				<u> </u>
	g.	Patient symptoms suspected by patie	ent to be due to ove	er dialy	sis?	<u> </u>
		(Email the DCC at fhn-dcc@b	bio.ri.ccf.org if an add	itional r	eason is ideni	tified)
11.		the planned deviation the result of log lysis unit? (0=No, skip to Q13, 1=Ye		_		
12	. If	Q11 is Yes, indicate which of the following	owing apply: (For	12a-b:	use 0=No,	1=Yes)
	a.	Staffing shortage?	•••••			······_
	b.	Scheduling issues preclude the desig (Email the DCC at fhn-dcc@b				
13.		her Comments: Please describe what ow up to 2000 characters)		-		
200	). D	ate this form completed (dd/mon/yyyy)				_//
201	1. U	sername of person reviewing completene	ss of this form	•••••		
Fo	r Cli	nical Center Use Only:				
202	2. T	Jsername of person entering this form: _		_		
203	3. I	Date Entered: (dd/mon/yyyy)/	/			

# Frequent Hemodialysis Network DETECTED THERAPY DEVIATION - FORM #310

This form should be completed following each calendar month in which the patient missed four or more dialysis sessions, or in which the actual treatment time averaged at least 30 minutes below the minimum allowable time over a period of 1 week or greater or received four or more treatments or greater as designated under the FHN protocol or for a nocturnal trial patient who dialyzed in-center rather than at home. Treatment deviations due to hospitalizations are not counted.

This form does not need to be completed if a Form 309 - Planned Therapy Deviation was completed for the given month.

C						
1. Participant ID# 2. Alpha 3a.Visit 3b. Visit Number 4. Date of 1st Detected Deviation: dd/mon/yyy						
Code Type	,					
5. This form is being completed because of the following reason(s): (For 5a-d: use 0=No, 1=Yes)						
a. The patient missed 4 or more treatments (from randomized treatment assignment) during the next month:						
b. The patient missed an average of at least 30 minutes or more treatment time for a period of at least 1 week:						
c. The patient had 4 or more extra treatments (from randomized treatment assignment) in a given month						
d. Nocturnal Trial only: the patient received some dialysis in-center this month						
instead of at home						
6. Anticipated length of time until correction of deviation:						
1=1 month or less 4=Remainder of study 2=1-2 months 5=Indefinite						
3=2-4 months						
7. Was the deviation the result of a hospitalization or travel or some other life event that precluded adherence? (0=No, skip to Q9, 1=Yes, answer Q8)						
8. If Q7 is Yes, indicate which of the following apply: (For 8a-b: use 0=No, 1=Yes)						
a. Hospitalization? (Be sure to complete Forms 302, 303)						
b. Travel?						
(Email the DCC at fhn-dcc@bio.ri.ccf.org if an additional reason is identified)						
9. Was deviation the result of a medical decision by a physician?						
10. If Q9 is Yes, indicate which of the following apply: (For 10 a-h, se 0=No, 1=Yes)						
a. Hypotension?						
b. Phosphate depletion?						
c. Patient fatigue?						
C. I aucht faugut!	···· —					

Revi	sion c	of 28/MAY/2009 PID: Date:/	Form #310 Page 2 of 3
Q10	(devi	ation due to medical reason continued: Code 0=No, 1=Yes)	
	d.	Symptoms of under dialysis?	
	e.	Problems controlling fluid intake and treating physician insists on additional sessions rather than hyperfiltration sessions	
	f.	Vascular access problem made no hemodialysis possible	
	g.	Moderate vascular access problem was judged to make dialysis possible no methan 3x per week	
	h.	Other medical indication described in text field (Q17)	
11.	Wa	as the deviation the result of patient non-adherence?	
		=No, skip to Q13, 1=Yes, answer Q12, <mark>2=Yes, other reason explained in Q17</mark> )	
12.	If (a.	Q11 is Yes, indicate which of the following apply: (For 12a-g, use 0=No, 1=Y Transportation difficulties?	
	b.	Inadequate caregiver assistance?	
	c.	Employment constraints?	<u> </u>
	d.	Concern over vascular access?	<u> </u>
	e.	Other time commitments?	<u> </u>
	f.	Patient burn-out?	<u> </u>
	g.	Patient symptoms suspected by patient to be due to over dialysis?(Email the DCC at fhn-dcc@bio.ri.ccf.org if an additional reason is identified)	<u> </u>
13.		as the deviation the result of logistical or scheduling issues with the alysis unit? (0=No, skip to Q15, 1=Yes, answer Q14)	
14.	If (	Q13 is Yes, indicate which of the following apply: (For 14a-b: use 0=No, 1=Y	(es)
	a.	Staffing shortage?	<u> </u>
	b.	Scheduling issues preclude the designated dialysis treatment schedule? (Email the DCC at fhn-dcc@bio.ri.ccf.org if an additional reason is identified)	
15. V		he deviation the result of logistical or other issues with performing dialysis the home? (0=No, skip to Q17, 1=Yes, answer Q16)	<u> </u>
16. I	f Q15 a.	is Yes, indicate which of the following apply: (For 16a-c: use 0=No, 1=Yes) Dialysis machine breakdown?	
	b.	Water treatment breakdown or other plumbing issue?	<u> </u>
	c.	Lack of dialysis supplies?(Email the DCC at fhn-dcc@bio.ri.ccf.org if an additional reason is identified)	

Revision of 28/MAY/2009 PID:	Date:	_/	_/	Form #310 Page 3 of 3
17. Other Comments: Please describe what is going needed). (Database will allow up to 2000 characters)	g on with t	his patie	ent (Use the back of	of the paper form, if
200. Date this form completed (dd/mon/yyyy)		/	'/	
201. Username of person reviewing completeness of	this form.		. — — — — —	
For Clinical Center Use Only:				
202. Username of person entering this form:				
203. Date Entered: (dd/mon/yyyy)/	/			

# Frequent Hemodialysis Network CENTRAL HOLTER READING FACILITY CLINICAL ALERTS FORM - FORM #311

This form is to be completed and entered by the Central Holter Reading Facility when a clinical alert(s) has been identified.

	1. Participant ID#  2. Alpha Code  3. Start date of Holter: dd/mon/yyyy
4.	Date data received at central facility(dd/mon/yyyy)/
5.	Date data read at central facility (dd/mon/yyyy)/
6.	Username of person reading the Holter
Clin	ical Alerts (For items 7-13: 0=No, 1=Yes)
7.	Ventricular tachycardia?
8.	Torsades de pointes?
9.	AV block 2b?
10.	AV block 3?
11.	Sinus arrest or SA blocks?
12.	Atrial fibrillation?
13.	Other significant clinical finding?
<mark>14.</mark>	Comments:
Fa	Control Holton Dooding Facility Has Only
	Central Holter Reading Facility Use Only:
	Date this form completed (dd/mon/yyyy)
	Username of person entering this form:
202.	Date Entered: (dd/mon/yyyy)///

# Frequent Hemodialysis Network CENTRAL CARDIAC MRI FACILITY CLINICAL ALERTS FORM - FORM #312

This form is to be completed and entered by the Central Cardiac MRI Facility when a clinical alert(s) has been identified.

	1. Participant ID #  2. Alpha Code  3. Date of MRI: dd/mon/yyyy
4.	Date data received at central facility: (dd/mon/yyyy) /
5.	Date data read at central facility: (dd/mon/yyyy)//
6.	Username of person reading the cardiac MRI:
Clin	nical Alerts (For items 7-11: 0=No, 1=Yes)
7.	Lung mass?
8.	Esophageal mass?
9.	Cardiac mass?
10.	Large pericardial effusion?
11.	Other significant clinical finding?
<mark>12.</mark>	Comments:
For	Central Cardiac MRI Facility Use Only:
	Date this form completed (dd/mon/yyyy)
	Username of person entering this form:
202.	Date Entered: (dd/mon/yyyy)//

# Frequent Hemodialysis Network POST RANDOMIZATION PATIENT TRANSPLANT OR PERITONEAL DIALYSIS FORM #313

	uctions: This Form 313 should be completed by a study coordinator when a randomized and that has a renal transplant or switches to peritoneal dialysis.
•	1. Participant ID #  2. Alpha Code  3. Event Date: dd/mon/yyyy
4.	What patient event are you reporting?
5.	Briefly describe what happened in the text field below, noting especially whether this event could have been predicted. (Use back of sheet if necessary.)
	Date this form completed (dd/mon/yyyy)
	Clinical Center Use Only:
202.	Username of person entering this form:
203.	Date Entered: (dd/mon/yyyy) / /

Revision 05/DEC/2008 Form #400 Page 1 of 1

## Frequent Dialysis Network TRANSFER FORM - FORM # 400

This form is completed whenever a participant transfers to another FHN *clinical center or participating dialysis unit.* This form is completed at the participating site and faxed to the DCC at 216-445-2781 for data entry.

216-445-2781 for data entry.					
1. Participant ID Number 2. Alpha Code					
3. Date of transfer(dd/mmm/yyyy)//					
a. Clinical Center number where participant is transferring to					
b. Dialysis unit number where participant is transferring to					
200. Date this form completed(dd/mmm/yyyy)//					
201. Username of person completing this form					
Date transferred out of FHN: (dd/mmm/yyyy)/					
Date received at the DCC (dd/mmm/yyyy) / /					
Username of DCC person entering this form					
This page will be printed out separately so that the DCC does not receive confidential information					
Participant Information (May be written on another sheet.)  Stored locally. Not key entered into the study database. Do not forward this information to the DCC.					
Name of participant:					
Address:					
Address:					
Phone number:					
Alternate contact:					
Physicians' names:					
Contact information:					

# Frequent Dialysis Network RE-ENROLLMENT OF A PREVIOUSLY ENROLLED PATIENT FORM - FORM # 401

This form is completed whenever a previously enrolled participant re-enrolls in the FHN trial. You will need to fax this form to the DCC (216-445-2781) in order for it to be entered into the database. Fax only Form 401 to the DCC.

	1. Participant ID Number 2. Alpha Code	
3.	Date dropped:(dd/mon/yyyy)//	-
	Before faxing this Form 401 to the DCC, you must have the following forms fully completed and ready to re-enroll: 100/110, 202,206, 273, and 274.	
	Identify the date these new forms were completed:	
4.	a. Form 100/110 completed date: (dd/mon/yyyy)/	
	b. Form 202 completed date: (dd/mon/yyyy)/	
	c. Form 206 completed date: (dd/mon/yyyy)/	
	d. Form 273 completed date: (dd/mon/yyyy)/	
	e. Form 274 completed date: (dd/mon/yyyy)/	
5.	Date re-enrolled:	_
200.	Date this form completed(dd/mon/yyyy)/	_
201.	Username of person completing this form	-
For l	DCC Use Only:	
	received at the DCC (dd/mon/yyyy)://	
User	name of DCC person entering this form:	

## Frequent Hemodialysis Network CANADIAN CENTERS VITAL STATUS FORM - FORM #404

This form should be completed for randomized patients who have reached a point in the study where **only vital and dialysis status is available**. This form should be completed semi-annually based on their date of randomization.

	1. Participant ID # 2. Alpha Code							
	Status date (dd/mon/yyyy)							
	Vital Status (0=Dead, 1=Alive)							
5.	Patient is:  0 = Dead  1 = Currently refusing any dialysis  2 = Currently refusing dialysis "as prescribed"  3 = Currently on in-center hemodialysis 3 times per week  4 = Currently on in-center hemodialysis 4-5 times per week  5 = Currently on in-center hemodialysis 6 times per week  6 = Currently on in-center hemodialysis elsewhere  7 = Currently on home 3x/wk during the day hemodialysis  8 = Currently on home nocturnal hemodialysis  9 = Currently on peritoneal dialysis  10= Had a kidney transplant  11= Regained renal function  12=Pt receiving short daily dialysis (< 4 hrs/day for 5-6 days/week)  (If there was some other reason, contact the DCC and a new code will be provided)							
200	. Date this form completed (dd/mon/yyyy)							
201	. Username of person reviewing completeness of this form							
For	Clinical Center Use Only:							
202	. Username of person entering this form:							
203	. Date Entered: (dd/mon/yyyy)//							

## Frequent Hemodialysis Network END OF TRIAL PATIENT STATUS FORM - FORM #405

**Instructions:** The DCC will provide each clinical center with a list of randomized patient who are alive (not identified as having died) and still on hemodialysis (not identified as having switched to PD or transplanted) according the DCC's database. Find each of these patients and ask them to participate in the Extended Follow-up Study.

This end-of-trial status form is used to capture information on each randomized patient's vital and dialysis status now or at the last time you could find the patient. This form also identifies which patients have consented to the Extended Follow-up Study.

COI	iselied to the Extended Follow-up Study.
	1. Participant ID # 2. Alpha Code
3.	Vital Status (0=Dead, 1=Alive/not known to have died)
4.	Status date (dd/mon/yyyy)
5.	Usual dialysis pattern (as of date this form completed):  1 = Refusing any dialysis  2 = in-center hemodialysis, 2-3 times per week  3 = in-center hemodialysis, 4-5 times per week  4 = in-center hemodialysis, 6-7 times per week  5 = in-center nocturnal hemodialysis, 2-3 times per week  6 = in-center nocturnal hemodialysis, 4-5 times per week
	7 = in-center <u>nocturnal</u> hemodialysis, 4-3 times per week 8 = in-center hemodialysis, no further information available 20 = at-home during the day hemodialysis, 2-3 times per week
	21 = at-home during the day hemodialysis, 4-5 times per week 22 = at-home during the day hemodialysis, 6-7 times per week 23 = at-home nocturnal hemodialysis, 2-3 times per week 24 = at-home nocturnal hemodialysis, 4-5 times per week
	25 = at-home nocturnal hemodialysis, 6-7 times per week

If response to Q5 is 30 or 31, skip to Q200 at end of form.

26 = at-home hemodialysis, no further information available

98 = We know patient is alive but dialysis status is unknown.

99 = Unknown. We cannot find this patient.

30 = On peritoneal dialysis 31 = Had a kidney transplant

6. If response to Q5=98 or 99, describe how you tried to determine dialysis status or tried to find the patient. Include the date that you searched the Social Security Death Index (try <a href="http://ssdi.rootsweb.ancestry.com">http://ssdi.rootsweb.ancestry.com</a>) and who did the search. Include the price paid for peoplefinder or another in-person or on-line search. Include family members and neighbors a team member spoke to, which team member spoke to them and when the team member spoke to them. (see next page)

Revisi	on of 07/MAY/2010 ID Date// Form #405 Page 2 of 2
Q6, co	nt
	commended that randomized patients alive and still on hemodialysis, according to the DCC's database, ed to consent to the extended follow-up study. <i>If a patient cannot be asked, this can be documented in</i>
7. Ext	ended Follow-up Study Consent:
	Patient was not asked to consent to the extended follow-up study
	Patient was asked but did <b>not</b> consent to the extended follow-up study  Patient consented to the extended follow-up study
	Dialysis Unit is not participating in FHN Extended Follow-up Study
	lete Q8 and Q9 for those asked to consent:
-	rname of FHN person who asked patient to consent:
	sent status date (dd/mon/yyyy)
	date asked for those who did not consent and date of consent for those who consented.)
Comp	lete Q10 if the patient consented to the extended follow-up study:
10. Pa	tient response: Repository Consent
	No; Patient did <b>not</b> consent to serum/plasma sample collection for storage at Biorepository. Yes; Patient consented to serum/plasma sample collection for storage at Biorepository.
-	lete Q11 if the patient was not asked to consent $(Q7 = 1)$ or if the patient did not consent to the ion $(Q7 = 2)$ or if the patient consented to extension but not repository storage $(Q10 = 0)$ .
11. Ex	aplain why patient was not asked or not consenting to extended follow-up study or sample collection:
200 B	
	ate this form completed (dd/mon/yyyy)
	sername of person reviewing completeness of this form
	linical Center Use Only:
202.	Username of person entering this form:
203.	Date Entered: (dd/mon/yyyy)/ /

### FREQUENT HEMODIALYSIS NETWORK Consent for Repositories Form - Form #406

This form should be completed for all individuals who were asked to participant in the Repository collections, **even if they refused**. If a participant was asked to participate in the Repository collections and refused, complete questions 1, 2, 3, 200 and 201.

	1. Participant ID # 2. Alpha Code			
	Did the participant consent for collection of biological specimens (serum) on a consent form that has been approved by the NIDDK repository leadership? (0=No, 1=Yes)			
4.	Date biological specimens consent signed:(dd/mon/yyyy)//			
<b>DCC</b>	Use Only:			
	te patient withdrew consent to store samples repository?			
111 1				
200. I	Date this form completed (dd/mon/yyyy)			
201. U	Username of person reviewing completeness of this form			
For Clinical Center Use Only:				
202.	Username of person entering this form:			
203.	Date Entered: (dd/mon/yyyy)/			

# Frequent Hemodialysis Network OUTCOMES COMMITTEE HOSPITALIZATION REVIEW FORM #501

Th	is form is to be completed by the assigned Outcomes Committee (OC) member.					
	1. Participant ID # 2. Alpha 3a. Date of hospital admission: dd/mon/yyyy					
	1. Participant ID # 2. Alpha 3a. Date of hospital admission: dd/mon/yyyy Code					
OC	C Member reviews the hospitalization and re-checks whether it was a CV or access-related hospitalization.					
	ansplant Status  Transplant hospitalization status					
	required diarysis at time of hospital discharge.					
	cess Related Issues					
<b>~.</b>	1=This was a "Non-Access hospitalization," admitted for a problem unrelated to access. 2=Admitted for an access problem, "Access hospitalization," without non-access complications. 3=Admitted for an access problem, "Access hospitalization," with non-access complications that were not due to access problems. 4=This was an "Access hospitalization" with non-access complications that were due to access problems.					
5.	Cardiovascular disease (For 5a-e: 0=No, 1=Yes)  a. Was there new onset of or worsening angina pectoris or ischemic heart disease?					
	b. Was there new onset of or worsening congestive heart failure (left ventricular dysfunction)?					
	c. Was there a myocardial infarction?					
	d. Was there new onset of or worsening arrhythmias?					
	e. Was there new onset of or worsening other heart disease (exclude pericarditis)					
	a. Was there bacteremia or sepsis?					
	b. Was there organ or deep tissue infection (serious)?					
Tr	ial Relatedness					
	a. In the Reviewer's judgment, was this event caused by any device, procedure, or intervention that was done as part of the FHN Trial Protocol?					

Revision of 3/MAR/20010	PID	Date	//	Form #501 Page 2 of 2
Q7, continued				
If the answer to question 7a was	s nossibly prob	ably or definitely wa	s the AF/SAF	
caused by: (Code 0=)		ably, of definitely, wa	s tile AL/SAL	
•	· ·			<u> </u>
7.a.2. Blood tubing s	ets:			
		blood leaks		
	-			
•				_
b. In the Reviewer's judgm		_		
0=No, 1=Unirkely, 2=	=Possibly, 3=Pr	obably, 4=Definitely,	8=Not Applicable	<del>)"</del>
c. If the event was possibly	, probably, or d	lefinitely caused by an	y device, procedu	re,
or intervention that was				
by the patient's randoml				
described in the study co				
1=Unexpected – not i		e consent han mentioned in the c	concent	
3=Expected and accu			Mischi	
8=Not Applicable*				
Treatment Arm	- O-4			
8. Which treatment arm did th randomized to?				
1=Definitely standard (		•••••		······
2=Probably standard (3				
3=Could not determine	•			
4=Probably frequent (6)	•			
5=Definitely frequent (	5x) arm			
200. Date this form completed (	dd/mon/yyyy)		·····	_/
201. Username of Outcomes Co	ommittee Review	wer completing of this	form	
E DOCH OI				
For DCC Use Only:				
202. Username of person enter	ering this form	:	_	
203. Date entered: (dd/mon/y	/ <b>yyy</b> )/	/		
Based on OC Review:				
204. Hospitalization Code - Pri	mary Reason:			
205. Hospitalization Code - Sec	condary Reason	n:		
206. Hospitalization Code - Otl	her Reason:			

# Frequent Hemodialysis Network OUTCOMES COMMITTEE PATIENT DEATH REVIEW FORM #503

Thi	is form is to be completed by the assigned Outcomes Committee (OC) reviewer.
	1. Participant ID # 2. Alpha 3a. Date of death: dd/mon/yyyy Code
2h	Was this death the outcome of a reported hospitalization?
30.	Was this death the outcome of a reported hospitalization?
	1=Yes, patient hospitalized at time of death, complete item 3b.1.
	3. b.1. Hospital admission date:
	dd/mon/yyyy
3c.	Transplant status
	1=There was no transplant at time of death.
	2=There was a transplant and new kidney was functioning. Patient no longer required dialysis at time of death.
	3=There was a transplant but it failed. Patient still required dialysis at time of death.
	4=There was a transplant, but the new kidney had delayed graft function. Patient
	required dialysis at time of death.
4.	
	1=This was a "Non-Access death"
	2="Access death," <u>without</u> non-access complications. 3="Access death," <u>with</u> non-access complications that <u>were not</u> due to access problems.
	4="Access death" with non-access complications that were due to access problems.
_	Double due to Condinuosculor diagona (For 50 or 0, No. 1, Voc)
5.	Death due to <b>Cardiovascular</b> disease (For 5a-e: 0=No, 1=Yes)  a. Was there new onset of or worsening angina pectoris or ischemic heart disease?
	b. Was there new onset of or worsening congestive heart failure (left ventricular dysfunction)?
	c. Was there a myocardial infarction?
	d. Was there new onset of or worsening arrhythmias?
	e. Was there new onset of or worsening other heart disease (exclude pericarditis)
	(Note - if any of the above are "Yes", this was a cardiovascular death)
6.	Death due to <b>Infection</b> (Code 0=No, 1=Yes)  a. Was there bacteremia or sepsis?
	b. Was there organ or deep tissue infection (serious)?
	(Note – if either of the above are true, this was an infection death)
To •	
1 ri 7.	ial Relatedness  a. In the Reviewer's judgment, was this death caused by any device, procedure, or intervention
	that was done as part of the FHN Trial Protocol?
	0=No, 1=Unlikely, 2=Possibly, 3=Probably, 4=Definitely, 8=Not Applicable*

Revision of 13/FEB/2009 ID	Date/	Form #503 Page 2 of 2
		rage 2 01 2
Q7 continued		
7.a.2. Blood tubing sets:	blood leaks.	
	eath caused by the gimen? robably, 4=Definitely, <mark>8=Not Applicable*</mark>	
or intervention that was done as part of by the patient's randomly assigned dial	than mentioned in the consent	<u> </u>
Treatment Arm		
8. Which treatment arm did the Outcomes Co	•	
randomized to?		
200. Date this form completed (dd/mon/yyyy)		/
201. Username of Outcomes Committee Review	ewer completing of this form	
For DCC Use Only: 202. Username of person entering this form 203. Date entered: (dd/mon/yyyy)/_		
Based on OC Review:		
204. Death Code - Primary Reason:		
205. Death Code - Secondary Reason:		
206. Death Code - Other Reason:	<del></del>	

### Frequent Hemodialysis Network STUDY STAFF INFORMATION FORM - #600

**Instructions:** Complete and enter this form for each member of your study staff. All information on this form will be used to create a separate report.

This form keeps track of your phone numbers and shipping addresses so you will need to make sure that these contact items are kept up to date. You may update study staff records at any time and as many times as needed. Updates will be forwarded to DCC staff for the address directory and aliases, as needed.

The first time a staff member's information is entered, you can just start entering information. If you need to update any information for a staff member that is already entered in the system, use F7 to query up the record (Click on Enter Query [or F7], type individual's last name, click on Execute Query [or F8]).

Note: If an individual is no longer a member of the FHN team, you will need to go to Form 601, personnel table to inactivate the staff member status. This in turn, will inactivate any links on Form(s) 603.

	r names, the computer will store 30 upper case characters.  Last name?
2.	First name?
3.	Middle initial or name?
4.	E-mail address:
5.	Office telephone number:
6	Extension number:
	Fax number:
	a. Pager number:()
	b. Code number for pager, if needed:
9.	Cell phone number:()
10.	. Mailing Address:
	a. Line 1:
	b. Line 2:
	c. Line 3:
	d. Line 4:
	e. City/Town:
	f State/Province:

Revi	sion of <mark>26/FEB/2008</mark>	Staff Member Name:	Form : Page 2	
٤	g. Zip/Postal Code:			
ŀ	n. Country: (1=U.S., 2	2=Canada, 3=Australia)		
		ng Address: (required) (tele 5, unless otherwise specifie	phone number used for shipping will be thd.)	ıe
8	a. Line 1:			
ł	o. Line 2:			
f	State/Province:			
٤	g. Zip/Postal Code:			
ŀ	n. Country: (1=U.S., 2	2=Canada, Australia)		
12.	Clinical Center number	er		
13.	For those with two cer	nters, enter your second cer	ter number	
14.		Principal Investigator rincipal Investigator Study Coordinator or er than coordinator) iac MRI Physician	10=Dialysis Unit Medical Director 11=Dialysis Unit Nurse 12=Dialysis Unit Staff Member 13=Lab Technician 14=Supervising Lab Technician 15=Billing Staff Member 16=Data entry 17=MRI facility administrator	
	-	y completed for the staff mo/mon/yyyy)	ember 	_
		ipdate (dd/mon/yyyy):		
		entering this form:		
203.	Date initially entered	d: (dd/mon/yyyy)/_	/	

## Frequent Hemodialysis Network CLINICAL CENTER FORM - #601

**Instructions:** Complete this form for each clinical center. Names of each study facility have been provided to the Data Coordinating Center (DCC) and a specific number was assigned to each one. If you do not see the name of your Clinical Center (CC), contact the DCC. This form can be updated as many times as needed and should be kept current throughout the FHN Trial period.

To start entering on Form 601, you must first query up the CC you want to update. Use F7 to query up the record (click on Enter Query [or F7], type your CC number or use list of values, click on Execute Query [or F8]). All updates for your study's facilities should be made on this form. (For updates to individual staff members, use Form 600 to update pertinent information.)

Form updates will be forwarded to the DCC for various reports, FHN trial aliases and address directory. For names, the computer will store 30 upper case characters. Use this form to deactivate any staff member who no longer works on the FHN trial.

Before patients can be enrolled, you will need to complete other facility related forms, too: Form 603 must be completed for each participating dialysis unit.

Form 602 must be completed to identify each local laboratory used to process lab specimens and provide results for the FHN trial. Form 602 for each Holter lab used in the Daily Study. Form 604 identifies the Cardiac MRI Facilities associated with your clinical center and the dialysis units that will be using that MRI facility.

The information provided on this form and Forms 600, 602, 603 and 604 links all other facility and staff.

Use this form to inactivate former FHN staff members (Go to Q204-Saff Member Status. Place cursor on the row of the individual you want to inactivate, type in "2-inactive", In Q205-Status Date, identify the date the staff member stopped working on the FHN trial. Once saved, the database will inactivate this staff member on all other forms to which this individual was linked.

#### **Section 1: Facility Information**

1.		me of this facility?
2.	Fac	cility Mailing Address: (required)
	a.	Line 1:
		Line 2:
		Line 3:
		Line 4:
		City/Town:
		State/Province:
		Zip/Postal Code:

Re	visi	on of 26/FEB/2008 Clinical Center #		Form #601 Page 2 of 4
	h.	Country: (1=U.S., 2=Canada, 3=Australia)		······ —
3.	Fe	deral Express Shipping Address: (required)		
	a.	Line 1:		
	b.	Line 2:		
		Line 3:		
		Line 4:		
	e.	City/Town:		
	f.	State/Province:		
	g.	Zip/Postal Code:		
	h.	Country: (1=U.S., 2=Canada, 3=Australia)		
	i.	Telephone number:		
	j.	Extension		·
IR	B I	nformation		
_			/	1
4.	Da	te protocol submitted to IRB/REB:(dd/mon/yyyy)	/	/
5.	IR)	B Assurance #(Example: FWA 0000####)		
6.	a.	Date of IRB approval of main protocol: (dd/mon/yyyy)	/	/
	b.	Date of IRB approval of protocol revision 2.1: (dd/mon/yyyy)	/	/
	c.	Date <u>nocturnal protocol v3.0</u> submitted to IRB:(dd/mon/yyyy)	/	/
	d.	Date of IRB approval of <u>nocturnal protocol revision 3.0</u> : (dd/mon/yyyy)	/	/
	e.	Daily: date pre-enrollment screening form submitted to IRB. (dd/mon/yyyy)	/	/
	f.	Daily: date IRB approved pre-enrollment screening form: (dd/mon/yyyy)	/	/
•		one blank copy of the approved consent form and one copy of the I r Consortium Core, 2. the Data Coordinating Center <i>and 3. the NIL</i>		
7.	Da	te of submission of repository consent to NIDDK(dd/mon/yyyy)	/	/
8.	Da	te of IRB approval for collection of repository biologic specimens:(dd/mon/yyyy)	/	/
9.	Da	te of approval by NIDDK(dd/mon/yyyy)	/	/
10.	Da	te test repository kit approved by NIDDK staff:(dd/mon/yyyy)	/	/

the important links to other study forms that have already been entered.

A	Form 600	) must	already	be entered	l in the	e database	for this	person in	order to	complete	this ta	able

- 200. Staff member's last name: Type in the last name of the staff member you want linked to this ............ clinical center.
- 201. Staff member's first name: Type in the first name of the staff member.
- 202. Staff ID number: This number will automatically populate this column once Q200 and 201 ...... are entered. You can use this id number to query up an individual if you need to update any ...... roles.
- 203. Role. Use the responses below to identify this individual's primary role at this dialysis unit.
  - 01=Consortium Core Principal Investigator
  - 02=Clinical Center Principal Investigator
  - 03=Co-Investigator
  - 04=Consortium Core Study Coordinator
  - 05=Study Coordinator
  - 06=Study Nurse (other than coordinator)
  - 07=Supervising Cardiac MRI Physician
  - 08=MRI Technician

  - 09=Holter Technician

- 10=Dialysis Unit Medical Director
- 11=Dialysis Unit Nurse
- 12=Dialysis Unit Staff Member
- 13=Lab Technician
- 14=Supervising Lab Technician
- 15=Billing Staff Member
- 16=Data entry
- 17=MRI facility administrator
- 204. Staff member status: Use the following responses to record this person's status on the study.
  - 1=Active (individual is actively participating as a member of the FHN study team)
  - 2=Inactive (individual is no longer part of the FHN study team, no longer employed at this dialysis unit, etc.)
- 205. Date of staff member status: Provide the date when the staff member status changed using dd/mon/yyyy format.
- 206. Express shipping address: Use the following responses to provide the appropriate address to ............. be used

to ship items to this addressee.

- 1=Use this individual's shipping address provided on Form 600.
- 2=Use this unit's shipping address identified above in Item 3.
- 3=Use this unit's clinical center address identified on Form 603.
- 207. Mailing address: Use the following responses to provide the appropriate address to be used to ship items to this addressee.
  - 1=Use this individual's mailing address provided on Form 600.
  - 2=Use this unit's mailing address identified above in Item 2.
  - 3=Use this unit's clinical center address identified on Form 603.

Table appears on page 4.

	T	~			T ~	_	
<b>Last Name (200)</b>	First Name	Staff	Role in	Staff	Status	Express	Mailing
	(201)	ID#	Study	Status	Date	Address	Address
	(201)		-				
		(202)	(203)	(204)	(205)	(206)	(207)

#### Codes:

203. Role. Individual's primary role at this unit.

01=Consortium Core Principal Investigator 10=Dialysis Unit Medical Director

02=Clinical Center Principal Investigator 11=Dialysis Unit Nurse

03=Co-Investigator

12=Dialysis Unit Staff Member

04=Consortium Core Study Coordinator 13=Lab Technician

05=Study Coordinator 14=Supervising Lab Technician

06=Study Nurse (other than coordinator) 15=Billing Staff Member

07=Supervising Cardiac MRI Physician 16=Data entry

08=MRI Technician 17=MRI facility administrator

09=Holter Technician

204. Staff member status: 1=Active, 2=Inactive

206. Express shipping address: 1=Use this individual's shipping address provided on Form 600, 2=Use this center's shipping address identified in Item 3.

207. Mailing address: 1=Use this individual's mailing address provided on Form 600, 2=Use this center's mailing address identified in Item 2.

## Frequent Hemodialysis Network OTHER STUDY FACILITIES FORM - #602

**Instructions:** Please complete this Form 602 for any local biochemistry laboratory that may be used for the FHN Trial. If this is a local laboratory that is new to the FHN Trial, you will need to contact the Data Coordinating Center (fhn-dcc@bio.ri.ccf.org) for a pre-assigned laboratory number, prior to entering data into the database. Provide the name of the local lab, address and telephone number. Complete a separate Form 602 for each Holter lab used in the Daily Study. (Complete Form 604 for cardiac MRI facility.)

To start entering information on Form 602, you must first query up the laboratory you want to update. Use F7 to query up the record (click on Enter Query [or F7], type your lab number or use list of values, click on Execute Query [or F8]). All updates for your study's local laboratory(ies) should be made on this form.

The information provided on this form along with Form 603 links the dialysis unit. All updates for this facility should be made on this form. Updates will be forwarded to the DCC for various reports and address directory.

Sec	ction 1: Facility Information	ion	
1.	Name of this facility?		

If Item #2=Biochemistry Lab, complete Items #5-6; otherwise skip to Section 2.

- 5. Lower limit of normal range for parathyroid hormone at this lab: ......\_\_\_\_\_\_\_\_\_\_\_

Section 2. Dialysis Unit Linkage The table in this section links all the dialysis units that will be using this facility. Please review the instructions thoroughly before trying to complete this section as this table provides the important links to other study forms that have already been entered.

A Form 603 must already be entered in the database in order to complete this table.

- 200. Dialysis Unit Name: Enter name of Dialysis Unit (use list of values) you want linked to this facility.
- 201. Dialysis Unit ID number: This number will automatically populate this column once Q200 is entered.
- 202. Start date of this facility: Provide the date in dd/mon/yyyy format when the dialysis unit started using this facility.
- 203. End date of facility: Provide the date in dd/mon/yyyy format when the dialysis unit stopped using this facility.

Revision of 28/FEB/2008 ID Date/	Form #602
	Page 2 of 2

Dialysis Unit Name (200)	DU ID# (201)	Start Date (202)	End Date (203)

### Frequent Hemodialysis Network **DIALYSIS UNIT FORM - #603**

**Instructions:** Each dialysis unit associated with your clinical center will have a separate form. The name of each dialysis unit (DU) has been provided to the Data Coordinating Center (DCC) and a specific number assigned to each one. If you do not see the name of the DU you want, contact the DCC. You only need to complete Section 3 only once. The other sections of this form should be updated as needed.

This form must be completed in its entirety before a dialysis unit (along with other information contained on other forms\*) is considered ready to enroll patients. A Ready-To-Enroll report appears on the FHN Trial's information page under "Reports and Graphs."

To start entering information on Form 603, you must first query up the DU you want.. Use F7 to query up the record (click on Enter Query [or F7], type your DU number or use list of values, click on Execute Query [or F8]). All updates for your DU should be made on this form. (For updates to individual staff members, use Form 600 to update pertinent information.)

\*Before patients can be enrolled, you will need to complete other facility related forms, too: Form 603 must be completed for each participating dialysis unit.

Form 602 must be completed to identify each local laboratory used to process lab specimens and provide results for the FHN trial. Form 602 for each Holter lab used in the Daily Study. Form 604 identifies the Cardiac MRI Facilities associated with your clinical center and the dialysis units that will be using that MRI facility.

### Coation 1. Dialogia IInit Inform

Sectio	n 1: Dialysis Unit Information					
101.	Name of this unit?					
	(Use list of values to pull up the name and number of the facility)					
102.	Unit's Mailing Address:					
a.	Line 1:					
b.	Line 2:					
c.	Line 3:					
d.	Line 4:					
e.	City/Town:					
f.	State/Province:					
g.	Zip/Postal Code:					
h.	Country: (1=U.S., 2=Canada, 3=Australia)					
103. a.	Federal Express Shipping Address: Line 1:					
b.	Line 2:					
C	Line 3.					

			Page 2	01 0
d.	Line 4:			
e.	City/Town:			
f.	State/Province:			
g.	Zip/Postal Code:			
h.	Country: (1=U.S., 2=Canada, 3=Australia)			
i.	Telephone number:			
j.	Extension		··	
IRB I	nformation			
104.	Does this dialysis unit use the IRB specified on its clinical center's F 0=No, complete items 105-110, 1=Yes, skip to Section 2	Form 601	?	
105.	Date protocol submitted to IRB: (dd/mon/yyyy) _	/	/	
106.	IRB Assurance # ( Example: FWA 0000####)			
107. a.	Date of IRB approval of main protocol:(dd/mon/yyyy) _	/	/	
b	Date of IRB approval of protocol revision 2.1: (dd/mon/yyyy) _	/	/	
c.	Date nocturnal protocol v3.0 submitted to IRB:(dd/mon/yyyy) _	/	/	
d	Date of IRB approval of <u>nocturnal protocol revision 3.0</u> : (dd/mon/yyyy) _	/	/	
e.	Daily: date pre-enrollment screening form submitted to IRB. (dd/mon/yyyy)_	/	/	
f.	Daily: date IRB approved pre-enrollment screening form: (dd/mon/yyyy) _	/	/	
	one blank copy of the approved consent form and one copy of the Consortium Core, 2. the Data Coordinating Center and 3. the N		-	er to
108.	Date of submission of repository consent to NIDDK	/	/	
109.	Date of IRB approval for collection of repository biologic specimens:(dd/mon/yyyy) _	/	/	
110.	Date of approval by NIDDK(dd/mon/yyyy) _	/	/	

Form #603

Revision of 26/FEB/2008 Unit # \_\_ \_ \_ \_ \_

**SECTION 2.** Personnel Linkage The table in this section links all the facility and staff forms. Please review the instructions thoroughly before trying to complete this section as this table provides the important links to other study forms that have already been entered.

A Form 600 must already be entered in the database for this person in order to complete this table.

200. Staff member's last name: Type in the last name of the staff member you want linked to this site.

201. Staff member's first name: Type in the first name of the staff member.

203. Role. Use the responses below to identify this individual's primary role at this dialysis unit.

01=Consortium Core Principal Investigator 10=Dialysis Unit Medical Director

02=Clinical Center Principal Investigator 11=Dialysis Unit Nurse

03=Co-Investigator 12=Dialysis Unit Staff Member

04=Consortium Core Study Coordinator 13=Lab Technician

07 C. 1 C. 1' C. 1

05=Study Coordinator 14=Supervising Lab Technician

06=Study Nurse (other than coordinator) 15=Billing Staff Member

07=Supervising Cardiac MRI Physician 16=Data entry

08=MRI Technician 17=MRI facility administrator

09=Holter Technician

204. Staff member status: Use the following responses to record this person's status on the study.

1=Active (individual is actively participating as a member of the FHN study team)

2=Inactive (individual is no longer part of the FHN study team, no longer employed at this dialysis unit, etc.)

- 205. Date of staff member status: Provide the date when the staff member status changed using dd/mon/yyyy format.
- 206. Express shipping address: Use the following responses to provide the appropriate address to be used to ship items to this addressee.
  - 1=Use this individual's shipping address provided on Form 600.
  - 2=Use this unit's shipping address identified above in Item 103.
  - 3=Use this unit's clinical center address identified on Form 601.
- 207. Mailing address: Use the following responses to provide the appropriate address to be used to ship items to this addressee.
  - 1=Use this individual's mailing address provided on Form 600.
  - 2=Use this unit's mailing address identified above in Item #102.
  - 3=Use this unit's clinical center address identified on Form 601.

Table appears on page 4 of this form.

Last Name (200)	First Name (201)	Staff ID # (202)	Role in Study (203)	Staff Status (204)	Status Date (205)	Express Address (206)	Mailing Address (207)
		(202)	(200)	(204)	(200)	(200)	(201)
					_		

#### Codes:

203. Role. Individual's primary role at this unit.

01=Consortium Core Principal Investigator

02=Clinical Center Principal Investigator

03=Co-Investigator

04=Consortium Core Study Coordinator

05=Study Coordinator

06=Study Nurse (other than coordinator)

07=Supervising Cardiac MRI Physician

08=MRI Technician

09=Holter Technician

10=Dialysis Unit Medical Director

11=Dialysis Unit Nurse

12=Dialysis Unit Staff Member

13=Lab Technician

14=Supervising Lab Technician

15=Billing Staff Member

16=Data entry

17=MRI facility administrator

204. Staff member status: 1=Active, 2=Inactive

206. Express shipping address: 1=Use this individual's shipping address provided on Form 600, 2=Use this unit's shipping address identified in Item #103. 3=Use this unit's clinical center address identified on Form 601.

207. Mailing address: 1=Use this individual's mailing address provided on Form 600, 2=Use this unit's mailing address identified in Item #102. 3=Use this unit's clinical center address identified on Form 601.

### **Section 3. Dialysis Unit Details**

313.

	ctions: You will need to first obtain data prior to entering any data in this section. You will ave to complete this once for each dialysis unit.
301.	If U.S. site, CMS/HCFA Provider Identification Number:
302.	Does this unit need a centrifuge? (1=No, 2=Yes)
303.	Is this unit rural, suburban or urban? 1=Rural, 2=Suburban, 3=Urban
	clinical site is a nocturnal home HD training site, for questions 304-313, indicate the ation for the inpatient unit affiliated with the home HD training center.
304.	Type of flow monitoring used?
305.	How many stations are currently used at this unit?
306.	Approximately, how many (total) chronic (3 x weekly) hemodialysis patients could be treated per week in this unit with the current number of shifts?
307.	Is this dialysis unit for profit or non-profit? (1=Profit, 2=Non-profit, 3=Mixed)
308.	What water standards are being used for patients on conventional hemodialysis in this unit?1=AAMI Standards 2=European Pharmacopoeia 3=Canadian
309.	Are additional ultrafilters being used to produce ultrapure water for the majority of patients on conventional hemodialysis in this unit? (0=No, 1=Yes)
310.	Do the machines at this unit allow for volumetric control of hyperfiltration?(0=No, 1=Yes)
311.	a. Does this unit have experience with frequent in-center daily dialysis (>5 days/week)? (0=No, skip to Q312, 1=Yes, continue)
	b. If yes, what year did this unit start performing frequent daily dialysis?
	c. Approximately, total number of patients who have been treated with in-center frequent daily hemodialysis before this study?
312.	a. Does this unit reuse dialyzers? (0=No, skip to Q313, 1=Yes, complete Q312b.)
	b. If yes, what sterilant(s) are used?,,,,

Does this dialysis unit have access to the following health care professionals?

For in-patient dialysis units participating in the nocturnal study, provide confirmation:

315.

1=Inpatient, 2=Outlying

316. Can you confirm that patients enrolled in this study will not reuse membranes from patients when study patients are dialyzed at this dialysis unit? (0=No, Yes, confirmed) ......\_\_

Is this an inpatient dialysis unit or an outlying dialysis unit?.....\_\_\_\_

Outlying dialysis units participating in the nocturnal study are asked not to reuse membranes if possible.

### Frequent Hemodialysis Network CARDIAC MRI FACILITY FORM - #604

**Instructions:** Please complete this Form 604 for any Cardiac MRI Facilities that may be used for the FHN Study. If this is a cardiac MRI facility new to the FHN study, you will need to contact the Data Coordinating Center for a <u>pre-assigned MRI unit number</u>, prior to entering data into the database.

To start entering information on Form 604, you must first query up the MRI facility you want to update. Use F7 to query up the record (click on Enter Query [or F7], type your MRI facility number or use list of values, click on Execute Query [or F8]). All updates for your study's MRI facilities should be made on this form. (For updates to individual staff members, use Form 600 to update pertinent information.)

The information provided on this form along with Form 603 links the dialysis units.	
Section 1: Facility Information	
1. Name of this Cardiac MRI facility?	
(Use list of values)	

Section 2. Dialysis Unit Linkage. The table in this section links all the dialysis units that will be using this Cardiac MRI facility. Please review the instructions thoroughly before trying to complete this section as this table provides the important links to other study forms that have already been entered.

A Form 603 must already be entered in the database in order to complete this table.

- 200. Dialysis Unit Name: Enter name of Dialysis Unit (use list of values) you want linked to this cardiac MRI facility.
- 201. Dialysis Unit ID number: This number will automatically populate this column once Q200 is entered.
- 202. Start date of MRI facility: Provide the date in dd/mon/yyyy format when the dialysis unit started using this facility.
- 203. End date of MRI facility: Provide the date in dd/mon/yyyy format when the dialysis unit stopped using this facility.

Dialysis Unit Name (200)	DU ID# (201)	Start Date (202)	End Date (203)

#### Section 3. Personnel Linkage. The table in this section links all the facility and staff forms.

Please review the instructions thoroughly before trying to complete this section as this table provides the important links to other study forms that have already been entered.

A Form 600 must already be entered in the database for this person in order to complete this table.

- 300 Staff member's last name: Type in the last name of the staff member you want linked to this site.
- 301 Staff member's first name: Type in the first name of the staff member.
- 302 Staff ID number: This number ill automatically populate this column once Q300 and 301 are entered. You can use this id number to query up an individual if you need to update any roles.
- Role. Use the responses below to identify this individual's primary role at the MRI Facility.

01=Consortium Core Principal Investigator 10=Dialysis Unit Medical Director

02=Clinical Center Principal Investigator 11=Dialysis Unit Nurse

03=Co-Investigator 12=Dialysis Unit Staff Member

04=Consortium Core Study Coordinator 13=Lab Technician

05=Study Coordinator 14=Supervising Lab Technician

06=Study Nurse (other than coordinator) 15=Billing Staff Member

07=Supervising Cardiac MRI Physician 16=Data entry

08=MRI Technician 17=MRI facility Administrator

09=Holter Technician

- 304 Staff member status: Use the following responses to record this person's status on the study.
  - 1=Active (individual is actively participating as a member of the FHN study team)
  - 2=Inactive (individual is no longer part of the FHN study team, no longer employed at this dialysis unit, etc.)
- 305. Date of staff member status: Provide the date when the staff member status changed using dd/mon/yyyy format.

Last Name (300)	First Name (301)	Staff ID # (302)	Role in Study (303)	Staff Status (304)	Status Date (305)

## Frequent Hemodialysis Network CONSORTIUM CORE FORM - #605

**Instructions:** Please complete this form for your Consortium Core. Names of each study facility have been provided to the Data Coordinating Center (DCC) and a specific number assigned to each. If you do not see the name of the facility you want, contact the DCC.

A Form 601 should be completed for each participating clinical center. A separate form, Form 602 should be completed for each biochemistry laboratory used to process lab specimens and provide results for the FHN study. Complete a Form 602 for each Holter lab used in the Daily Study. Cardiac MRI Facility information is on Form 604.

The information provided on this form and Forms 600, 601, 602, 603 and 604 links all other facility and staff .

All updates for your core should be made on this form. (For updates to individual staff members, use Form 600 to update pertinent information.)

Form updates will be forwarded to the DCC for various reports and address directory. For names, the computer will store 30 upper case characters.

#### **Section 1: Core Consortium Information**

1.	Na	me of this Consortium
	(U	se list of values to pull up the name and number of the facility)
2.	Fac	cility Mailing Address: (required)
	a.	Line 1:
	b.	Line 2:
	c.	Line 3:
	d.	Line 4:
		City/Town:
	f.	State/Province:
	g.	Zip/Postal Code:
	h.	Country: (1=U.S., 2=Canada)
3.	Fee	deral Express Shipping Address: (required)
	a.	Line 1:
		Line 2:
	c.	Line 3:
	d.	Line 4:

	Page 2 of 4
	e. City/Town:
	f. State/Province:
	g. Zip/Postal Code:
	h. Country: (1=U.S., 2=Canada)
	i. Telephone number:
IR	B Information
<mark>4</mark> .	Date protocol submitted to IRB:(dd/mon/yyyy)//
<mark>5</mark> .	IRB Assurance #( Example: FWA 0000####)
<mark>6</mark> .	Date of IRB approval of main protocol:(dd/mon/yyyy)//
-	end one blank copy of the approved consent form and one copy of the IRB approval letter to the Data Coordinating Center <i>and 2. the NIDDK repository</i> )
<mark>7</mark> .	Date of submission of repository consent to NIDDK(dd/mon/yyyy) /
<mark>8</mark> .	Date of IRB approval for collection of repository biologic specimens:(dd/mon/yyyy)//
<mark>9</mark> .	Date of approval by NIDDK(dd/mon/yyyy)//
Ple the	CCTION 2. Personnel Linkage The table in this section links all the facility and staff forms. ease review the instructions thoroughly before trying to complete this section as this table provides a important links to other study forms that have already been entered.  Form 600 must already be entered in the database for this person in order to complete this table.  O. Staff member's last name: Type in the last name of the staff member you want linked to this site.
20	1. Staff member's first name: Type in the first name of the staff member.

Staff ID number: This number will automatically populate this column once Q200 and 201

are entered. You can use this id number to query up an individual if you need to update any

Form #605

Revision of 11/OCT/2005 Core # \_\_\_

202.

roles.

203. Role. Use the responses below to identify this individual's primary role at this core.

01=Consortium Core Principal Investigator 10=Dialysis Unit Medical Director

02=Clinical Center Principal Investigator

03=Co-Investigator

04=Consortium Core Study Coordinator

05=Study Coordinator

06=Study Nurse (other than coordinator)

07=Supervising Cardiac MRI Physician

08=MRI Technician

09=Holter Technician

11=Dialysis Unit Nurse

12=Dialysis Unit Staff Member

13=Lab Technician

14=Supervising Lab Technician

15=Billing Staff Member

16=Data entry

17=MRI facility Administrator

Staff member status: Use the following responses to record this person's status on the study. 204.

1=Active (individual is actively participating as a member of the FHN study team)

2=Inactive (individual is no longer part of the FHN study team, no longer employed at this dialysis unit, etc.)

205. Date of staff member status: Provide the date when the staff member status changed using dd/mon/yyyy format.

Express shipping address: Use the following responses to provide the appropriate address to 206. be used

to ship items to this addressee.

1=Use this individual's shipping address provided on Form 600.

2=Use this unit's shipping address identified above in Item 3.

3=Use this unit's clinical center address identified on Form 603.

207. Mailing address: Use the following responses to provide the appropriate address to be used to ship items to this addressee.

1=Use this individual's mailing address provided on Form 600.

2=Use this unit's mailing address identified above in Item 2.

3=Use this unit's clinical center address identified on Form 603.

Last Name (200)	First Name (201)	Staff ID # (202)	Role in Study (203)	Staff Status (204)	Status Date (205)	Express Address (206)	Mailing Address (207)

#### Codes:

203.Role. Individual's primary role at this unit.

01=Consortium Core Principal Investigator

02=Clinical Center Principal Investigator

03=Co-Investigator

04=Consortium Core Study Coordinator

05=Study Coordinator

 $06=Study\ Nurse\ (other\ than\ coordinator)$ 

07=Supervising Cardiac MRI Physician

08=MRI Technician 09=Holter Technician 10=Dialysis Unit Medical Director

11=Dialysis Unit Nurse

12=Dialysis Unit Staff Member

13=Lab Technician

14=Supervising Lab Technician

15=Billing Staff Member

16=Data entry

17=MRI facility Administrator

204. Staff member status: 1=Active, 2=Inactive

206. Express shipping address: 1=Use this individual's shipping address provided on Form 600, 2=Use this center's shipping address identified in Item 3.

207. Mailing address: 1=Use this individual's mailing address provided on Form 600, 2=Use this center's mailing address identified in Item 2.

# Frequent Hemodialysis Network DOCUMENTATION OF LOCAL LABORATORY METHOD, INSTRUMENT, AND NORMAL RANGES - FORM 606

This form is completed for each local lab used by an FHN dialysis unit once at the start of data collection then again every three months to see whether any method, any instrument, or normal range changes for serum albumin, creatinine, phosphorus or PTH.

	V											
L	]	la. ID	numbe	er of Laboratory (from Form 602)			1b. Q	tr (mr	n)/Ye	ar (yy	уу)	
		The	e dat	abase will list all those dialysis units using th	is lab j	providi	ng tl	ne D	U is	link	ed o	n
F	orm	602.	If yo	ou identify that a Dialysis Unit is not linked to	o this f	orm, yo	ou m	nust	upda	te F	orm	602.
2	_	T., : 4	۔ اہا۔	ata aallaatian		. •			•			
2	. a.			ata collection	•••••	••••••	•••••	• • • • • • •	• • • • • • •	• • • • • • •	•••••	
				nswer 2b,								
		1=1	es, c	complete <u>all</u> fields on this form)								
	b.	Qu	arter	ly lab check								
		0=N	No, sl	cip to Q3,								
		1=5	es, c	complete only the fields within the section(s)	that ne	eed upd	atin	g				
C.				•		•	•					
<u> </u>	erui	m AL	BUI	VIIIN								
3	. D	ate of	f seru	um albumin test change: (dd/mon/yyyy)		····	_/		/_			
4	1	/letho	d an	d Instrument								
_	. 1			nding-BCG: Abbott Aeroset	•••••	• • • • • • • • • • • • • • • • • • • •	•••••	• • • • • •	• • • • • •	• • • • • •		
				nding-BCG: Abbott Architect								
				nding-BCG: Bayer Advia 1650/2400								
				nding-BCG: Beckman Synchron LX20								
			•	nding-BCG: Dade Behrg Dimension								
				nding-BCG: OLY 400-640/2700/5400								
		07=D	ye Bi	nding-BCG: Roche Cobas Fara/Mira								
		08 = D	ye Bi	nding-BCG: Roche Cobas Integra								
				nding-BCG: Roche Modular								
				nding-BCG: Roche/Hitachi 747								
				nding-BCG: Roche/Hitachi 911								
				nding-BCG: Roche/Hitachi 912								
				nding-BCG: Roche/Hitachi 917								
				nding-BCG: Toshiba TBA-FR Series								
				inding-BCG: Vitros 250 Chem System								
				inding-BCG: Vitros 5, 1 FS Chem System								
				inding-BCG: Vitros 950 Chem System								
				nding-BCG w/RA: Roche Cobas Integra inding-BCP: Abbot Aeroset								
				nding-BCP: W/Ra: Abbott Architect								
				inding-BCP: W/Ra: Abbout Architect inding-BCP: W/Ra: Beck Syn CX3-7D, CX9ALX								
				Inding-BCP: W/Ra: Beck Syn CX4/5CE, 7/RTS								
				Inding-BCP: W/Ra: Beckman Synchron CX4/5								
				Inding-BCP: W/Ra: Beckman Synchron LX 20								
					respons	ses conti	nued	on ne	ext pa	ge		

	26=Dye Binding-BCP: W/Ra: Dade Behrg Dimension 27=Dye Binding-BCP: Roche Modular 28=Dye Binding-BCP: Roche/Hitachi 917 29=Nephelometry 30= Dye Binding BCP: Instrument unspecified	
5.	Low end of normal range for serum albumin (g/dI	<u></u>
6.	High end of normal range for serum albumin (g/d	L)
SI	<u>Units</u>	
7.	Low end of normal range for serum albumin (g/L)	
8.	High end of normal range for serum albumin (g/L	
<u>Ser</u>	rum CREATININE	
9.	Date of serum creatinine test change: (dd/mon/yyy	y)
10.	Method and Instrument	<u> </u>
	01=Alk Picrate w/Lloyds: Dade Behrg Dimension 02= Alk Picrate w/o Lloyds: Beck Syn CX3-7D, Cx9ALX 03= Alk Picrate w/o Lloyds: Beck Syn CX4/5CE, 7/RTS 04= Alk Picrate w/o Lloyds: Beckman Synchron LX20 05= Alk Picrate w/o Lloyds: Dade Behrg Dimension 06= Alk Picrate w/o Lloyds: Roche Cobas Integra 07=Enzymatic: Bayer Advia 1650/2400 08=Enzymatic: Oly 400-640/2700/5400 09=Enzymatic: Roche Cobas Integra 10=Enzymatic: Roche Modular 11=Enzymatic: Roche/Hitachi 747 12=Enzymatic: Roche/Hitachi 917 13=Enzymatic: Toshiba TBA-FR Series 14=Enzymatic: Vitros 250 Chem System 15=Enzymatic: Vitros 950 Chem System 16=Enzymatic: Vitros 950 Chem System 17=Enzymatic: Vitros DT6011 Chem System 18=Kinetic Alk. Picrate: Abbott Aeroset 19=Kinetic Alk. Picrate: Beck Syn CX3-7D, CX9ALX 22=Kinetic Alk. Picrate: Beck Syn CX3-7D, CX9ALX 22=Kinetic Alk. Picrate: Beck Syn CX4/5CE, 7/RTS 23=Kinetic Alk. Picrate: Beckman Synchron CX3 24=Kinetic Alk. Picrate: Beckman Synchron CX4/5 25=Kinetic Alk. Picrate: Beckman Syncron LX20 26=Kinetic Alk. Picrate: Dade Behrg Dimension 28=Kinetic Alk. Picrate: Dade Behrg Dimension 28=Kinetic Alk. Picrate: Roche Cobas Fara/Mira 30=Kinetic Alk. Picrate: Roche Cobas Integra 31=Kinetic Alk. Picrate: Roche Cobas Integra	
	36=Rate-Blk Kin Alk Pic: Bayer Advia 1650/2400	responses continued on next page

	37=Rate-Blk Kin Alk Pic: Beck Syn CX3-7d, CX9ALX 38=Rate-Blk Kin Alk Pic: Beckman Synchron LX20 39=Rate-Blk Kin Alk Pic: Dade Behrg Dimension 40=Rate-Blk Kin Alk Pic: Roche Cobas Integra 41=Rate-Blk Kin Alk Pic: Roche Modular 42=Rate-Blk Kin Alk Pic: Roche/Hitachi 912 43=Rate-Blk Kin Alk Pic: Roche/Hitachi 917 44=Kinetic Alk Picrate: Instrument Unspecified
11.	Low end of normal range for serum creatinine (mg/dL)
12.	High end of normal range for serum creatinine (mg/dL)
<u>SI U</u>	<u>Units</u>
13.	Low end of normal range for serum creatinine (µmol/L)
14.	High end of normal range for serum creatinine (μmol/L)
Seri	um PHOSPHORUS
15.	Date of serum phosphorus test change: (dd/mon/yyyy)//
16.	Method and Instrument
17.	Low end of normal range for serum phosphorus (mg/dL)

<u>SI U</u>	<u>Jnits</u>
19.	Low end of normal range for serum phosphorus (mmol/d)
20.	High end of normal range for serum phosphorus (mmol/d)
PTI	<u>H</u>
21	Date of PTH test change: (dd/mon/yyyy)
22.	Instrument
	01=Bayer Acs:180 02=Bayer Advia Centaur 03=Diasorin IRMA 04=DPC immulite 2000 05=DPC immulite 2500 06=DPC immulite Turbo 07=DPC immulite/1000 08=Roche E170 09=Roche Elecsys 1010/2010 10=Beckman DxL
23.	Low end of normal range for PTH for normal patients (pg/mL = ng/L)
24.	High end of normal range for PTH for normal patients (pg/mL = ng/L)
<u>SI U</u>	<u>Units</u>
25.	Low end of normal range for PTH for normal patients (pmol)
26.	High end of normal range for PTH for normal patients (pmol)
27.	Low end of normal range for PTH for ESRD patients (pg/mL = ng/L)
28.	High end of normal range for PTH for ESRD patients (pg/mL = ng/L)
<u>SI U</u>	<u>Units</u>
29.	Low end of normal range for PTH for ESRD patients (pmol)
30.	High end of normal range for PTH for ESRD patients (pmol)
200	. Date this form completed (dd/mon/yyyy)
201	
	Clinical Center Use Only:
	•
202	
203.	. Date entered: (dd/mon/yyyy)//

## Frequent Hemodialysis Network THIRTY DAYS AFTER F12 DATA - FORM #700

#### **Instructions:**

Starting with the first dialysis session held at least 30 days after a patient's F12 month ends, one week of data should be obtained from the dialysis unit's run sheets. This data will include start time, end time, and pre-and-post weight and blood pressure for each dialysis session held during that week.

The table accommodates up to 6 sessions. Use as many columns as needed (starting from the left) to cover all treatments in the one week that starts with the first dialysis session held at least 30 days after a patient's F12 month ends . Include both dialysis sessions and treatments with isolated ultrafiltration only.

1. Part	ticipant	ID#		2 <mark>a.</mark>	Alp	ha Cod	e

For	A 11	Subjects	A ftor	End	of the	FHN	Trial
ror	ΑH	Simplects	Aller	rana	oi ine	rhn	า เม

2 <mark>b</mark>	. Where does pt. currently receive his/her hemodialysis? (1=Home, 2=In-Center)
2c	. Has this pt experienced any SAE's between the end of the study and when F700 entered?

(0=No, 1=Yes – complete appropriate forms)

Data Item	3. Session – #1	4. Session – #2	5. <b>Session</b> – #3
a. Treatment Date (dd/mon/yyyy)	/	/	/
b. Start Time (24 hr clock)	:	:	:
c. End Time (24 hr clock)	:	:	:
d. Predialysis weight (kg)			
e. Minimum intradialytic systolic BP <sup>2</sup>			
f. Minimum intradialytic diastolic BP <sup>2</sup>			
g. Hypotensive episode? <sup>1</sup>	_	_	_
h. Significant interruption? <sup>3</sup>	_	_	_
i. Pre-dialysis systolic BP			
j. Pre-dialysis diastolic BP			
k. Post-dialysis systolic BP			
l. Post-dialysis diastolic BP			
m. Post-dialysis weight (kg)			
p. Was this a dialysis session? (0=No, isolated ultrafiltration; 1=Yes)	_	_	_

<sup>&</sup>lt;sup>1</sup>For Item g, hypotensive episode, enter 0=No, 1=Symptoms of hypotension led to lowering of UF rate or reduced blood flow, 2=Symptoms of hypotension led to administration of saline, 3=Symptoms of hypotension led to lowering of UF rate and administration of saline.

<sup>&</sup>lt;sup>2</sup>For Item e: specify systolic and diastolic blood pressure at time of minimum systolic blood pressure.

<sup>&</sup>lt;sup>3</sup>For Item h, significant interruption, enter 0=No, 1=Yes. For an in-center dialysis treatment, a significant interruption is any interruption of 15 minutes or greater. For a home dialysis treatment, a significant interruption is any interruption of 30 minutes or greater.

Revision of 17/JUN/2008 PID: Date:/Post-Study Form #700						
			Page 2 of 2			
Data Item	6. Session – #4	7. <b>Session</b> – #5	8. <b>Session</b> – #6			
a. Treatment Date (dd/mon/yyyy)	/	/	/			
b. Start Time (24 hr clock)	: <u>_</u> _	:	:			
c. End Time (24 hr clock)	:	:	: <u>_</u> _			
d. Predialysis weight (kg)	·_		<u>-</u> -			
e. Minimum intradialytic systolic BP <sup>2</sup>						
f. Minimum intradialytic diastolic BP <sup>2</sup>						
g. Hypotensive episode? <sup>1</sup>			_			
h. Significant interruption? <sup>3</sup>			_			
i. Pre-dialysis systolic BP						
j. Pre-dialysis diastolic BP						
k. Post-dialysis systolic BP						
1. Post-dialysis diastolic BP						
m. Post-dialysis weight (kg)	·_					
p. Was this a dialysis session? (0=No, isolated ultrafiltration; 1=Yes)	_	_	_			
200. Date this form completed (dd/mon/yyyy)						
201. Username of person reviewing completeness of this form						

Username of person entering this form: \_\_ \_ \_ \_ \_ \_

For Clinical Center Use Only:

202.

203.

<sup>&</sup>lt;sup>1</sup>For Item g, hypotensive episode, enter 0=No, 1=Symptoms of hypotension led to lowering of UF rate or reduced blood flow, 2=Symptoms of hypotension led to administration of saline, 3=Symptoms of hypotension led to lowering of UF rate and administration of saline.

<sup>&</sup>lt;sup>2</sup>For Item e: specify systolic and diastolic blood pressure at time of minimum systolic blood pressure.

<sup>&</sup>lt;sup>3</sup>For Item h, significant interruption, enter 0=No, 1=Yes. For an in-center dialysis treatment, a significant interruption is any interruption of 15 minutes or greater. For a home dialysis treatment, a significant interruption is any interruption of 30 minutes or greater.